

KING PHARMACEUTICALS INC

Form 10-Q

November 05, 2009

Table of Contents

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Form 10-Q

(Mark One)

- QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**
For the quarterly period ended September 30, 2009
- OR**
- TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**
For the transition period from to

Commission File No. 001-15875

King Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Tennessee

(State or other jurisdiction of incorporation or organization)

54-1684963

(I.R.S. Employer Identification No.)

501 Fifth Street, Bristol, TN

(Address of principal executive offices)

37620

(Zip Code)

(423) 989-8000

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Edgar Filing: KING PHARMACEUTICALS INC - Form 10-Q

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Number of shares outstanding of registrant's common stock as of November 3, 2009: 248,242,387

TABLE OF CONTENTS

	Page
<u>Part I Financial Information</u>	
<u>Item 1.</u>	
<u>Financial Statements</u>	3
<u>Condensed Consolidated Balance Sheets</u>	3
<u>Condensed Consolidated Statements of Operations</u>	4
<u>Condensed Consolidated Statements of Changes in Shareholders' Equity and Other Comprehensive Income</u>	5
<u>Condensed Consolidated Statements of Cash Flows</u>	6
<u>Notes to Condensed Consolidated Financial Statements</u>	7
<u>Item 2.</u>	40
<u>Item 3.</u>	69
<u>Item 4.</u>	70
<u>Part II Other Information</u>	
<u>Item 1.</u>	70
<u>Item 1A.</u>	70
<u>Item 5.</u>	72
<u>Item 6.</u>	72
<u>Signatures</u>	73
<u>EX-31.1</u>	
<u>EX-31.2</u>	
<u>EX-32.1</u>	
<u>EX-32.2</u>	

Table of Contents**PART I FINANCIAL INFORMATION****Item 1. Financial Statements****KING PHARMACEUTICALS, INC.****CONDENSED CONSOLIDATED BALANCE SHEETS****(In thousands)****(Unaudited)**

	September 30, 2009	December 31, 2008
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 479,968	\$ 940,212
Investments in debt securities	39,624	6,441
Marketable securities	1,930	511
Accounts receivable, net of allowance of \$3,966 and \$4,713	227,030	245,070
Inventories	207,650	258,303
Deferred income tax assets	100,577	89,513
Income taxes receivable	12,051	
Prepaid expenses and other current assets	99,374	129,214
Total current assets	1,168,204	1,669,264
Property, plant and equipment, net	401,162	417,259
Intangible assets, net	822,589	934,219
Goodwill	453,008	450,548
Deferred income tax assets	250,017	267,749
Investments in debt securities	292,034	353,848
Other assets (includes restricted cash of \$16,649 and \$16,580)	75,379	122,826
Assets held for sale	7,900	11,500
Total assets	\$ 3,470,293	\$ 4,227,213

LIABILITIES AND SHAREHOLDERS EQUITY

Current liabilities:		
Accounts payable	\$ 87,111	\$ 140,908
Accrued expenses	309,962	411,488
Income taxes payable		10,448
Short-term debt	4,101	5,230
Current portion of long-term debt	122,449	439,047
Total current liabilities	523,623	1,007,121

Edgar Filing: KING PHARMACEUTICALS INC - Form 10-Q

Long-term debt	505,904	877,638
Other liabilities	105,358	110,022
Total liabilities	1,134,885	1,994,781
Commitments and contingencies (Note 10)		
Shareholders' equity	2,335,408	2,232,432
Total liabilities and shareholders' equity	\$ 3,470,293	\$ 4,227,213

See accompanying notes.

Table of Contents**KING PHARMACEUTICALS, INC.****CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS****(In thousands, except per share data)
(Unaudited)**

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2009	2008	2009	2008
Revenues:				
Net sales	\$ 451,417	\$ 369,989	\$ 1,295,995	\$ 1,156,072
Royalty revenue	11,932	18,456	41,399	61,257
Total revenues	463,349	388,445	1,337,394	1,217,329
Operating costs and expenses:				
Cost of revenues, exclusive of depreciation, amortization and impairments shown below	162,797	101,465	469,829	295,111
Selling, general and administrative, exclusive of co-promotion fees	134,315	93,291	390,885	307,102
Acquisition related costs			6,733	
Co-promotion fees	1,427	5,987	4,022	34,007
Total selling, general and administrative expense	135,742	99,278	401,640	341,109
Research and development	22,640	33,855	71,098	111,025
Research and development-in-process upon acquisition				5,500
Total research and development	22,640	33,855	71,098	116,525
Depreciation and amortization	53,349	29,894	159,560	121,749
Asset impairments				39,429
Restructuring charges (Note 14)	1,653	1,153	51,178	1,670
Total operating costs and expenses	376,181	265,645	1,153,305	915,593
Operating income	87,168	122,800	184,089	301,736
Other income (expense):				
Interest income	1,027	8,110	5,321	31,000
Interest expense	(22,218)	(5,300)	(72,913)	(15,571)
Gain (loss) on investments	521		(826)	
Other, net	1,526	(1,024)	2,859	(1,851)
Total other (expense) income	(19,144)	1,786	(65,559)	13,578

Edgar Filing: KING PHARMACEUTICALS INC - Form 10-Q

Income before income taxes	68,024	124,586	118,530	315,314
Income tax expense	25,536	42,114	48,829	106,525
Net income	\$ 42,488	\$ 82,472	\$ 69,701	\$ 208,789
Net income per common share:				
Basic net income per common share	\$ 0.17	\$ 0.34	\$ 0.29	\$ 0.86
Diluted net income per common share	\$ 0.17	\$ 0.34	\$ 0.28	\$ 0.85

See accompanying notes.

Table of Contents**KING PHARMACEUTICALS, INC.****CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN
SHAREHOLDERS EQUITY AND OTHER COMPREHENSIVE INCOME****(In thousands, except share data)****(Unaudited)**

	Common Stock		Retained	Accumulated Other Comprehensive	
	Shares	Amount	Earnings	Income (Loss)	Total
Balance at December 31, 2007	245,937,709	\$ 1,359,817	\$ 1,213,057	\$ 1,957	\$ 2,574,831
Comprehensive income:					
Net income			208,789		208,789
Net unrealized loss on investments in debt securities, net of taxes of \$8,693				(13,897)	(13,897)
Foreign currency translation				(1,018)	(1,018)
Total comprehensive income					193,874
Stock-based award activity	531,630	21,617			21,617
Balance at September 30, 2008	246,469,339	\$ 1,381,434	\$ 1,421,846	\$ (12,958)	\$ 2,790,322
Balance at December 31, 2008	246,487,232	\$ 1,389,698	\$ 871,021	\$ (28,287)	\$ 2,232,432
Adoption of FASB statement on other-than-temporary investments, net of taxes of \$396			646	(646)	
Comprehensive income:					
Net income			69,701		69,701
Reclassification of unrealized losses on investments in debt securities, net of taxes of \$542				885	885
Net unrealized gain on marketable securities, net of tax of \$539				880	880
Net unrealized gain on investments in debt securities, net of taxes of \$3,354				5,472	5,472
Foreign currency translation				3,227	3,227
Total comprehensive income					80,165
Stock-based award activity	1,739,351	22,811			22,811
Balance at September 30, 2009	248,226,583	\$ 1,412,509	\$ 941,368	\$ (18,469)	\$ 2,335,408

See accompanying notes.

Table of Contents**KING PHARMACEUTICALS, INC.****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS****(In thousands)****(Unaudited)**

	Nine Months Ended	
	September 30,	
	2009	2008
Cash flows provided by operating activities	\$ 262,164	\$ 349,884
Cash flows from investing activities:		
Transfers to restricted cash	(69)	(6)
Purchases of investments in debt securities		(279,175)
Proceeds from maturities and sales of investments in debt securities	38,473	1,185,830
Purchases of property, plant and equipment	(29,608)	(45,523)
Proceeds from sale of property and equipment	337	10,390
Proceeds from the sale of Kadian®	59,800	
Acquisition of Alpharma	(70,230)	
Acquisition of Avinza®	(8)	(43)
Forward foreign exchange contracts	(8,906)	
Purchases of intellectual property and product rights	(2,178)	(7,890)
Net cash (used in) provided by investing activities	(12,389)	863,583
Cash flows from financing activities:		
Proceeds from exercise of stock options	1,742	347
Net payments related to stock-based award activity	(3,554)	(2,372)
Payments on long-term debt	(710,429)	
Debt issuance costs	(1,313)	
Net cash used in financing activities	(713,554)	(2,025)
Effect of exchange rate changes on cash	3,535	
(Decrease) increase in cash and cash equivalents	(460,244)	1,211,442
Cash and cash equivalents, beginning of period	940,212	20,009
Cash and cash equivalents, end of period	\$ 479,968	\$ 1,231,451

See accompanying notes.

Table of Contents**KING PHARMACEUTICALS, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****September 30, 2009 and 2008****(In thousands, except share and per share data)****(Unaudited)****1. General**

The accompanying unaudited interim condensed consolidated financial statements of King Pharmaceuticals, Inc. (King or the Company) were prepared by the Company in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and, accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of items of a normal recurring nature) considered necessary for a fair presentation are included. Operating results for the three and nine months ended September 30, 2009 are not necessarily indicative of the results that may be expected for the year ending December 31, 2009. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2008. The year-end condensed balance sheet was derived from the audited consolidated financial statements and has been adjusted to reflect adoption of a Financial Accounting Standards Board (FASB) statement that requires the Company to separately account for the liability and equity components of its \$400,000 11/4% Convertible Senior Notes due April 1, 2026 (the Convertible Senior Notes), but does not include all disclosures required by generally accepted accounting principles. This FASB statement was effective January 1, 2009 and required retrospective application. Please see Note 9 for additional information on its adoption.

These unaudited interim condensed consolidated financial statements include the accounts of King and all of its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

The Company has performed an evaluation of subsequent events through November 5, 2009, which is the date the financial statements were issued.

2. Earnings Per Share

The basic and diluted net income per common share were determined using the following share data:

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2009	2008	2009	2008
Basic net income per common share:				
Weighted average common shares	244,963,911	243,695,777	244,515,264	243,475,338
Diluted net income per common share:				
Weighted average common shares	244,963,911	243,695,777	244,515,264	243,475,338
Effect of stock options	115,844	84,090	47,087	52,631
Effect of dilutive share awards	3,185,797	2,054,129	2,807,487	1,655,874

Edgar Filing: KING PHARMACEUTICALS INC - Form 10-Q

Weighted average common shares	248,265,552	245,833,996	247,369,838	245,183,843
--------------------------------	-------------	-------------	-------------	-------------

For the three months ended September 30, 2009, the weighted average shares that were anti-dilutive, and therefore excluded from the calculation of diluted net income per share, included options to purchase 5,010,109 shares of common stock, and 138,640 long-term performance units (LPU). For the nine months ended September 30, 2009, the weighted average shares that were anti-dilutive, and therefore excluded from the calculation of diluted net income per share included options to purchase 6,356,694 shares of common stock, 202,632 restricted stock awards (RSAs) and 221,362 LPUs. For the three months ended September 30, 2008, the weighted average shares that were anti-dilutive, and therefore excluded from the calculation of diluted net income per share, included options to purchase 6,011,915 shares of common stock, 304,000 RSAs and 268,935 LPUs. For the nine months ended September 30, 2008, the weighted average shares that were anti-dilutive, and therefore

Table of Contents

KING PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

excluded from the calculation of diluted net income per share included options to purchase 5,818,026 shares of common stock, 373,653 RSAs and 455,515 LPUs. The Convertible Senior Notes could be converted into the Company's common stock in the future, subject to certain contingencies. Shares of the Company's common stock associated with this right of conversion were excluded from the calculation of diluted net income per share because these notes are anti-dilutive since the conversion price of the notes was greater than the average market price of the Company's common stock for all periods presented.

3. Skelaxin®

As previously disclosed, the Company has been involved in multiple legal proceedings over patents relating to its product Skelaxin® (metaxalone). In January 2009, the U.S. District Court for the Eastern District of New York issued an order ruling invalid two of these patents. In June 2009, the Court entered judgment against the Company. The Company has appealed the judgment and intends to vigorously defend its interests. The entry of the order may lead to generic versions of Skelaxin® entering the market sooner than previously anticipated, which would likely cause the Company's sales of Skelaxin® to decline significantly. Net sales of Skelaxin® were \$446,243 in 2008, and \$102,080 and \$304,857, respectively, in the three and nine months ended September 30, 2009. For additional information regarding Skelaxin® litigation, please see Note 10. For additional information regarding Skelaxin® intangible assets, please see Note 8. For additional information regarding Skelaxin® restructuring action, please see Note 14.

4. Fair Value Measurements

Cash and Cash Equivalents. The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of September 30, 2009 and December 31, 2008, the Company's cash and cash equivalents consisted of institutional money market funds and bank time deposits. There were no cumulative unrealized holding gains or losses associated with these money market funds and time deposits as of September 30, 2009 and December 31, 2008.

Derivatives. The Company had forward foreign exchange contracts outstanding during the three and nine months of 2009 on certain non-U.S. cash balances. The forward exchange contracts were not designated as hedges. The Company recorded these contracts at fair value and changes in fair value were recognized in current earnings. All foreign exchange contracts expired in the third quarter of 2009.

In connection with the Company's acquisition of Alpharma on December 29, 2008, the Company borrowed \$425,000 in principal under its Senior Secured Revolving Credit Facility (Revolving Credit Facility) as amended on December 5, 2008. The Company also borrowed \$200,000 pursuant to the Senior Secured Term Facility (Term Facility). The terms of the Revolving Credit Facility and the Term Facility require the Company to maintain hedging agreements that will fix the interest rates on 50% of the Company's total outstanding long-term debt beginning 90 days after the amendment to the facility for a period of two years. The Revolving Credit Facility and the Term Facility have variable interest rates. The Convertible Senior Notes of the Company are at a fixed interest rate. Accordingly, in March 2009, the Company entered into an interest rate swap agreement on interest under the Revolving Credit Facility with an aggregate notional amount of \$112,500, which expires in March 2011. The interest rate swap was designated as a cash flow hedge and was being used to offset the overall variability of cash flows. For a cash flow hedge, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income and reclassified into earnings in the period during which the hedged transaction affects earnings. As a result of the

reduction of its variable rate long-term debt, the Company maintains greater than 50% of its outstanding long-term debt at fixed rates and therefore an interest rate swap is no longer required. In September 2009, the Company terminated the interest rate swap for \$838 and recognized the cost as interest expense in the third quarter 2009. For additional information on the Revolving Credit Facility and the Term Facility, please see Note 9.

Table of Contents**KING PHARMACEUTICALS, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The following tables summarize the effect of derivative instruments on the condensed consolidated statements of operations for the three and nine months ended September 30, 2009:

	Three Months Ended September 30, 2009			Nine Months Ended September 30, 2009		
	Gain or (Loss) Reclassified			Gain or (Loss) Reclassified		
Derivatives in Cash Flow Hedging Relationships	Gain or (Loss) in Other Comprehensive Income on Derivative (Effective Portion)	from Accumulated Other Comprehensive Income into Derivative (Effective Portion)	Gain or (Loss) Recorded (Ineffective Portion)	Gain or (Loss) in Other Comprehensive Income on Derivative (Effective Portion)	from Accumulated Other Comprehensive Income into Derivative (Effective Portion)	Gain or (Loss) Recorded (Ineffective Portion)
	Interest rate swap	\$	\$ (232)	\$ (606)	\$	\$ (232)

Derivatives not Designated as Hedging Instruments	Three Months Ended September 30, 2009		Nine Months Ended September 30, 2009	
	Gain or (Loss) Recognized in Income on Derivative Amount		Gain or (Loss) Recognized in Income on Derivative Amount	
Foreign currency contracts			\$ (5,789)	\$ (5,360)
	Other income			

Marketable Securities. As of September 30, 2009 and December 31, 2008, the Company's investment in marketable securities consisted solely of Palatin Technologies, Inc. common stock with a cost basis of \$511. The cumulative unrealized holding gain in this investment as of September 30, 2009 was \$1,419. There were no cumulative unrealized holding gains or losses in this investment as of December 31, 2008.

Investments in Debt Securities. Tax-exempt auction rate securities are long-term variable rate bonds tied to short-term interest rates that are intended to reset through an auction process generally every seven, 28 or 35 days. The Company classifies auction rate securities as available-for-sale at the time of purchase. Temporary gains or losses are included in accumulated other comprehensive income (loss) on the Condensed Consolidated Balance Sheets.

Other-than-temporary credit losses are included in Gain (loss) on investments in the Condensed Consolidated Statements of Operations. Non-credit related other-than-temporary losses are recorded in accumulated other comprehensive income (loss) on the Consolidated Balance Sheets, as the Company has no intent to sell the securities and believes that it is more likely than not that it will not be required to sell the securities prior to recovery.

As of September 30, 2009 and December 31, 2008, the par value of the Company's investments in debt securities was \$377,175 and \$417,075, respectively, and consisted solely of tax-exempt auction rate securities associated with municipal bonds and student loans. The Company has not invested in any mortgage-backed securities or any securities backed by corporate debt obligations. The Company's investment policy requires it to maintain an investment portfolio with a high credit quality. Accordingly, the Company's investments in debt securities were limited to issues which were rated AA or higher at the time of purchase.

On February 11, 2008, the Company began to experience auction failures with respect to its investments in auction rate securities. In the event of an auction failure, the interest rate on the security is reset according to the contractual terms in the underlying indenture. The funds associated with failed auctions will not be accessible until a successful auction occurs, the issuer calls or restructures the underlying security, the underlying security matures or it is purchased by a buyer outside the auction process.

Excluding the municipal bond discussed below, as of September 30, 2009, there were cumulative unrealized holding losses of \$36,961 recorded in accumulated other comprehensive income (loss) on the Condensed Consolidated Balance Sheets associated with investments in debt securities with a par value of \$323,875, which were classified as available for sale. All of these investments in debt securities have been in continuous unrealized

Table of Contents

KING PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

loss positions for greater than twelve months. As of September 30, 2009 the Company believed the decline associated with the underlying securities was temporary and it was probable that the par amount of these auction rate securities would be collectible under their contractual terms.

The Company adopted as of April 1, 2009 a new FASB statement that provides guidance in determining whether impairments in debt securities are other-than-temporary, and modifies the presentation and disclosures surrounding such instruments. During the fourth quarter of 2008, the Company recognized unrealized losses of \$6,832 in other income (expense) for a municipal bond with a par value of \$15,000 for which the holding losses were determined to be other-than-temporary. The Company determined that \$1,042 (or \$646 net-of-tax) of this previously recognized loss was non-credit related. Upon the adoption of this statement, the Company was required to reclassify this non-credit related loss from retained earnings to accumulated other comprehensive income (loss). As of September 30, 2009, there were cumulative unrealized holding gains of \$863 associated with this security recorded in accumulated other comprehensive income (loss) on the Condensed Consolidated Balance Sheets. For the three and nine months ended September 30, 2009, no other-than-temporary impairment losses associated with available for sale investments in debt securities were recognized.

During the second quarter of 2009, the Company sold certain auction rate securities associated with student loans with a par value of \$20,350 for \$18,923 to the issuer and realized a loss of \$1,427 in the Condensed Consolidated Statement of Operations. During the fourth quarter of 2009, the Company received and accepted offers from two separate issuers of certain auction rate securities associated with student loans that were outstanding at September 30, 2009 with par values totaling \$60,900 for \$56,712. The estimated fair market value of these auction rate securities at September 30, 2009 was \$52,320. The unrealized loss of \$8,580 was recorded in accumulated other comprehensive income (loss) on the accompanying Condensed Consolidated Balance Sheet at September 30, 2009 as the Company had no intent to sell and believed it was more likely than not that it would not be required to sell the security prior to recovery. During the fourth quarter of 2009 a realized loss of \$4,188 will be recorded in the Condensed Consolidated Statement of Operations. The Company has not sold any other investments in debt securities below par value during the periods presented in the accompanying Condensed Consolidated Statement of Operations.

During the fourth quarter of 2008, the Company accepted an offer from UBS Financial Services, Inc. (UBS) providing the Company the right to sell at par value certain auction rate securities outstanding at September 30, 2009 with a par value of \$38,300 to UBS during the period from June 30, 2010 to July 2, 2012 (the right). The Company has elected the fair value option to account for this right. As a result, gains and losses associated with this right are recorded in other income (expense) in the Condensed Consolidated Statement of Operations. The value of the right to sell certain auction rate securities to UBS was estimated considering the present value of future cash flows, the fair value of the auction rate security and counterparty risk. As of September 30, 2009 and December 31, 2008, the fair value of the right to sell the auction rate securities to UBS at par was \$3,611 and \$4,024, respectively. With respect to this right, during the third quarter and first nine months of 2009, the Company recognized an unrealized gain of \$44 and an unrealized loss of \$413, respectively, in other income (expense) in the accompanying Condensed Consolidated Statement of Operations.

In addition, during the fourth quarter of 2008, the Company reclassified the auction rate securities that are included in this right from available-for-sale securities to trading securities. As of September 30, 2009 and December 31, 2008, the fair value of the investments in debt securities classified as trading was \$34,671 and \$36,007, respectively. During the third quarter and first nine months of 2009, the Company recognized unrealized gains related to these securities of

\$477 and \$1,014, respectively, in other income (expense) in the accompanying Condensed Consolidated Statement of Operations.

As of September 30, 2009, the Company has classified \$39,624 of auction rate securities as current assets and \$292,034 as long-term assets.

Table of Contents**KING PHARMACEUTICALS, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The following tables summarize the Company's assets and liabilities that are measured at fair value on a recurring basis:

Description	9/30/2009	Fair Value Measurements at 9/30/2009 Using		
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets:				
Money market funds	\$ 463,942	\$ 463,942	\$	\$
U.S. government securities	4,893	4,893		
Marketable securities	1,930	1,930		
Investments in debt securities	331,658			331,658
Right to sell debt securities	3,611			3,611
Total assets	\$ 806,034	\$ 470,765	\$	\$ 335,269

Description	12/31/2008	Fair Value Measurements at 12/31/2008 Using		
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets:				
Money market funds	\$ 833,653	\$ 833,653	\$	\$
Marketable securities	511	511		
Investments in debt securities	360,289		2,400	357,889
Right to sell debt securities	4,024			4,024
Total assets	\$ 1,198,477	\$ 834,164	\$ 2,400	\$ 361,913
Liabilities:				
Forward foreign exchange contracts	\$ 2,582	\$	\$ 2,582	\$

The fair value of marketable securities within the Level 1 classification is based on the quoted price for identical securities in an active market as of the valuation date.

The fair value of investments in debt securities within the Level 2 classification is at par based on public call notices from the issuer of the security.

The fair value of investments in debt securities within the Level 3 classification is based on a trinomial discount model. This model considers the probability at the valuation date of three potential occurrences for each auction event through the maturity date of the security. The three potential outcomes for each auction are (i) successful auction/early redemption, (ii) failed auction and (iii) issuer default. Inputs in determining the probabilities of the potential outcomes include, but are not limited to, the security's collateral, credit rating, insurance, issuer's financial standing, contractual restrictions on disposition and the liquidity in the market. The fair value of each security is determined by summing the present value of the probability-weighted future principal and interest payments determined by the model. As of September 30, 2009, the Company assumed a weighted average discount rate of approximately 4.5% and an expected term of approximately three to five years. The discount rate was determined as the loss-adjusted required rate of return using public information such as spreads on near-risk free to risk free assets. The expected term is based on the Company's estimate of future liquidity as of September 30, 2009. Transfers out of Level 3 classification occur only when public call notices have been announced by the issuer prior to the date of the valuation.

Table of Contents**KING PHARMACEUTICALS, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The following table provides a reconciliation of assets measured at fair value on a recurring basis using significant unobservable inputs (Level 3):

	2009	2008
Beginning balance, January 1	\$ 361,913	\$
Total gains or losses (realized/unrealized)		
Included in earnings	(823)	
Included in other comprehensive income (loss)	(4,300)	(28,418)
Settlements	(8,000)	(154,950)
Transfers in and/or out of Level 3	1,700	724,725
Ending balance, March 31	\$ 350,490	\$ 541,357
Total gains or losses (realized/unrealized)		
Included in earnings	(524)	
Included in other comprehensive income (loss)	13,781	(5,648)
Settlements	(25,650)	(151,425)
Transfers in and/or out of Level 3	700	31,675
Ending balance, June 30	\$ 338,797	\$ 415,959
Total gains or losses (realized/unrealized)		
Included in earnings	521	
Included in other comprehensive income (loss)	2,201	11,476
Settlements	(6,250)	(11,700)
Transfers in and/or out of Level 3		
Ending balance, September 30	\$ 335,269	\$ 415,735

5. Inventories

Inventories consist of the following:

	September 30, 2009	December 31, 2008
Raw materials	\$ 83,550	\$ 82,273
Work-in-process	29,005	62,836
Finished goods (including \$6,187 and \$7,385 of sample inventory, respectively)	150,982	176,582

Inventory valuation allowance	263,537 (55,887)	321,691 (63,388)
Total inventories	\$ 207,650	\$ 258,303

6. Property, Plant and Equipment

During the first quarter of 2009, the Company classified as held for sale a pharmaceutical manufacturing facility which was acquired as a result of the acquisition of Alpharma Inc. The manufacturing facility is recorded at estimated fair value less cost to sell. The Company finalized its determination of fair value of this asset in the first quarter of 2009, reduced the value by \$3,600 and adjusted goodwill accordingly.

Table of Contents**KING PHARMACEUTICALS, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The net book value of some of the Company's manufacturing facilities currently exceeds fair market value. Management currently believes that the long-term assets associated with these facilities are not impaired based on estimated undiscounted future cash flows. However, if the Company were to approve a plan to sell or close any of the facilities for which the carrying value exceeds fair market value, the Company would have to write off a portion of the assets or reduce the estimated useful life of the assets which would accelerate depreciation.

7. Acquisitions, Dispositions, Co-Promotions and Alliances

On December 29, 2008, the Company completed its acquisition of Alpharma Inc. (Alpharma). Alpharma had a growing specialty pharmaceutical franchise in the U.S. pain market with its Flector® Patch (diclofenac epolamine topical patch) 1.3% and a pipeline of new pain medicines led by Embeda™. Alpharma is also a provider of medicated feed additives and water-soluble therapeutics used primarily for poultry, cattle and swine. The Company paid a cash price of \$37.00 per share for the outstanding shares of Class A Common Stock, together with the associated preferred stock purchase rights of Alpharma, totaling approximately \$1,527,354, \$61,120 associated with Alpharma employee stock-based awards (which were paid in the first quarter of 2009), and incurred \$30,430 of expenses related to the transaction, resulting in a total purchase price of \$1,618,904. Contemporaneously with the acquisition of Alpharma and in accordance with a consent order with the U.S. Federal Trade Commission (the FTC), the Company divested Alpharma's Kadian® assets to Actavis Elizabeth, L.L.C. (Actavis LLC).

Management believes the Company's acquisition of Alpharma is particularly significant because it strengthens King's portfolio and development pipeline of pain management products and increases its capabilities and expertise in this market. The development pipeline provides the Company with both near-term and long-term revenue opportunities and Alpharma's animal health business further diversifies King's revenue base. As a result, management believes the acquisition of Alpharma improves the Company's foundation for sustainable, long-term growth.

The accompanying Condensed Consolidated Statement of Operations for the three- and nine-months ended September 30, 2008 do not include any activity for Alpharma because the Company acquired Alpharma in the fourth quarter of 2008.

The allocation of the initial purchase price and acquisition costs is as follows:

	Valuation
Current assets	\$ 915,296
Current deferred income taxes	31,589
Property, plant and equipment	157,649
Intangible assets, net	300,000
Goodwill	323,858
In-process research and development	590,000
Other long-term assets	26,679
Current liabilities	(268,636)
Convertible debentures	(385,227)
Long-term deferred income taxes	(22,005)

Other long-term liabilities	(50,299)
Total purchase price	\$ 1,618,904

Table of Contents**KING PHARMACEUTICALS, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The valuation of the intangible assets acquired is as follows:

	Valuation	Weighted Average Amortization Period
Flector® Patch	\$ 130,000	11 years
Animal Health intangibles	170,000	19 years
Total	\$ 300,000	

None of the goodwill is expected to be deductible for tax purposes. The goodwill has been allocated to the Company's segments as follows:

Branded prescription pharmaceuticals	\$ 235,561
Animal Health	88,297
Total	\$ 323,858

The above allocation of the purchase price is not yet finalized as the acquisition was completed close to the end of 2008 and management is continuing its initial estimate of the valuation of certain assets and liabilities. The most significant valuation estimates that remain open as of September 30, 2009 are related to certain tax assets and liabilities, fixed assets, and a lease liability.

The acquisition was financed with available cash on hand, borrowings under the Revolving Credit Facility of \$425,000 and borrowings under the Term Facility of \$200,000. For additional information on the borrowings, please see Note 9.

As indicated above, \$590,000 of the purchase price for Alpharma was allocated to acquired in-process research and development for the Embeda™, Oxycodone NT and Hydrocodone NT projects in the amounts of \$410,000, \$90,000 and \$90,000, respectively. The value of the acquired in-process research and development projects was expensed on the date of acquisition, as they had not received regulatory approval at the time of the acquisition and had no alternative future use. The projects were valued through the application of probability-weighted, discounted cash flow approach. The estimated cash flows were projected over periods of 10 to 14 years utilizing a discount rate of 25% to 30%.

In August 2009, the U.S. Food and Drug Administration (FDA) approved Embeda (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules, a long-acting Schedule II opioid analgesic for the management of moderate-to-severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

Oxycodone NT and Hydrocodone NT are long-acting opioids for the treatment of moderate to severe chronic pain that are in the early stages of clinical development. These products are designed to resist certain common methods of misuse and abuse associated with currently available oxycodone and hydrocodone opioids. If the clinical development program is successful, the Company would not expect to commercialize Oxycodone NT any sooner than 2012 and Hydrocodone NT any sooner than 2015. The estimated cost to complete the development of Oxycodone NT and Hydrocodone NT is approximately \$35,000 each. The Company believes there is a reasonable probability of completing these projects successfully, but the success of the projects depends on the outcome of the clinical development programs and approval by the FDA.

Table of Contents**KING PHARMACEUTICALS, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The following unaudited pro forma summary presents the financial information as if the acquisition of Alpharma had occurred January 1, 2008 for the three and nine months ended September 30, 2008. These pro forma results have been prepared for comparative purposes and do not purport to be indicative of the Company's financial results had the acquisition been made on January 1, 2008, nor are they indicative of future results. The pro forma results for the nine months ended September 30, 2008 do not include the \$590,000 in-process research and development expense noted above.

	Three Months Ended September 30, 2008	Nine Months Ended September 30, 2008
Total revenues	\$ 513,001	\$ 1,581,042
Income from continuing operations	\$ 58,521	\$ 62,442
Net income	\$ 58,521	\$ 266,131
Basic net income per common share	\$ 0.24	\$ 1.09
Diluted net income per common share	\$ 0.24	\$ 1.09

In connection with the acquisition of Alpharma, the Company and Alpharma executed a consent order (the Consent Order) with the FTC. The Consent Order required the Company to divest the assets related to Alpharma's branded oral long-acting opioid analgesic drug Kadian® to Actavis LLC. In accordance with the Consent Order, effective upon the acquisition of Alpharma, on December 29, 2008, the Company divested the Kadian® product to Actavis LLC. Actavis LLC is entitled to sell Kadian® as a branded or generic product. Prior to the divestiture, Actavis LLC supplied Kadian® to Alpharma.

Actavis LLC will pay a purchase price of up to an aggregate of \$127,500 in cash based on the achievement of certain Kadian® quarterly gross profit-related milestones for the period beginning January 1, 2009 and ending June 30, 2010. The maximum purchase price payment associated with each calendar quarter is as follows:

	Maximum Purchase Price Payment
First Quarter 2009	\$ 30,000
Second Quarter 2009	\$ 25,000
Third Quarter 2009	\$ 25,000
Fourth Quarter 2009	\$ 20,000
First Quarter 2010	\$ 20,000
Second Quarter 2010	\$ 7,500

None of the quarterly payments above, when combined with all prior payments made by Actavis LLC, shall exceed the aggregate amount of gross profits from the sale of Kadian® in the United States by Actavis LLC and its affiliates for the period beginning on January 1, 2009 and ending on the last day of such calendar quarter. Any quarterly purchase price payment that is not paid by Actavis LLC due to the application of such provision will be carried

forward to the next calendar quarter, increasing the maximum quarterly payment in the subsequent quarter. However, the cumulative purchase price payable by Actavis LLC will not exceed the lesser of (a) \$127,500 and (b) the gross profits from the sale of Kadian® in the United States by Actavis LLC and its affiliates for the period from January 1, 2009 through June 30, 2010. The Company recorded a receivable of \$115,000 at the time of the divestiture, reflecting the present value of the estimated future purchase price payments from Actavis LLC. There was no gain or loss recorded as a result of the divestiture. In accordance with the agreement, quarterly payments will be received one quarter in arrears. During the third quarter of 2009 the Company received \$25,000 from Actavis LLC related to the second quarter of 2009 gross profit from sales. During the first nine months of 2009 the Company received \$59,800 from Actavis LLC, \$55,000 related to gross profit from sales during the first and second quarters of 2009 and \$4,800 related to inventory sold to Actavis LLC at the time of the divestiture.

Table of Contents**KING PHARMACEUTICALS, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****8. Intangible Assets and Goodwill**

Intangible assets consist primarily of patents, licenses, trademarks and product rights. A summary of the gross carrying amount and accumulated amortization is as follows:

	September 30, 2009		December 31, 2008	
	Gross Carrying Amount	Accumulated Amortization	Gross Carrying Amount	Accumulated Amortization
Branded prescription pharmaceuticals	\$ 1,252,300	\$ 727,881	\$ 1,252,300	\$ 627,233
Animal Health	170,000	7,167	170,000	
Meridian Auto-Injector	182,587	47,480	179,879	41,281
Royalties	3,731	3,501	3,731	3,177
Total intangible assets	\$ 1,608,618	\$ 786,029	\$ 1,605,910	\$ 671,691

Amortization expense for the three months ended September 30, 2009 and 2008 was \$38,011 and \$20,240, respectively. Amortization expense for the nine months ended September 30, 2009 and 2008 was \$114,338 and \$92,211, respectively.

In January 2009, the U.S. District Court for the Eastern District of New York issued an order ruling invalid two Skelaxin® patents. In June 2009, the Court entered judgment against the Company. The Company has appealed, and intends to vigorously defend its interests. The entry of the order may lead to generic versions of Skelaxin® entering the market sooner than previously anticipated, which would likely cause the Company's sales of Skelaxin® to decline significantly. The Company believes that the intangible assets associated with Skelaxin® are not currently impaired based on estimated undiscounted cash flows associated with these assets. However, as a result of the order described above, the Company reduced the estimated remaining useful life of the intangible assets of Skelaxin® during the first quarter of 2009. If the Company's current estimates regarding future cash flows adversely change, the Company may have to further reduce the estimated remaining useful life and/or write off a portion or all of these intangible assets. As of September 30, 2009, the net intangible assets associated with Skelaxin® totaled approximately \$56,856. For additional information regarding Skelaxin® litigation, please see Note 10.

In April 2009, a competitor entered the market with a generic substitute for Cytomel®. As a result, the Company lowered its future sales forecast for this product. As of September 30, 2009, the net intangible assets associated with Cytomel® totaled approximately \$10,607. The Company believes that the intangible assets associated with Cytomel® are not currently impaired based on estimated undiscounted cash flows associated with these assets. However, if the Company's current estimates regarding future cash flows adversely change, the Company may have to reduce the estimated remaining useful life and/or write off a portion or all of these intangible assets.

As a result of a decline in end-user demand for Synercid[®], the Company lowered its future sales forecast for this product, which decreased the estimated undiscounted future cash flows associated with the Synercid[®] intangible assets to a level below their carrying value. Accordingly, the Company recorded an intangible asset impairment charge of \$38,064 during the second quarter of 2008 to adjust the carrying value of the Synercid[®] intangible assets on the Company's balance sheet to reflect the estimated fair value of these assets. The Company determined the fair value of the intangible assets associated with Synercid[®] based on its estimated discounted future cash flows. Synercid[®] is included in the Company's branded pharmaceutical segment. If the Company's current estimates regarding future cash flows adversely change, the Company may have to reduce the estimated remaining useful life and/or write off an additional portion of the intangible assets. As of September 30, 2009, the net intangible assets associated with Synercid[®] totaled approximately \$24,555.

Table of Contents**KING PHARMACEUTICALS, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Goodwill at September 30, 2009 and December 31, 2008 is as follows:

	Branded Segment	Animal Health Segment	Meridian Segment	Total
Goodwill at December 31, 2008	\$ 258,092	\$ 84,046	\$ 108,410	\$ 450,548
Adjustment to Alharma acquisition	(1,791)	4,251		2,460
Goodwill at September 30, 2009	\$ 256,301	\$ 88,297	\$ 108,410	\$ 453,008

The adjustment to goodwill is due to management's continuing initial estimation of the valuation of certain assets and liabilities related to the Alharma acquisition. During the third quarter of 2009, the Company recorded a reserve of \$42,500 related to an agreement in principle with the U.S. Department of Justice (DOJ) as an adjustment to goodwill associated with the purchase of Alharma. Evaluation of the DOJ investigation and therefore the allocation period associated with this preacquisition contingency continued into the third quarter of 2009. For additional information regarding the DOJ investigation, please see Note 10.

During the first quarter of 2009, the Company recorded an additional deferred tax asset of \$28,856 as an adjustment to goodwill associated with the purchase of Alharma, for which management obtained additional information about the status of these assets as of the acquisition date.

9. Long-Term Debt

Long-term debt consists of the following:

	September 30, 2009	December 31, 2008
Convertible senior notes	\$ 327,713	\$ 314,416
Senior secured revolving credit facility	272,231	425,000
Senior secured term facility	28,409	192,042
Alharma convertible senior notes		385,227
Total long-term debt	628,353	1,316,685
Less current portion	122,449	439,047
Long-term portion	\$ 505,904	\$ 877,638

Convertible Senior Notes

Effective January 1, 2009, the Company adopted the new FASB statement that requires the liability and equity components of convertible debt instruments that may be settled in cash upon conversion (including partial cash settlement) be separately accounted for in a manner that reflects an issuer's nonconvertible debt borrowing rate. This statement requires retrospective application to all periods presented.

The separate components of debt and equity of the Company's Convertible Senior Notes were determined using an interest rate of 7.13%, which reflects the nonconvertible debt borrowing rate of the Company at the date of issuance. As a result, the initial components of debt and equity were \$271,267 and \$128,733, respectively. The debt component is being amortized retrospectively beginning April 1, 2006 through March 31, 2013.

Table of Contents**KING PHARMACEUTICALS, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The following tables reflect the changes in the Company's previously reported results due to the adoption of this FASB statement:

**Condensed Consolidated Statement of Operations
Three months ended September 30, 2008**

	As Currently Reported	As Reported Prior to Adoption	Effect of Change
Depreciation and amortization	\$ 29,894	\$ 29,695	\$ 199
Total operating costs and expenses	265,645	265,446	199
Operating income	122,800	122,999	(199)
Interest expense	(5,300)	(1,828)	(3,472)
Total other income	1,786	5,258	(3,472)
Income before income taxes	124,586	128,257	(3,671)
Income tax expense	42,114	43,507	(1,393)
Net income	\$ 82,472	\$ 84,750	\$ (2,278)
Income per common share:			
Basic net income per common share	\$ 0.34	\$ 0.35	\$ (0.01)
Diluted net income per common share	\$ 0.34	\$ 0.34	\$ (0.00)
Total comprehensive income	\$ 88,905	\$ 91,183	\$ (2,278)

**Condensed Consolidated Statement of Operations
Nine months ended September 30, 2008**

	As Currently Reported	As Reported Prior to Adoption	Effect of Change
Depreciation and amortization	\$ 121,749	\$ 121,198	\$ 551
Total operating costs and expenses	915,593	915,042	551
Operating income	301,736	302,287	(551)
Interest expense	(15,571)	(5,470)	(10,101)
Total other income	13,578	23,679	(10,101)
Income before income taxes	315,314	325,966	(10,652)
Income tax expense	106,525	110,562	(4,037)

Edgar Filing: KING PHARMACEUTICALS INC - Form 10-Q

Net income	\$	208,789	\$	215,404	\$	(6,615)
Income per common share:						
Basic net income per common share	\$	0.86	\$	0.88	\$	(0.02)
Diluted net income per common share	\$	0.85	\$	0.88	\$	(0.03)
Total comprehensive income	\$	193,874	\$	200,489	\$	(6,615)

Table of Contents**KING PHARMACEUTICALS, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Condensed Consolidated Balance Sheet
As of December 31, 2008**

	As Currently Reported	As Reported Prior to Adoption	Effect of Change
Property, plant and equipment, net	\$ 417,259	\$ 409,821	\$ 7,438
Deferred income tax assets	267,749	303,722	(35,973)
Other assets	122,826	124,774	(1,948)
Total assets	4,227,213	4,257,696	(30,483)
Long-term debt	877,638	963,222	(85,584)
Total liabilities	1,994,781	2,080,365	(85,584)
Retained earnings	871,021	892,297	(21,276)
Shareholders' equity	2,232,432	2,177,331	55,101
Total liabilities and shareholders' equity	4,227,213	4,257,696	(30,483)

The Company's previously reported results as of December 31, 2007 reflect a change of \$76,377 in Shareholders' equity and a change of \$(12,303) in Retained earnings.

A summary of the gross carrying amount, unamortized debt cost and the net carrying value of the liability component of the Convertible Senior Notes are as follows:

	September 30, 2009	December 31, 2008
Gross carrying amount	\$ 400,000	\$ 400,000
Unamortized debt discount	72,287	85,584
Net carrying amount	\$ 327,713	\$ 314,416

During the first quarter of 2009, Alpharma and its U.S. subsidiaries became guarantors of the Convertible Senior Notes.

The fair value of the Company's Convertible Senior Notes at September 30, 2009 and December 31, 2008 was approximately \$344,000 and \$293,000, respectively, using quoted market prices.

Senior Secured Revolving Credit Facility

During the three and nine months ended September 30, 2009, the Company made payments of \$18,584 and \$152,769, respectively, on the Revolving Credit Facility, \$91,322 in excess of that required by the terms of the Revolving Credit

Facility during the nine months ended September 30, 2009.

The availability for borrowing under the Revolving Credit Facility was reduced to \$336,511 as of September 30, 2009. The remaining undrawn commitment amount under the Revolving Credit Facility totals approximately \$61,315 after giving effect to outstanding letters of credit totaling \$2,965.

In connection with the borrowings, the Company incurred approximately \$22,219 of deferred financing costs that are being amortized ratably through the maturity date.

The fair value of the Revolving Credit Facility approximates its carrying value. Changes in interest rates are reflected in earnings and cash flow from operations.

Senior Secured Term Facility

During the three and nine months ended September 30, 2009, the Company made payments of \$105,489 and \$171,305, respectively, on the Term Facility, \$97,611 and \$131,515, respectively, in excess of that required by the repayment schedule and the provisions related to mandatory prepayments under the Senior Secured Term Facility.

Table of Contents

KING PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

In connection with the borrowings, the Company incurred approximately \$8,738 of deferred financing costs that were amortized ratably from the date of the borrowing based on the Company's repayments.

The fair value of the Term Facility approximates its carrying value. Changes in interest rates are reflected in earnings and cash flow from operations.

In October 2009, the Company paid the outstanding balance of the Term Facility, of \$28,695, completing its repayment obligations under the facility.

Alpharma Convertible Senior Notes

At the time of the acquisition of Alpharma by the Company, Alpharma had \$300,000 of Convertible Senior Notes outstanding (Alpharma Notes). The Alpharma Notes were convertible into shares of Alpharma's Class A common stock at an initial conversion rate of 30.6725 Alpharma common shares per \$1,000 principal amount. The conversion rate of the Alpharma Notes was subject to adjustment upon the direct or indirect sale of all or substantially all of Alpharma's assets or more than 50% of the outstanding shares of the Alpharma common stock to a third party (a Fundamental Change). In the event of a Fundamental Change, the Alpharma Notes included a make-whole provision that adjusted the conversion rate by a predetermined number of additional shares of Alpharma's common stock based on (1) the effective date of the Fundamental Change and (2) Alpharma's common stock market price as of the effective date. The acquisition of Alpharma by the Company was a Fundamental Change. As a result, any Alpharma Notes converted in connection with the acquisition of Alpharma were entitled to be converted at an increased rate equal to the value of 34.7053 Alpharma common shares, at the acquisition price of \$37 per share, per \$1,000 principal amount of Alpharma Notes, at a date no later than 35 trading days after the occurrence of the Fundamental Change. During the first quarter of 2009, the Company paid \$385,227 to redeem the Alpharma Notes.

10. Commitments and Contingencies

Intellectual Property Matters

Altace®

Lupin Ltd. (Lupin) filed an Abbreviated New Drug Application (ANDA) with the FDA seeking permission to market a generic version of Altace®. In addition to its ANDA, Lupin filed a Paragraph IV certification challenging the validity and infringement of U.S. Patent No. 5,061,722 (the '722 patent'), a composition of matter patent covering Altace®, and seeking to market its generic version of Altace® before expiration of the '722 patent. The companies litigated the matter, and the court ultimately invalidated the Company's '722 patent. On June 9, 2008, Lupin received approval from the FDA to market its generic ramipril product.

The Company was previously involved in patent infringement litigation with Cobalt Pharmaceuticals, Inc. (Cobalt), a generic drug manufacturer located in Mississauga, Ontario, Canada, regarding an ANDA it filed with the FDA seeking permission to market a generic version of Altace®. The parties submitted a joint stipulation of dismissal on April 4, 2006, and the Court granted dismissal. Following the court's decision in the Company's litigation with Lupin, Cobalt launched a generic substitute for Altace® in December 2007. A number of other competitors launched generic substitutes for Altace® in June 2008.

On August 2, 2006 and August 2, 2007, the Company received civil investigative demands (CIDs) for information from the FTC. The CIDs required the Company to provide information related to the Company s collaboration with Arrow International Limited (Arrow) to develop novel formulations of Altac, the dismissal without prejudice of the Company s patent infringement litigation against Cobalt under the Hatch-Waxman Act of

Table of Contents**KING PHARMACEUTICALS, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

1984 and other information. Arrow and Cobalt are affiliates of one another. The Company is cooperating with the FTC in this investigation.

Skelaxin[®]

Eon Labs, Inc. (Eon Labs), CorePharma, LLC (Core) and Mutual Pharmaceutical Co., Inc. (Mutual) each filed an ANDA with the FDA seeking permission to market a generic version of Skelaxin[®] 400 mg tablets. Additionally, Eon Labs ANDA seeks permission to market a generic version of Skelaxin[®] 800 mg tablets. United States Patent Nos. 6,407,128 (the 128 patent) and 6,683,102 (the 102 patent), two method-of-use patents relating to Skelaxin listed in the FDA's Orange Book and do not expire until December 3, 2021. Eon Labs and Core each filed Paragraph IV certifications against the 128 and 102 patents alleging noninfringement, invalidity and unenforceability of those patents. Mutual has filed a Paragraph IV certification against the 102 patent alleging noninfringement and invalidity of that patent. A patent infringement suit was filed against Eon Labs on January 2, 2003 in the U.S. District Court for the Eastern District of New York; against Core on March 7, 2003 in the U.S. District Court for the District of New Jersey (subsequently transferred to the U.S. District Court for the Eastern District of New York); and against Mutual on March 12, 2004 in the U.S. District Court for the Eastern District of Pennsylvania, concerning their proposed 400 mg products. Additionally, the Company filed a separate suit against Eon Labs on December 17, 2004 in the U.S. District Court for the Eastern District of New York, concerning its proposed generic version of the 800 mg Skelaxin[®] product. On May 17, 2006, the U.S. District Court for the Eastern District of Pennsylvania placed the Mutual case on the Civil Suspense Calendar pending the outcome of the FDA activity described below. On June 16, 2006, the U.S. District Court for the Eastern District of New York consolidated the Eon Labs cases with the Core case. In January 2008, the Company entered into an agreement with Core providing it with, among other things, the right to launch an authorized generic version of Skelaxin[®] pursuant to a license in December 2012 or earlier under certain conditions. On January 8, 2008, the Company and Core submitted a joint stipulation of dismissal without prejudice. On January 15, 2008, the Court entered an order dismissing the case without prejudice.

Pursuant to the Hatch-Waxman Act, the filing of the suits against Eon Labs provided the Company with an automatic stay of FDA approval of Eon Labs ANDA for its proposed 400 mg and 800 mg products for 30 months (unless the patents are held invalid, unenforceable or not infringed) from no earlier than November 18, 2002 and November 3, 2004, respectively. The 30-month stay of FDA approval for Eon Labs ANDA for its proposed 400 mg product expired in May 2005 and Eon Labs subsequently withdrew its 400 mg ANDA in September 2006. The 30-month stay of FDA approval for Eon Labs 800 mg product was tolled by the Court from January 10, 2005 to April 30, 2007, and the stay expired in early August 2009. On April 30, 2007, Eon Labs 400 mg case was dismissed without prejudice, although Eon Labs claim for fees and expenses was severed and consolidated with Eon Labs 800 mg case. On August 27, 2007, Eon Labs served a motion for summary judgment on the issue of infringement. The Court granted the Company discovery for purposes of responding to Eon's motion until March 14, 2008 and set a briefing schedule. On March 7, 2008, the Company filed a letter with the Court regarding Eon Labs inability to adhere to the discovery schedule and the Court took Eon Labs motion for summary judgment on the issue of infringement off the calendar. Subsequently, Eon Labs filed an amended motion for summary judgment on the issue of infringement on April 4, 2008. Eon Labs also filed a motion for summary judgment on the issue of validity on April 16, 2008. On May 8, 2008, Eon Labs filed amended pleadings. On May 22, 2008, the Company moved to dismiss certain defenses and counterclaims. On June 6, 2008, the Company responded to Eon Labs motion for summary judgment on the issue of validity. On January 20, 2009, the Court issued an order ruling invalid the 128 and 102 patents. The order was issued without the benefit of a hearing in response to Eon Labs motion for summary judgment. The order also allowed Eon Labs to pursue its claim

for exceptional case, and on March 31, 2009, Eon Labs filed its motion for this purpose, which was opposed by the Company and Elan Pharmaceuticals, Inc. (Elan). Eon Labs has replied and the motion remains pending before the Court. On May 20, 2009, Eon Labs asked for entry of final judgment, and on June 4, 2009, the Court granted this request. On July 1, 2009, the Company filed a notice of appeal of the Court s entry of judgment and on July 2, 2009, Elan did the same. The appeals were docketed by the Federal Circuit on July 10, 2009. In late July 2009, the companies moved to dismiss the appeals for lack of jurisdiction. On September 30, 2009, the Federal Circuit denied the

Table of Contents

KING PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

motions to dismiss. The Company and Elan have until November 2009 to file opening appeal briefs. The Company intends to vigorously defend its interests.

On December 5, 2008, the Company, along with co-plaintiff Pharmaceutical IP Holding, Inc. (PIH) initiated suit in the U.S. District Court of New Jersey against Sandoz, Inc. (Sandoz) for infringement of U.S. Patent No. 7,122,566 (the 566 patent). The 566 patent is a method-of-use patent relating to Skelaxin[®] listed in the FDA's Orange Book; it expires on February 6, 2026. The 566 patent is owned by PIH and licensed to the Company. The Company and PIH sued Sandoz, alleging that Eon Labs' submission of its ANDA seeking approval to sell a generic version of a 800 mg Skelaxin[®] tablet prior to the expiration of the 566 patent constitutes infringement of the patent. Sandoz, which acquired Eon Labs, is the named owner of Eon Labs' ANDA and filed a Paragraph IV certification challenging the validity and alleging non-infringement of the 566 patent. On January 13, 2009, Sandoz answered the complaint and filed counterclaims of invalidity and non-infringement. The Company filed a reply on February 5, 2009. The parties are currently conducting fact discovery.

On March 9, 2004, the Company received a copy of a letter from the FDA to all ANDA applicants for Skelaxin[®] stating that the use listed in the FDA's Orange Book for the 128 patent may be deleted from the ANDA applicants product labeling. The Company believes that this decision is arbitrary, capricious and inconsistent with the FDA's previous position on this issue. The Company filed a Citizen Petition on March 18, 2004 (supplemented on April 15, 2004 and on July 21, 2004), requesting the FDA to rescind that letter, require generic applicants to submit Paragraph IV certifications for the 128 patent and prohibit the removal of information corresponding to the use listed in the Orange Book. The Company concurrently filed a petition for stay of action requesting the FDA to stay approval of any generic Skelaxin[®] products until the FDA has fully evaluated the Company's Citizen Petition.

On March 12, 2004, the FDA sent a letter to the Company explaining that the Company's proposed labeling revision for Skelaxin[®], which includes references to additional clinical studies relating to food, age and gender effects, was approvable and only required certain formatting changes. On April 5, 2004, the Company submitted amended labeling text that incorporated those changes. On April 5, 2004, Mutual filed a petition for stay of action requesting the FDA to stay approval of the Company's proposed labeling revision until the FDA has fully evaluated and ruled upon the Company's Citizen Petition, as well as all comments submitted in response to that petition. The Company, CorePharma and Mutual have filed responses and supplements to their pending Citizen Petitions and responses. On December 8, 2005, Mutual filed another supplement with the FDA in which it withdrew its prior petition for stay, supplement and opposition to the Company's Citizen Petition. On November 24, 2006, the FDA approved the revision to the Skelaxin[®] labeling. On February 13, 2007, the Company filed another supplement to the Company's Citizen Petition to reflect FDA approval of the revision to the Skelaxin[®] labeling. On May 2, 2007, Mutual filed comments in connection with the Company's supplemental submission. These issues are pending. On July 27, 2007 and January 24, 2008, Mutual filed two other Citizen Petitions in which it seeks a determination that Skelaxin[®] labeling should be revised to reflect the data provided in its earlier submissions. These petitions were denied on July 18, 2008.

Net sales of Skelaxin[®] were \$446,243 in 2008 and \$102,080 and \$304,857, respectively, in the three and nine months ended September 30, 2009. As of September 30, 2009, the Company had net intangible assets related to Skelaxin[®] of \$56,856. If a generic version of Skelaxin[®] enters the market, the Company may have to write off a portion or all of these intangible assets, and the Company's business, financial condition, results of operations and cash flows could be materially adversely affected. See Note 8 for information regarding the Skelaxin[®] intangible assets.

Avinza[®]

Actavis, Inc. (Actavis) filed an ANDA with the FDA seeking permission to market a generic version of Avinza[®]. U.S. Patent No. 6,066,339 (the 399 patent) is a formulation patent relating to Avinza[®] that is listed in the Orange Book and expires on November 25, 2017. Actavis filed a Paragraph IV certification challenging the validity and alleging non-infringement of the 339 patent, and the Company and Elan Pharma International LTD (EPI), the owner of the 339 patent, filed suit on October 18, 2007 in the U.S. District Court for the District of New Jersey to defend the rights under the patent. Pursuant to the Hatch-Waxman Act, the filing of the lawsuit against Actavis

Table of Contents**KING PHARMACEUTICALS, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

provided the Company with an automatic stay of FDA approval of Actavis' ANDA for up to 30 months (unless the patent is held invalid, unenforceable or not infringed) from no earlier than September 4, 2007. On November 18, 2007, Actavis answered the complaint and filed counterclaims of non-infringement and invalidity. The Company and EPI filed a reply on December 7, 2007. The initial scheduling conference was held on March 11, 2008. Fact discovery is largely complete and the parties continue to await a hearing date for claim construction.

Sandoz filed an ANDA with the FDA seeking permission to market generic versions of Avinza at the 30 mg and 120 mg dosages and provided the Company with a Paragraph IV certification challenging the validity and alleging non-infringement of the 339 patent. The Company and EPI filed suit on July 21, 2009 in the U.S. District Court for the District of New Jersey to defend the rights under the patent. Pursuant to the Hatch-Waxman Act, the filing of the lawsuit against Sandoz provided the Company with an automatic stay of FDA approval of Sandoz's ANDA for up to 30 months (unless the patent is held invalid, unenforceable or not infringed) from no earlier than June 11, 2009. Sandoz subsequently sent the Company and EPI a second Paragraph IV certification adding the 45 mg, 60 mg, 75 mg and 90 mg dosages. The Company and EPI initiated another suit against Sandoz in New Jersey on September 1, 2009. On October 2, 2009, Sandoz answered the complaints and filed counterclaims of non-infringement and invalidity. The Company and EPI filed a reply on October 22, 2009.

The Company intends to vigorously defend its rights under the 339 patent. Net sales of Avinza® were \$135,452 in 2008 and \$30,774 and \$98,646, respectively, in the three and nine months ended September 30, 2009. As of September 30, 2009, the Company had net intangible assets related to Avinza® of \$216,852. If a generic form of Avinza® enters the market, the Company may have to write off a portion or all of these intangible assets, and the Company's business, financial condition, results of operations and cash flows could be otherwise materially adversely affected.

Adenoscan®

On February 15, 2008, the Company, along with co-plaintiffs Astellas US LLC and Astellas Pharma US, Inc. (collectively Astellas), and Item Development AB (Item) initiated suit in the U.S. District Court for the Central District of California against Anazao Health Corp. (Anazao), NuView Radiopharmaceuticals, Inc. (NuView), Paul J. Crowe (Crowe) and Keith Rustvold (Rustvold) for the unauthorized sale and attempted sale of generic adenosine to hospitals and outpatient imaging clinics for use in Myocardial Perfusion Imaging procedures for an indication that has not been approved by the FDA. On July 2, 2008, plaintiffs filed a notice of dismissal as to Anazao. The Company and co-plaintiffs have alleged infringement of U.S. Patent Nos. 5,731,296 (the 296 patent) and 5,070,877 (the 877 patent), which cover a method of using adenosine in Myocardial Perfusion Imaging and which Astellas sells under the tradename Adenoscan®; unfair competition in violation of the California Business and Professions Code, and violations of various other sections of the California Business and Professions Code, concerning the labeling, advertising and dispensing of drugs; and intentional interference with Company and co-plaintiffs' prospective economic advantage. On June 30, 2008, NuView, Crowe and Rustvold filed an answer raising defenses and counterclaims of non-infringement, invalidity, unenforceability due to inequitable conduct and patent misuse, and unfair competition under California state law. On August 28, 2008, the Company filed a reply. On November 20, 2008, the Company and other plaintiffs amended their complaint to add MTS Health Supplies, Inc., Nabil Saba and Ghassan Salaymeg (collectively, MTS) as defendants. On November 21, 2008, defendant NuView amended its answer and counterclaims to allege patent misuse antitrust violations by plaintiffs. On April 10, 2009, a Final Judgment and Injunction on Consent was entered by the Court against NuView, Crowe and Rustvold. On April 13,

2009, the Court entered a Final Judgment and Injunction on Consent against all remaining defendants and terminated the action.

Epi-Pen

On November 11, 2008, the Company was granted U.S. Patent 7,449,012 (the 012 patent) covering the next generation autoinjector (NGA) for use with epinephrine to be sold under the Epi-Pen brand name. The 012 patent expires September 11, 2025. The 012 patent was listed in FDA s Orange Book on July 17, 2009 under the Epi-Pen NDA. On July 21, 2009, the Company received a Paragraph IV certification from Teva Pharmaceutical Industries

Table of Contents

KING PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Ltd. (Teva) giving notice that it had filed an ANDA to commercialize an epinephrine injectable product and challenging the validity and alleging non-infringement of the 012 patent. On August 28, 2009, the Company filed suit against Teva in the U.S. Court for the District of Delaware to defend its rights under the 012 patent. On October 21, 2009, Teva filed its answer asserting non-infringement and invalidity of the 012 patent.

Embedatm

On November 17, 2008 Alpharma, Inc. filed a declaratory judgment action against Purdue Pharma L.P. (Purdue) in the U.S. District Court for the Western District of Virginia, seeking an order declaring that several of Purdue s patents are invalid and/or would not be infringed by the commercialization of Embedatm. The complaint was served on March 12, 2009, and on April 22, 2009 Purdue filed a motion requesting that the court dismiss the action for lack of subject matter jurisdiction or, alternatively, to transfer the action to the District of Connecticut. On July 9, 2009, the court denied Purdue s motion to dismiss or transfer. On August 6, 2009, Purdue filed its answer and counterclaims, and filed a motion for an order certifying the court s July 9 order for immediate appeal. On August 26, 2009, the court denied Purdue s motion to certify for immediate appeal and issued an order scheduling certain discovery and hearing dates and setting a trial date of July 7, 2010.

Average Wholesale Price Litigation

In August 2004, the Company and Monarch Pharmaceuticals, Inc. (Monarch), a wholly-owned subsidiary of the Company, were named as defendants along with 44 other pharmaceutical manufacturers in an action brought by the City of New York (NYC) in Federal court in the State of New York. NYC claims that the defendants fraudulently inflated their average wholesale prices (AWP) and fraudulently failed to accurately report their best prices and their average manufacturer s prices and failed to pay proper rebates pursuant to federal law. Additional claims allege violations of federal and New York statutes, fraud and unjust enrichment. For the period from 1992 to the present, NYC is requesting money damages, civil penalties, declaratory and injunctive relief, restitution, disgorgement of profits and treble and punitive damages. The U.S. District Court for the District of Massachusetts has been established as the multidistrict litigation court for the case, *In re: Pharmaceutical Industry Average Wholesale Pricing Litigation* (the MDL Court).

Since the filing of the NYC case, 48 New York counties have filed lawsuits against the pharmaceutical industry, including the Company and Monarch. The allegations in all of these cases are virtually the same as the allegations in the NYC case. All of these lawsuits are currently pending in the MDL Court, except for the Erie, Oswego and Schenectady County cases, which were removed in October 2006 and remanded to New York state court in September 2007. Motions to dismiss were granted in part and denied in part for all defendants in all NYC and county cases pending in the MDL Court. The Erie motion to dismiss was granted in part and denied in part by the state court before removal. Motions to dismiss were filed in October 2007 in the Oswego and Schenectady cases, and these cases were subsequently transferred to Erie County for coordination with the Erie County case. A hearing on these motions to dismiss is scheduled for December 10, 2009. It is not anticipated that any trials involving the Company will be set in any of these cases within the next year.

In January 2005, the State of Alabama filed a lawsuit in Alabama state court against 79 defendants, including the Company and Monarch. The four causes of action center on the allegation that all defendants fraudulently inflated the AWP of their products. A motion to dismiss was filed and denied by the Court, but the Court did require an amended

complaint to be filed. The Company filed an answer and counterclaim for return of rebates overpaid to the state. Alabama filed a motion to dismiss the counterclaim, which was granted. The Company appealed the dismissal. The Alabama Supreme Court affirmed the dismissal. In a separate appeal of a motion to sever denied by the trial court, the Alabama Supreme Court severed all defendants into single-defendant cases. Trials against AstraZeneca International, Novartis Pharmaceuticals, SmithKline Beecham Corporation and Sandoz resulted in verdicts for the State. These defendants appealed their verdicts. On October 16, 2009, the Alabama Supreme Court reversed all of the verdicts against AstraZeneca, Novartis and SmithKline Beecham and rendered judgment in favor of these companies. A trial against Watson in June 2009 resulted in a deadlocked jury. In April 2009, the Court established various trial dates for all defendants. The Company was scheduled for trial in January 2011.

Table of Contents

KING PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

In October 2005, the State of Mississippi filed a lawsuit in Mississippi state court against the Company, Monarch and 84 other defendants, alleging fourteen causes of action. Many of those causes of action allege that all defendants fraudulently inflated the AWP's and wholesale acquisition costs of their products. A motion to dismiss the criminal statute counts and a motion for more definite statement were granted. Mississippi filed an amended complaint dismissing the Company and Monarch from the lawsuit without prejudice. These claims could be refiled.

Over half of the states have filed similar lawsuits but the Company has not been named in any other case except Iowa's. The Company filed a motion to dismiss the Iowa complaint. On February 20, 2008, the Iowa case was transferred to the MDL Court. The relief sought in all of these cases is similar to the relief sought in the NYC lawsuit. The MDL Court granted in part and denied in part the Company's motion to dismiss, and the Company has filed its answer. Discovery is proceeding in these cases. The Company intends to defend all of the AWP lawsuits vigorously, but is currently unable to predict the outcome or reasonably estimate the range of potential loss.

See also AWP Litigation under the section Alpha Matters below.

Governmental Pricing Investigation and Related Matters

As previously reported, during the first quarter of 2006, the Company paid approximately \$129,268 related to underpayment of rebates owed to Medicaid and other governmental pricing programs during the period from 1994 to 2002. On October 31, 2005, the Company also entered into a five-year corporate integrity agreement with the Office of the Inspector General of the United States Department of Health and Human Services.

Beginning in March 2003, a number of purported class action complaints were filed by holders of the Company's securities against the Company, its directors, former directors, executive officers, former executive officers, a Company subsidiary and a former director of the subsidiary. These cases were settled in January 2007.

Beginning in March 2003, four purported shareholder derivative complaints were also filed in Tennessee state court alleging a breach of fiduciary duty, among other things, by some of the Company's current and former officers and directors. These cases were consolidated. The parties reached agreement on a stipulation of settlement on August 21, 2008. The settlement requires the Company to maintain and/or adopt certain corporate governance measures and provides for payment of attorneys' fees and expenses to plaintiffs' counsel in the amount of \$13,500. This amount has been paid by the Company's insurance carriers. The stipulation of settlement was filed with the Court on August 22, 2008. The Court entered an order approving the settlement on December 17, 2008. A shareholder appealed the Court's approval of the settlement, but this appeal was later voluntarily withdrawn. The Company regards the matter as concluded.

During the third quarter of 2006, the second quarter of 2007, the second quarter of 2008 and the third quarter of 2008, the Company recorded anticipated insurance recoveries of legal fees in the amounts of \$6,750, \$3,398, \$3,001 and \$8,000, respectively, for the class action and derivative suits described above. In November 2006, July 2007, August 2008 and October 2008, respectively, the Company received payments from its insurance carriers for the recovery of these legal fees.

Fen-Phen Litigation

Many distributors, marketers and manufacturers of anorexigenic drugs have been subject to claims relating to the use of these drugs. Generally, the lawsuits allege that the defendants (1) misled users of the products with respect to the dangers associated with them, (2) failed to adequately test the products and (3) knew or should have known about the negative effects of the drugs, and should have informed the public about the risks of such negative effects. Claims include product liability, breach of warranty, misrepresentation and negligence. The actions have been filed in various state and federal jurisdictions throughout the United States. A multidistrict litigation court has been established in Philadelphia, Pennsylvania, *In re Fen-Phen Litigation*. The plaintiffs seek, among other things, compensatory and punitive damages and/or court-supervised medical monitoring of persons who have ingested these products.

Table of Contents

KING PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

The Company's wholly-owned subsidiary, King Research and Development, is a defendant in approximately 50 multi-plaintiff (approximately 200 plaintiffs) lawsuits involving the manufacture and sale of dexfenfluramine, fenfluramine and phentermine. These lawsuits have been filed in various jurisdictions throughout the United States and in each of these lawsuits King Research and Development, as the successor to Jones Pharma Incorporated (Jones), is one of many defendants, including manufacturers and other distributors of these drugs. Although Jones did not at any time manufacture dexfenfluramine, fenfluramine or phentermine, Jones was a distributor of a generic phentermine product and, after its acquisition of Abana Pharmaceuticals, was a distributor of Obenix[®], Abana's branded phentermine product. The manufacturer of the phentermine purchased by Jones filed for bankruptcy protection and is no longer in business. The plaintiffs in these cases, in addition to the claims described above, claim injury as a result of ingesting a combination of these weight-loss drugs and are seeking compensatory and punitive damages as well as medical care and court-supervised medical monitoring. The plaintiffs claim liability based on a variety of theories, including, but not limited to, product liability, strict liability, negligence, breach of warranty, fraud and misrepresentation.

King Research and Development denies any liability incident to Jones' distribution and sale of Obenix[®] or Jones' generic phentermine product. King Research and Development's insurance carriers are currently defending King Research and Development in these lawsuits. The manufacturers of fenfluramine and dexfenfluramine have settled many of these cases. As a result of these settlements, King Research and Development has routinely received voluntary dismissals without the payment of settlement proceeds. In the event that King Research and Development's insurance coverage is inadequate to satisfy any resulting liability, King Research and Development will have to assume defense of these lawsuits and be responsible for the damages, if any, that are awarded against it.

While the Company cannot predict the outcome of these lawsuits, management believes that the claims against King Research and Development are without merit and intends to vigorously pursue all defenses available. The Company is unable to disclose an aggregate dollar amount of damages claimed because many of these complaints are multi-party suits and do not state specific damage amounts. Rather, these claims typically state damages as may be determined by the court or similar language and state no specific amount of damages against King Research and Development. Consequently, the Company cannot reasonably estimate possible losses related to the lawsuits.

Hormone Replacement Therapy

Currently, the Company is named as a defendant by 22 plaintiffs in lawsuits involving the manufacture and sale of hormone replacement therapy drugs. The first of these lawsuits was filed in July 2004. Numerous other pharmaceutical companies have also been sued. The Company was sued by approximately 1,000 plaintiffs, but most of those claims were voluntarily dismissed or dismissed by the Court for lack of product identification. The remaining 22 lawsuits were filed in Alabama, Arkansas, Missouri, Pennsylvania, Ohio, Florida, Maryland, Mississippi and Minnesota. A federal multidistrict litigation court has been established in Little Rock, Arkansas, *In re: Prempro Products Liability Litigation*, and all of the plaintiffs' claims have been transferred and are pending in that Court except for one lawsuit pending in Philadelphia, Pennsylvania state court. Many of these plaintiffs allege that the Company and other defendants failed to conduct adequate research and testing before the sale of the products and post-sale monitoring to establish the safety and efficacy of the long-term hormone therapy regimen and, as a result, misled consumers when marketing their products. Plaintiffs also allege negligence, strict liability, design defect, breach of implied warranty, breach of express warranty, fraud and misrepresentation. Discovery of the plaintiffs' claims against the Company has begun but is limited to document discovery. No trial has occurred in the hormone

replacement therapy litigation against the Company or any other defendants except Wyeth and Pfizer. The trials against Wyeth have resulted in verdicts for and against Wyeth, with several verdicts against Wyeth reversed on post-trial motions. Pfizer has lost two jury verdicts. One of these verdicts was later reversed, and the other is being appealed. The Company does not expect to have any trials set in the next year. The Company intends to defend these lawsuits vigorously but is currently unable to predict the outcome or to reasonably estimate the range of potential loss, if any. The Company may have limited insurance for these claims. The Company would have to assume defense of the lawsuits and be responsible for damages, fees and expenses, if any, that are awarded against it or for amounts in excess of the Company's product liability coverage.

Table of Contents

KING PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Alpharma Matters

The following matters relate to our Alpharma subsidiary and/or certain of its subsidiaries.

Department of Justice Investigation

As previously disclosed, Alpharma, acquired by the Company in December 2008, received a subpoena from DOJ in February, 2007 in connection with its investigation of alleged improper sales and marketing practices related to the sale of the pain medicine Kadian[®]. The Company divested Alpharma's Kadian[®] assets to Actavis LLC simultaneously with the closing of the acquisition of Alpharma.

In September 2009, the Company reached an agreement in principle with the U.S. Attorney's Office and DOJ which would, if completed, resolve this investigation. The Company recorded a reserve of \$42,500 in connection with this development in the third quarter of 2009 as an adjustment to the goodwill associated with the purchase of Alpharma. Final agreement is subject to the execution of a definitive settlement agreement approved by King's Board of Directors and the DOJ.

Chicken Litter Litigation

Alpharma and one of its subsidiaries are two of multiple defendants that have been named in several lawsuits that allege that one of its animal health products causes chickens to produce manure that contains an arsenical compound which, when used as agricultural fertilizer by chicken farmers, degrades into inorganic arsenic and may have caused a variety of diseases in the plaintiffs (who allegedly live in close proximity to such farm fields). Alpharma provided notice to its insurance carriers and its primary insurance carriers have responded by accepting their obligations to defend or pay Alpharma's defense costs, subject to reservation of rights to later reject coverage for these lawsuits. One of the carriers has filed a declaratory judgment action in state court in which it has sought a ruling concerning the allocation of its coverage obligations to Alpharma among the several insurance carriers and, to the extent Alpharma does not have full insurance coverage, to Alpharma. Further, this declaratory judgment action requests that the Court rule that certain of the carrier's policies provide no coverage because certain policy exclusions allegedly operate to limit its coverage obligations under said policies. The insurance carriers may take the position that some, or all, of the applicable insurance policies contain certain provisions that could limit coverage for future product liability claims arising in connection with product sold on and after December 16, 2003.

In addition to the potential for personal injury damages to the approximately 155 plaintiffs, the plaintiffs are asking for punitive damages and requesting that Alpharma be enjoined from the future sale of the product at issue. In September 2006, in the first trial, which was brought by three plaintiffs, the Circuit Court of Washington County, Arkansas, Second Division entered a jury verdict in favor of Alpharma. The plaintiffs appealed the verdict, challenging certain pretrial expert rulings; however, in May 2008, the Supreme Court of Arkansas denied plaintiffs' challenges. In its ruling, the Supreme Court of Arkansas also overturned the trial court's grant of summary judgment that had the effect of dismissing certain poultry company co-defendants from the case. The case was tried against the poultry company co-defendants in April and May 2009, resulting in a defense verdict. In July 2009, the plaintiffs filed a notice of appeal of that verdict. It is expected that the appeal of the case will be heard in 2010. No additional cases have been set for trial. Subsequent cases may be tried against both the poultry companies and Alpharma together.

While the Company can give no assurance of the outcome of any future trial in this litigation, it believes that it will be able to continue to present credible scientific evidence that its product is not the cause of any injuries the plaintiffs may have suffered. There is also the possibility of an adverse customer reaction to the allegations in these lawsuits, as well as additional lawsuits in other jurisdictions where the product has been sold. Worldwide sales of this product were approximately \$19,600 in 2008, and approximately \$6,053 and \$16,086, respectively, in the three and nine months ended September 30, 2009.

AWP Litigation

Alpharma, and in certain instances one of its subsidiaries, are defendants in connection with various elements of the litigation described above under the heading *Average Wholesale Price Litigation* , primarily related to sale of

Table of Contents

KING PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

Kadian® capsules. At present, Alharma is involved in proceedings in the following states: Alaska, Florida, Illinois, Iowa, New York, and South Carolina. The Mississippi and Texas cases against Alharma were dismissed without prejudice.

These lawsuits vary with respect to the particular causes of action and relief sought. The relief sought in these lawsuits includes statutory causes of action including civil penalties and treble damages, common law causes of action, declaratory and injunctive relief, and punitive damages, including, in certain lawsuits, disgorgement of profits. The Company believes it has meritorious defenses and intends to vigorously defend its positions in these lawsuits. Numerous other pharmaceutical companies are defendants in similar lawsuits.

Environmental Matters

In May 2009, the Company received an information request from the U.S. Environmental Protection Agency (EPA) pursuant to section 114 of the Clean Air Act regarding the Company s historic air emissions and its operation of certain pollution control equipment (Information Request). In June 2009, the Company provided EPA with its initial response to the Information Request, identifying past deviations from the requirements of its state conditional major air emissions operating permit related to the Company s operation of certain pollution control equipment at its Bristol, Tennessee facility. The Company has subsequently provided additional information to EPA and the Tennessee Department of Environment and Conservation. At this time, the Company cannot predict or determine the outcome of this matter or reasonably estimate the amount or range of amounts of fines or penalties, if any, that might result from an adverse outcome.

Other Contingencies

The Company has a supply agreement with a third party to produce metaxalone, the active ingredient in Skelaxin®. This supply agreement requires the Company to purchase certain minimum levels of metaxalone and expires in 2010. If sales of Skelaxin® are not consistent with current forecasts, the Company could incur losses in connection with purchase commitments for metaxalone, which could have a material adverse effect upon the Company s results of operations and cash flows.

11. Accounting Developments

In May 2008, the FASB issued a statement that requires the issuer of certain convertible debt instruments that may be settled in cash, or other assets, on conversion to separately account for the liability and equity components in a manner that reflects the issuer s non-convertible debt borrowing rate. Please see Note 9 for a discussion of the adoption of and the additional disclosures required by the FASB.

During the first quarter of 2009, the FASB required additional disclosures for derivative instruments and hedging activities. Please see Note 4 for these additional disclosures.

Effective January 1, 2009, the FASB issued an amendment to the accounting and disclosure requirements in the event of a business combination. This amendment addresses how an acquirer recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree and recognizes and measures the goodwill acquired in the business combination or a gain from a bargain purchase. This

amendment also requires an acquirer to recognize and measure in-process research and development projects as intangible assets at fair value on the acquisition date. They also set forth the disclosures required to be made in the financial statements to evaluate the nature and financial effects of the business combination. This amendment will be applied by the Company to business combinations occurring on or after January 1, 2009.

In December 2008, the FASB required enhanced disclosures about an employer's plan assets in a defined benefit pension plan or other postretirement plan. The required disclosures include a discussion on the inputs and valuation techniques used to develop fair value measurements of plan assets. In addition, the fair value of each major category of plan assets is required to be disclosed separately for pension plans and other postretirement benefit plans. This statement is effective for fiscal years ending after December 15, 2009. The Company does not anticipate this will have a material effect on its financial statements.

Table of Contents

KING PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

In April 2009, the FASB required disclosures about fair value of financial instruments in interim financial statements as well as in annual financial statements. This is effective for interim periods ending after June 15, 2009. Please see Note 4 and Note 9 for these additional disclosures.

In April 2009, the FASB provided additional guidance for determining fair value when the volume of activity for an asset or liability has significantly decreased or price quotations or observable inputs are not associated with orderly transactions. This guidance is effective for interim periods ending after June 15, 2009. The Company adopted this guidance on April 1, 2009, and the adoption did not have a material effect on our financial statements.

In March 2009, the FASB issued a statement that provided guidance in determining whether impairments in debt securities are other-than-temporary, and modifies the presentation and disclosures surrounding such instruments. This statement is effective for interim periods ending after June 15, 2009. The Company adopted this statement on April 1, 2009. Please see Note 4 for information regarding the adoption of this statement.

In May 2009, the FASB established the general standards of accounting for and disclosure of subsequent events. In addition, this statement requires disclosure of the date through which an entity has evaluated subsequent events and the basis for that date. The Company initially adopted this standard for the quarterly period ending June 30, 2009. The adoption did not have a material impact on our financial statements. Please see Note 1 for information regarding the adoption of this standard.

In June 2009, the FASB issued an amendment to the accounting and disclosure requirements for transfers of financial assets. This amendment requires greater transparency and additional disclosures for transfers of financial assets and the entity's continuing involvement with them and changes the requirements for derecognizing financial assets. In addition, this amendment eliminates the concept of a qualifying special-purpose entity (QSPE). This amendment is effective for financial statements issued for fiscal years beginning after November 15, 2009. The Company does not anticipate the adoption of this amendment will have a material effect on its financial statements.

In June 2009, the FASB also issued an amendment to the accounting and disclosure requirements for the consolidation of variable interest entities (VIEs). The elimination of the concept of a QSPE, as discussed above, removes the exception from applying the consolidation guidance within this amendment. This amendment requires an enterprise to perform a qualitative analysis when determining whether or not it must consolidate a VIE. The amendment also requires an enterprise to continuously reassess whether it must consolidate a VIE. Additionally, the amendment requires enhanced disclosures about an enterprise's involvement with VIEs and any significant change in risk exposure due to that involvement, as well as how its involvement with VIEs impacts the enterprise's financial statements. Finally, an enterprise will be required to disclose significant judgments and assumptions used to determine whether or not to consolidate a VIE. This amendment is effective for financial statements issued for fiscal years beginning after November 15, 2009. The Company does not anticipate the adoption of this amendment will have a material effect on its financial statements.

In June 2009, the FASB Accounting Standards Codification (Codification) was issued. The Codification will become the single source for all authoritative generally accepted accounting principles (GAAP) recognized by the FASB to be applied for financial statements issued for periods ending after September 15, 2009. The Codification does not change GAAP and it will not have a material effect on the Company's financial statements.

12. Income Taxes

During the three months and nine months ended September, 30, 2009, the Company's effective income tax rate was 37.5% and 41.2%, respectively. These rates were higher than the statutory rate of 35% primarily due to losses from foreign subsidiaries with no tax benefit, taxes related to stock compensation and state taxes.

During each the three months and nine months ended September 30, 2008, the Company's effective income tax rate from continuing operations was 33.8%. This rate varied from the statutory rate of 35% in 2008 primarily due to

Table of Contents

KING PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

tax benefits related to tax-exempt interest income and domestic manufacturing deductions, which benefits were partially offset by state taxes.

13. Segment Information

The Company's business is classified into six reportable segments: branded prescription pharmaceuticals, Animal Health, Meridian Auto-Injector, royalties, contract manufacturing and all other. The branded prescription pharmaceuticals segment includes a variety of branded prescription products that are separately categorized into neuroscience, hospital and legacy products. These branded prescription products are aggregated because of their similarity in regulatory environment, manufacturing processes, methods of distribution and types of customer. The animal health business is a global leader in the development, registration, manufacture and marketing of medicated feed additives and water soluble therapeutics primarily for poultry, cattle and swine. Meridian Auto-Injector products are sold to both commercial and government markets. The principal source of revenues in the commercial market is the EpiPen® product, an epinephrine filled auto-injector which is primarily prescribed for the treatment of severe allergic reactions and which is primarily marketed, distributed and sold by Dey, L.P. Government revenues in the Meridian Auto-Injector segment are principally derived from the sale of nerve agent antidotes and other emergency medicine auto-injector products marketed to the U.S. Department of Defense and other federal, state and local agencies, particularly those involved in homeland security, as well as to approved foreign governments. Royalties include revenues the Company derives from pharmaceutical products after the Company has transferred the manufacturing or marketing rights to third parties in exchange for licensing fees or royalty payments. The contract manufacturing segment consists primarily of pharmaceutical manufacturing services provided to the Company's branded prescription pharmaceutical segment.

The Company primarily evaluates its segments based on segment profit. Reportable segments are separately identified based on revenues, segment profit (excluding depreciation, amortization and impairments) and total assets. Revenues among the segments are presented in the individual segments and removed through eliminations in the information below. Substantially all of the eliminations relate to sales from the contract manufacturing segment to the branded prescription pharmaceuticals segment.

The following represents selected information for the Company's reportable segments for the periods indicated. Note that for the three months and nine months ended September 30, 2008, the tables for revenues and segment profit below do not include revenues and segment profit for the animal health segment, or for the Flector® Patch product within the branded prescription pharmaceuticals segment, since these are part of Alpharma, a company that King acquired at the end of December 2008.

Table of Contents**KING PHARMACEUTICALS, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2009	2008	2009	2008
Total revenues:				
Branded prescription pharmaceuticals	\$ 283,414	\$ 301,879	\$ 836,228	\$ 986,966
Animal Health	95,843		258,502	
Meridian Auto-Injector	71,841	67,515	200,539	165,687
Royalties	11,932	18,456	41,399	61,257
Contract manufacturing	122,753	109,874	440,655	363,210
All other	(49)	(63)	(101)	2,345
Eliminations	(122,385)	(109,216)	(439,828)	(362,136)
Consolidated total net revenues	\$ 463,349	\$ 388,445	\$ 1,337,394	\$ 1,217,329
Segment profit:				
Branded prescription pharmaceuticals(1)	\$ 204,063	\$ 227,701	\$ 620,059	\$ 761,710
Animal Health(1)	42,471		88,028	
Meridian Auto-Injector	43,336	42,810	122,719	103,868
Royalties	10,452	16,175	36,294	53,772
Contract manufacturing	229	359	567	537
All other	1	(65)	(102)	2,331
Other operating costs and expenses	(213,384)	(164,180)	(683,476)	(620,482)
Other income	(19,144)	1,786	(65,559)	13,578
Income before tax	\$ 68,024	\$ 124,586	\$ 118,530	\$ 315,314

(1) The segment profit for branded prescription pharmaceuticals for the three months ended September 30, 2009 includes a charge of \$2,566 related to the mark up of inventory upon acquisition of Alpharma. The segment profit for branded prescription pharmaceuticals and Animal Health for the nine months ended September 30, 2009 includes charges of \$6,022 and \$34,128, respectively. For additional information, please see Note 7.

The following represents branded prescription pharmaceutical revenues by the Company's target markets:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2009	2008	2009	2008
Total revenues:				
Neuroscience	\$ 185,908	\$ 150,084	\$ 513,862	\$ 466,377

Edgar Filing: KING PHARMACEUTICALS INC - Form 10-Q

Hospital	46,350	70,084	151,007	207,987
Legacy:				
Cardiovascular/metabolic	35,507	63,441	113,293	251,623
Other	15,649	18,270	58,066	60,979
Consolidated branded pharmaceutical revenues	\$ 283,414	\$ 301,879	\$ 836,228	\$ 986,966

Table of Contents

KING PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

14. Restructuring Activities

First Quarter of 2009 Action

In January 2009, the U.S. District Court for the Eastern District of New York issued an order ruling invalid two patents relating to the Company's product Skelaxin[®]. In June 2009, the Court entered judgment against the Company. The Company has appealed the judgment and intends to vigorously defend its interests. The entry of the order may lead to generic versions of Skelaxin[®] entering the market sooner than previously anticipated, which would likely cause the Company's sales of Skelaxin[®] to decline significantly. For additional information regarding Skelaxin[®] litigation, please see Note 10.

Following the decision of the District Court, the Company's senior management team conducted an extensive examination of the Company and developed a restructuring initiative designed to partially offset the potential decline in Skelaxin[®] sales in the event that a generic competitor enters the market. This initiative included, based on an analysis of the Company's strategic needs: a reduction in sales, marketing and other personnel; leveraging of staff; expense reductions and additional controls over spending; and reorganization of sales teams.

The Company incurred restructuring charges of approximately \$50,000 during the nine months of 2009 related to severance pay and other employee termination expenses. Almost all of the restructuring charges are cash expenditures and were substantially paid in the second quarter of 2009. The remaining severance pay and other employee termination costs are expected to be fully paid by the third quarter of 2010.

The restructuring charges include employee termination costs associated with a workforce reduction of approximately 520 employees, including approximately 380 members of our sales force.

Fourth Quarter of 2008 Action

As part of the acquisition of Alpharma, management developed a restructuring plan to eliminate redundancies in operations created by the acquisition. This plan includes a reduction in personnel, staff leverage, reductions in duplicate expenses and a realignment of research and development priorities.

The Company has estimated total costs of \$69,265 associated with this restructuring plan, \$62,718 of which has been included in the liabilities assumed in the purchase price of Alpharma. The restructuring plan includes employee termination costs associated with a workforce reduction of 250 employees. The restructuring plan also includes contract termination costs of \$14,328 and other exit costs of \$181 as a result of the acquisition. All employee termination costs are expected to be paid by the end of 2011. All contract termination costs are expected to be paid by the end of 2018.

Table of Contents**KING PHARMACEUTICALS, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

A summary of the types of costs accrued and incurred are summarized below:

	Accrued Balance at December 31, 2008	Income Statement Impact	Alpharma Acquisition	Cash Payments	Non-Cash Costs	Accrued Balance at September 30, 2009
Third quarter of 2009 action						
Employee separation payments	\$	\$ 1,026	\$	\$	\$	\$ 1,026
First quarter of 2009 action						
Employee separation payments		48,563		44,557	3,187	819
Contract termination		575		575		
Other		459		459		
Accelerated depreciation(1)		485			485	
Fourth quarter of 2008 action						
Employee separation payments	49,437	1,000	4,015	34,612	(793)	20,633
Contract termination	16,801	(3)	(2,471)	6,472	(635)	8,490
Other	182	(1)		(1)		182
Accelerated depreciation(1)		196			196	
Third quarter of 2008 action						
Employee separation payments	9			9		
Third quarter of 2007 action						
Employee separation payments	103	(103)				
Contract termination		4		4		
Third quarter of 2006 action						
Employee separation payments	2,462	(342)		843	30	1,247
Accelerated depreciation(1)		582			582	
Fourth quarter of 2005 action						
Employee separation payments	8			8		
	\$ 69,002	\$ 52,441	\$ 1,544	\$ 87,538	\$ 3,052	\$ 32,397

(1) Included in depreciation and amortization on the Consolidated Statements of Operations.

The restructuring charges in 2009 primarily relate to the branded prescription pharmaceutical segment. The accrued employee separation payments as of September 30, 2009 are expected to be paid by the end of 2011.

15. Stock-Based Compensation

During the third quarter of 2009, the Company granted to certain employees pursuant to its Incentive Plan 65,000 RSAs and 15,600 RSUs.

During the second quarter of 2009, the Company granted 53,000 RSAs to certain employees, pursuant to its Incentive Plan, and 107,506 RSUs were granted to non-employee directors.

During the first quarter of 2009, the Company granted to certain employees, pursuant to its Incentive Plan, 843,990 RSAs, 561,450 LPUs with a one-year performance cycle, 240,580 LPUs with a three-year performance cycle, 1,580 restricted stock units and 1,985,690 nonqualified stock options.

The RSAs are grants of shares of common stock restricted from sale or transfer for three years from grant date.

RSUs represent the right to receive a share of common stock at the expiration of a restriction period, generally three years from grant, but may be restricted over other designated periods as determined by the Company's Board

Table of Contents**KING PHARMACEUTICALS, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

of Directors or a committee of the Board. The RSUs granted to non-employee directors under the current Compensation Policy for Non-Employee Directors have a restriction period that generally ends one year after the date of the grant, unless a deferral election is made in advance.

The LPUs are rights to receive common stock of the Company in which the number of shares ultimately received depends on the Company's performance over time. LPUs with a one-year performance cycle, followed by a two-year restriction period, will be earned based on 2009 operating targets. LPUs with a three-year performance cycle will be earned based on market-related performance targets over the years 2009 through 2011. At the end of the applicable performance period, the number of shares of common stock awarded is either 0% or between 50% and 200% of a target number. The final performance percentage on which the number of shares of common stock issued is based, considering performance metrics established for the performance period, will be determined by the Company's Board of Directors or a committee of the Board at its sole discretion.

The nonqualified stock options were granted at option prices equal to the fair market value of the common stock at the date of grant and vest approximately in one-third increments on each of the first three anniversaries of the grant date.

16. Pension Plans and Postretirement Benefits

The Company maintains two qualified noncontributory, defined benefit pension plans covering its U.S. (domestic) employees at its Alharma subsidiary: the previously frozen Alharma Inc. Pension Plan and the previously frozen Faulding Inc. Pension Plan. The benefits payable from these plans are based on years of service and the employee's highest consecutive five years' compensation during the last ten years of service. The Company's funding policy is to contribute annually an amount that can be deducted for federal income tax purposes. Ideally, the Plan assets will approximate the accumulated benefit obligation (ABO). The plan assets are held by two custodians and managed by two investment managers. Plan assets are invested in equities, government securities and bonds.

The Company also has an unfunded supplemental executive pension plan providing additional benefits to certain employees upon termination of employment or death. The Company has an unfunded postretirement medical and nominal life insurance plan (postretirement benefits) covering certain domestic employees who were eligible as of January 1, 1993. The plan has not been extended to any additional employees. Retired eligible employees are required to make premium contributions for coverage as if they were active employees.

The Company uses a measurement date of December 31, 2008 for its pension plans and other postretirement plans. The net periodic benefit costs for the Company's pension plans and other postretirement plans are, as follows:

	Three Months Ended		Nine Months Ended	
	September 30, 2009		September 30, 2009	
	Pension Benefits	Postretirement Benefits	Pension Benefits	Postretirement Benefits
Service Cost	\$	\$ 21	\$	\$ 63
Interest Cost	758	101	2,274	303

Expected return on plan assets	(707)		(2,121)	
Recognized net actuarial loss	24	53	72	159
Net periodic benefit cost	\$ 75	\$ 175	\$ 225	\$ 525

17. Change in Estimate

A competitor entered the market with a generic substitute for Altace in December 2007 and additional competitors entered the market in June 2008. The Company's calculation for Medicaid, Medicare and commercial rebate reserves are based on estimates of utilization by rebate-eligible customers, estimates of the level of inventory of the Company's products in the distribution channel that remain potentially subject to those rebates, and the terms of the Company's rebate obligations. During the first quarter of 2008, the Company estimated the effect that the

Table of Contents

KING PHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

initial generic substitute would have on Altace® utilization by rebate-eligible customers. Actual Altace® rebates for the first quarter were lower than originally anticipated, resulting in a change in estimate during the second quarter of 2008. This change in estimate resulted in a decrease in rebate expense of approximately \$5,000 and a corresponding increase in Altace® net sales in the second quarter of 2008. As a result of this increase in net sales, the co-promotion expense related to net sales of Altace® in the second quarter of 2008 increased by approximately \$1,000. Accordingly, the effect of the change in estimate on second quarter 2008 operating income was an increase of approximately \$4,000, fully offsetting the effect of the estimate in the first quarter of 2008.

18. Guarantor Financial Statements

Each of the Company's U.S. subsidiaries guaranteed on a full, unconditional and joint and several basis the Company's performance under the \$400,000 aggregate principal amount of the Convertible Senior Notes (such subsidiaries the Guarantor Subsidiaries).

There are no restrictions under the Company's current financing arrangements on the ability of the Guarantor Subsidiaries to distribute funds to the Company in the form of cash dividends, loans or advances. The following combined financial data provides information regarding the financial position, results of operations and cash flows of the Guarantor Subsidiaries for the \$400,000 aggregate principal amount of the Convertible Senior Notes (condensed consolidating financial data). Separate financial statements and other disclosures concerning the Guarantor Subsidiaries are not presented because management has determined that such information would not be material to the holders of the debt.

Table of Contents**KING PHARMACEUTICALS, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****GUARANTOR SUBSIDIARIES****CONDENSED CONSOLIDATING BALANCE SHEETS****(Unaudited)****(In thousands)**

King	September 30, 2009				December 31, 2008			
	Guarantor Subsidiaries	Non- Guarantor Subsidiaries	Eliminating Entries	King Consolidated	King	Guarantor Subsidiaries	Non- Guarantor Subsidiaries	Elimin Entr
ASSETS								
\$ 193,412	\$ 46,752	\$ 239,804	\$	\$ 479,968	\$ 401,657	\$ 52	\$ 538,503	\$
39,624				39,624	6,441			
1,930				1,930	511			
2,975	187,862	36,193		227,030	61	140,502	104,507	
83,627	94,037	31,393	(1,407)	207,650	59,279	26,406	172,618	
36,744	63,352	481		100,577	36,041	26,146	27,326	
15,008	(2,431)	(526)		12,051				
20,411	77,270	1,693		99,374	14,090	8,283	106,841	
393,731	466,842	309,038	(1,407)	1,168,204	518,080	201,389	949,795	
148,344	243,205	9,613		401,162	140,314	115,996	160,949	
	787,512	35,077		822,589		633,300	300,919	
	453,008			453,008		129,150	321,398	
(29,147)	281,306	(2,142)		250,017	(18,117)	340,764	(54,898)	
292,034				292,034	353,848			
50,144	24,916	319		75,379	72,442	23,704	26,680	
	7,900			7,900		11,500		
3,019,105	941,129	(68)	(3,960,166)		2,896,242			(2,896,242)

\$ 3,874,211 \$ 3,205,818 \$ 351,837 \$ (3,961,573) \$ 3,470,293 \$ 3,962,809 \$ 1,455,803 \$ 1,704,843 \$ (2,8

LIABILITIES AND SHAREHOLDERS EQUITY

\$ 30,133	\$ 54,805	\$ 2,173		\$ 87,111	\$ 61,255	\$ 20,107	\$ 59,546	\$
27,355	271,967	10,640		309,962	32,456	165,460	213,572	
		4,101		4,101	1,288	169	8,991	
122,449				122,449	53,820		385,227	
179,937	326,772	16,914		523,623	148,819	185,736	672,566	
505,904				505,904	877,638			
51,281	37,618	16,459		105,358	54,355	4,595	51,072	
801,681	(812,804)	11,123			649,565	(655,145)	5,580	
1,538,803	(448,414)	44,496		1,134,885	1,730,377	(464,814)	729,218	
2,335,408	3,654,232	307,341	(3,961,573)	2,335,408	2,232,432	1,920,617	975,625	(2,8
\$ 3,874,211	\$ 3,205,818	\$ 351,837	\$ (3,961,573)	\$ 3,470,293	\$ 3,962,809	\$ 1,455,803	\$ 1,704,843	\$ (2,8

Table of Contents**KING PHARMACEUTICALS, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****GUARANTOR SUBSIDIARIES****CONDENSED CONSOLIDATING STATEMENTS OF OPERATIONS****(Unaudited)****(In thousands)**

	Three Months Ended September 30, 2009					Three Months Ended September 30, 2008				
	King	Guarantor Subsidiaries	Non-Guarantor Subsidiaries	Eliminations	King Consolidated	King	Guarantor Subsidiaries	Non-Guarantor Subsidiaries	Eliminations	King Consolidated
Revenue	\$ 82,122	\$ 417,659	\$ 44,393	\$ (92,757)	\$ 451,417	\$ 96,526	\$ 372,073	\$ 1,141	\$ (99,751)	\$ 372,073
Expenses	82,122	429,591	44,393	(92,757)	463,349	96,526	390,529	1,141	(99,751)	390,529
Costs and expenses	18,865	210,844	26,561	(93,473)	162,797	27,727	172,779	755	(99,796)	172,779
Depreciation and amortization	51,790	76,525	7,427		135,742	51,926	47,297	55		47,297
Goodwill impairment and other	1,270	22,613	(1,243)		22,640	1,764	32,091			32,091
Restructuring charges	4,622	47,873	854		53,349	4,799	25,035	60		25,035
Other charges	732	921			1,653	26	1,127			1,127
Other income	77,279	358,776	33,599	(93,473)	376,181	86,242	278,329	870	(99,796)	278,329
Other expense	4,843	70,815	10,794	716	87,168	10,284	112,200	271	45	112,200
Other income	704	24	299		1,027	8,092	14	4		8,092
Other expense	(21,407)	(749)	(62)		(22,218)	(5,295)	(5)			(5,295)
Other income	521				521					521
Other expense	503	(939)	1,962		1,526	(1,084)	776	(716)		776
Other income	52,625	5,798	(100)	(58,323)		93,677			(93,677)	93,677
Other expense	(3,306)	12,791	(9,485)			(2,704)	2,710	(6)		(2,704)

Edgar Filing: KING PHARMACEUTICALS INC - Form 10-Q

ny interest come										
ncome	29,640	16,925	(7,386)	(58,323)	(19,144)	92,686	3,495	(718)	(93,677)	
) before s	34,483	87,740	3,408	(57,607)	68,024	102,970	115,695	(447)	(93,632)	
expense	(8,005)	30,788	2,753		25,536	20,498	21,601	15		
(loss)	\$ 42,488	\$ 56,952	\$ 655	\$ (57,607)	\$ 42,488	\$ 82,472	\$ 94,094	\$ (462)	\$ (93,632)	

Table of Contents**KING PHARMACEUTICALS, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****GUARANTOR SUBSIDIARIES****CONDENSED CONSOLIDATING STATEMENTS OF OPERATIONS (Continued)****(Unaudited)****(In thousands)**

Nine Months Ended September 30, 2009					Nine Months Ended September 30, 2008				
King	Guarantor Subsidiaries	Non-Guarantor Subsidiaries	Eliminations	King Consolidated	King	Guarantor Subsidiaries	Non-Guarantor Subsidiaries	Eliminations	
\$ 260,844	\$ 1,219,337 41,399	\$ 114,232	\$ (298,418)	\$ 1,295,995 41,399	\$ 326,231	\$ 1,157,558 61,257	\$ 1,420	\$ (329,137)	
260,844	1,260,736	114,232	(298,418)	1,337,394	326,231	1,218,815	1,420	(329,137)	
76,958	616,718	76,127	(299,974)	469,829	94,076	529,399	1,076	(329,440)	
157,662	222,845	21,133		401,640	186,684	154,349	76		
3,864	64,775	2,459		71,098	4,068	112,457			
14,272	142,582	2,706		159,560	14,941	106,628	180		
15,039	36,139			51,178	114 (330)	39,315 2,000			
267,795	1,083,059	102,425	(299,974)	1,153,305	299,553	944,148	1,332	(329,440)	
(6,951)	177,677	11,807	1,556	184,089	26,678	274,667	88	303	
3,132 (69,875)	301 (2,826)	1,888 (212)		5,321 (72,913)	30,910 (15,544)	81 (27)	9		
(826) 544	1,008	1,307		(826) 2,859	(1,613)	7	(245)		
124,175	17,846	(60)	(141,961)		204,349			(204,349)	

Edgar Filing: KING PHARMACEUTICALS INC - Form 10-Q

rest	(5,993)	22,264	(16,271)		(9,424)	9,443	(19)		
e	51,157	38,593	(13,348)	(141,961)	(65,559)	208,678	9,504	(255)	(204,349)
re	44,206	216,270	(1,541)	(140,405)	118,530	235,356	284,171	(167)	(204,040)
ce	(25,495)	72,624	1,700		48,829	26,567	79,917	41	
	\$ 69,701	\$ 143,646	\$ (3,241)	\$ (140,405)	\$ 69,701	\$ 208,789	\$ 204,254	\$ (208)	\$ (204,040)

Table of Contents**KING PHARMACEUTICALS, INC.****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****GUARANTOR SUBSIDIARIES****CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS****(Unaudited)****(In thousands)**

	Nine Months Ended September 30, 2009				Nine Months Ended September 30, 2008			
	King	Guarantor Subsidiaries	Non- Guarantor Subsidiaries	King Consolidated	King	Guarantor Subsidiaries	Non- Guarantor Subsidiaries	King Consolidated
Cash flows provided by operating activities	\$ (43,719)	\$ 285,141	\$ 20,742	\$ 262,164	\$ 69,823	\$ 279,846	\$ 215	\$ 349,884
Cash flows from investing activities:								
Transfers from (to) restricted cash	(42)	(27)		(69)	(6)			(6)
Purchases of investments in debt securities					(279,175)			(279,175)
Proceeds from maturities and sales of investments in debt securities	38,473			38,473	1,185,830			1,185,830
Purchases of property, plant and equipment	(22,506)	(6,892)	(210)	(29,608)	(34,901)	(10,622)		(45,523)
Proceeds from sale of property and equipment	10	327		337	10,350	40		10,390
Proceeds from sale of Kadian®		59,800		59,800				
Acquisition of Alpha	(13,533)	(56,697)		(70,230)				

Edgar Filing: KING PHARMACEUTICALS INC - Form 10-Q

Acquisition of Avinza®	(8)		(8)	(43)				(43)
Forward foreign exchange contracts			(8,906)	(8,906)				
Purchases of intellectual property and product rights		(2,178)		(2,178)		(7,890)		(7,890)
Net cash provided by (used in) investing activities	2,394	(5,667)	(9,116)	(12,389)	882,055	(18,472)		863,583
Cash flows from financing activities:								
Proceeds from exercise of stock options	1,742			1,742	347			347
Net payments related to stock-based award activity	(3,554)			(3,554)	(2,372)			(2,372)
Payments on long-term debt	(324,073)	(385,227)	(1,129)	(710,429)				
Debt issuance costs	(1,313)			(1,313)				
Intercompany	160,278	(137,491)	(22,787)		263,120	(263,125)	5	
Net cash provided by (used in) financing activities	(166,920)	(522,718)	(23,916)	(713,554)	261,095	(263,125)	5	(2,025)
Net cash flows from exchange rate changes			3,535	3,535				
Increase (decrease) in cash and cash equivalents	(208,245)	(243,244)	(8,755)	(460,244)	1,212,973	(1,751)	220	1,211,442
	401,657	289,996	248,559	940,212	\$ 9,718	\$ 4,645	\$ 5,646	\$ 20,009

Cash and cash
equivalents,
beginning of
period

Cash and cash
equivalents,
end of period

\$	193,412	\$	46,752	\$	239,804	\$	479,968	\$	1,222,691	\$	2,894	\$	5,866	\$	1,231,451
----	---------	----	--------	----	---------	----	---------	----	-----------	----	-------	----	-------	----	-----------

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion contains certain forward-looking statements that reflect management's current views of future events and operations. This discussion should be read in conjunction with the following: (a) Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2008, which are supplemented by the discussion under Risk Factors in this report; (b) our audited consolidated financial statements and related notes which are included in our Annual Report on Form 10-K for the year ended December 31, 2008; and (c) our unaudited consolidated financial statements and related notes which are included in this report on Form 10-Q. Please see the sections entitled Risk Factors and A Warning About Forward-Looking Statements in this report for a discussion of the uncertainties, risks and assumptions associated with these statements.

I. OVERVIEW

Our Business

We are a vertically integrated pharmaceutical company that performs basic research and develops, manufactures, markets and sells branded prescription pharmaceutical products and animal health products. By vertically integrated, we mean that we have the following capabilities:

research and development	distribution
manufacturing	sales and marketing
packaging	business development
quality control and assurance	regulatory management

Our branded prescription pharmaceuticals include neuroscience products (primarily pain medicines), hospital products, and legacy brands. We also manufacture and market acute care medicines that are delivered using an auto-injector. Our Alpharma Animal Health business is focused on medicated feed additives (MFAs) and water-soluble therapeutics primarily for poultry, cattle and swine.

Our corporate strategy is focused on specialty markets, particularly specialty-driven branded prescription pharmaceutical markets. We believe our target markets have significant potential, and our organization is aligned accordingly. Our growth in specialty markets is achieved through organic growth and acquisitions.

Under our corporate strategy we work to achieve organic growth by maximizing the potential of our currently marketed products through sales and marketing and prudent product life-cycle management. By product life-cycle management, we mean the extension of the economic life of a product, including seeking and gaining necessary related governmental approvals, by such means as:

securing from the U.S. Food and Drug Administration (FDA) additional approved uses (indications) for our products;

developing and producing different strengths;

producing different package sizes;

developing new dosage forms; and

developing new product formulations.

Our strategy also focuses on growth through the acquisition of novel branded prescription pharmaceutical products in various stages of development and the acquisition of prescription pharmaceutical technologies, particularly those products and technologies that we believe have significant market potential and complement the commercial footprint we have established in the neuroscience and hospital markets. Using our internal resources and a disciplined business development process, we strive to be a leader in developing and commercializing innovative, clinically-differentiated therapies and technologies in these target, specialty-driven markets. We may also seek company acquisitions that add products or products in development, technologies or sales and marketing capabilities to our existing platforms or that otherwise complement our operations. We also work to achieve organic growth by continuing to develop investigational drugs, as we have a commitment to research and development and advancing the products and technologies in our development pipeline.

Table of Contents

We market our branded prescription pharmaceutical products primarily through a dedicated sales force to general/family practitioners, internal medicine physicians, neurologists, pain specialists, surgeons and hospitals across the United States and in Puerto Rico. Branded prescription pharmaceutical products are innovative products sold under a brand name that have, or previously had, some degree of market exclusivity. When we refer to branded prescription pharmaceutical products, we mean branded prescription pharmaceutical products that are intended for humans.

The animal health products of our wholly-owned subsidiary Alpharma Inc. (Alpharma) are marketed through a staff of trained sales and technical service and marketing employees, many of whom are veterinarians and nutritionists. Sales offices are located in the U.S., Europe, Canada, Mexico, South America and Asia. Elsewhere, animal health products are sold primarily through the use of distributors and other third-party sales companies.

Recent Developments

Embeda™

In August 2009, the U.S. Food and Drug Administration approved Embeda™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules, a long-acting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Embeda™ contains pellets of an extended-release oral formulation of morphine sulfate, an opioid receptor agonist, surrounding an inner core of naltrexone hydrochloride, an opioid receptor antagonist. Embeda™ is the first FDA-approved long-acting opioid designed to reduce drug liking and euphoria when tampered with by crushing or chewing. However, the clinical significance of the degree of reduction in drug liking and euphoria reported in clinical studies has not yet been established. There is no evidence that the naltrexone in Embeda™ reduces the abuse liability of Embeda™. Embeda™ became commercially available in late September 2009.

On October 8, 2009, we received a warning letter from the FDA, Division of Drug Marketing, Advertising, and Communications (DDMAC) regarding certain materials utilized in our recent commercial launch of Embeda™. The letter indicated these materials are false or misleading because they omit and minimize the risks associated with the use of Embeda™, fail to present the limitations to its approved indication, and present misleading claims. We have ceased the dissemination of these materials and have taken steps to conform other materials we currently utilize with Embeda™ to the guidance set forth in the warning letter. On October 16, 2009, we responded to the warning letter, providing DDMAC with a list of materials that were discontinued and a comprehensive plan of action to appropriately disseminate corrective messages to those that received the original materials. We continue to cooperate fully with DDMAC in this matter. In addition, we will be meeting with members of the FDA staff to discuss the scope and meaning of certain provisions of the warning letter.

Remoxy®

In early July 2009, we met with the FDA to discuss the Complete Response Letter received by us in December 2008 regarding our New Drug Application (NDA) for Remoxy®. The outcome of this meeting provided us with a clearer path forward to resubmit the Remoxy® NDA and to address all FDA comments in the Complete Response Letter. We believe the timing of the resubmission will be determined principally by the generation of six-month stability data. We are not required by the FDA to conduct clinical trials in order to provide additional safety or efficacy data in patients with moderate to severe chronic pain. As part of the resubmission plan, and in order to strengthen the NDA, we will conduct a likeability study and a pharmacokinetic trial in volunteers. We anticipate the resubmission of the NDA could occur by approximately the middle of 2010.

Remoxy® is a unique long-acting formulation of oral oxycodone with a proposed indication for the management of moderate to severe pain when a continuous, around-the-clock, opioid analgesic is needed for an extended period of time. This formulation uses the Oradur™ platform technology which provides a unique physical barrier that is designed to provide controlled pain relief and resist certain common methods used to extract the opioid more rapidly than intended as can occur with products currently on the market. Common methods used to cause a rapid extraction of an opioid include crushing, chewing and dissolution in alcohol. These methods are typically used to cause failure of the controlled release dosage form, resulting in dose dumping of oxycodone, or the immediate release of the active drug.

Table of Contents

Acurox® Tablets

On June 30, 2009, the FDA issued a Complete Response Letter regarding the NDA for Acurox® Tablets. The Complete Response Letter raises issues regarding the potential abuse deterrent benefits of Acurox®. In early September 2009, we and Acura Pharmaceuticals, Inc. (Acura) met with the FDA to discuss the Complete Response Letter. The FDA and the Companies agreed to take the NDA to an FDA advisory committee to consider the evidence to support the potential opioid abuse deterrent effects of Acurox® Tablets. While the FDA indicated that no new clinical trials are required at this time, we and Acura plan to initiate an additional clinical study in volunteers to further assess the abuse deterrent features of Acurox®. The FDA has not yet set a meeting date for the Advisory Committee's review of the NDA. We expect the meeting to be convened in the first half of 2010.

Acurox® Tablets, a patented, orally administered, immediate release tablet containing oxycodone HCl as its sole active analgesic ingredient, has a proposed indication for the relief of moderate to severe pain. Acurox® uses Acura's patented Aversion® Technology, which is designed to deter misuse and abuse by intentional swallowing of excess quantities of tablets, intravenous injection of dissolved tablets and nasal snorting of crushed tablets. Attempts to extract oxycodone from an Acurox® Tablet by dissolving it in liquid result in the formation of a viscous gel which is intended to sequester the opioid and deter I.V. injection. Crushing an Acurox® Tablet for the purposes of nasal snorting releases an ingredient that is intended to cause nasal irritation and thereby discourage this method of misuse and abuse. Swallowing excessive numbers of Acurox® Tablets releases niacin in quantities that are intended to cause unpleasant and undesirable side effects.

CorVue™ (binodenoson) for Injection

In December 2008, we submitted an NDA for CorVue™ to the FDA. On October 19, 2009, we received a Complete Response Letter from the FDA with respect to the NDA for CorVue™. We are currently evaluating the FDA's Complete Response Letter. CorVue™ is a cardiac pharmacologic stress agent for use as an adjunct in SPECT (single-photon-emission computed tomographic) cardiac imaging intended for use in patients with or at risk for coronary artery disease who are unable to perform a cardiac exercise stress test.

Ketoprofen in Transfersome® Gel

In September 2007, Alpharma, acquired by us in December 2008, entered into an agreement with IDEA AG (IDEA), through which Alpharma obtained the exclusive U.S. license and distribution rights from IDEA to market ketoprofen in Transfersome® gel, a prescription topical NSAID (non-steroidal anti-inflammatory drug). Transfersome® gel is IDEA's proprietary technology platform for delivering drugs to targeted areas through the skin barrier.

Based upon a review of the progress of the licensed product's development and our view of its commercial potential, in August 2009, pursuant to provisions in the agreement, we provided written notice to IDEA of our intention to terminate the agreement. The agreement was terminated in October 2009.

Department of Justice Investigation

As previously disclosed, Alpharma, acquired by us in December 2008, received a subpoena from DOJ in February 2007 in connection with its investigation of alleged improper sales and marketing practices related to the sale of the pain medicine Kadian®. The Company divested Alpharma's Kadian® assets to Actavis LLC simultaneously with the closing of the acquisition of Alpharma.

In September 2009, we reached an agreement in principle with the U.S. Attorney's Office and DOJ which would, if completed, resolve this investigation. We recorded a reserve of \$42.5 million in connection with this development in

the third quarter of 2009 as an adjustment to the goodwill associated with the purchase of Alpharma. Final agreement is subject to the execution of a definitive settlement agreement approved by our Board of Directors and the DOJ.

Table of Contents**II. RESULTS OF OPERATIONS*****Three and Nine Months Ended September 30, 2009 and 2008***

The following table summarizes total revenues and cost of revenues by operating segment, excluding intercompany transactions:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2009	2008	2009	2008
	(In thousands)		(In thousands)	
Total Revenues				
Branded prescription pharmaceuticals	\$ 283,414	\$ 301,879	\$ 836,228	\$ 986,966
Animal Health	95,843		258,502	
Meridian Auto-Injector	71,841	67,515	200,539	165,687
Royalties	11,932	18,456	41,399	61,257
Contract manufacturing	368	658	827	1,074
Other	(49)	(63)	(101)	2,345
Total revenues	\$ 463,349	\$ 388,445	\$ 1,337,394	\$ 1,217,329
Cost of Revenues, exclusive of depreciation, amortization and impairments				
Branded prescription pharmaceuticals	\$ 79,351	\$ 74,178	\$ 216,169	\$ 225,256
Animal Health	53,372		170,474	
Meridian Auto-Injector	28,505	24,705	77,820	61,819
Royalties	1,480	2,281	5,105	7,485
Contract manufacturing	139	299	260	537
Other	(50)	2	1	14
Total cost of revenues	\$ 162,797	\$ 101,465	\$ 469,829	\$ 295,111

The following table summarizes our deductions from gross sales:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2009	2008	2009	2008
	(In thousands)		(In thousands)	
Gross Sales	\$ 548,854	\$ 458,171	\$ 1,578,731	\$ 1,482,548
Commercial Rebates	18,484	15,390	48,329	72,398
Medicare Part D Rebates	3,243	3,830	8,881	25,460
Medicaid Rebates	8,113	8,045	31,136	29,351
Chargebacks	28,155	21,283	83,035	67,069
Returns	5,926	2,927	14,154	11,352

Edgar Filing: KING PHARMACEUTICALS INC - Form 10-Q

Trade discounts/other	21,584	18,251	55,802	59,589
Net sales	\$ 463,349	\$ 388,445	\$ 1,337,394	\$ 1,217,329

Gross sales increased in the third quarter of 2009 compared to the third quarter of 2008 and in the first nine months of 2009 compared to the first nine months of 2008, primarily due to additional sales from the acquisition of Alpharma at the end of December 2008 and an increase in sales in the Meridian Auto-Injector segment. Gross sales of several key branded prescription pharmaceuticals products decreased due to market competition as discussed below.

Based on inventory data provided to us by our customers, we believe that wholesale inventory levels of our key products, Skelaxin[®], Thrombin-JMI[®], Flector[®] Patch, Avinza[®], and Levoxyl[®], are at or below normal levels as of

Table of Contents

September 30, 2009. We estimate that wholesale and retail inventories of our products as of September 30, 2009 represent gross sales of approximately \$120 million to \$130 million.

The following tables provide the activity and ending balances for our significant deductions from gross sales:

Accrual for Rebates, including Administrative Fees (in thousands):

	2009	2008
Balance at January 1, net of prepaid amounts	\$ 58,129	\$ 65,301
Current provision related to sales made in current period	28,512	67,155
Current provision related to sales made in prior periods	1,109	2,982
Alpharma acquisition	1,772	
Rebates paid	(34,482)	(83,660)
Balance at March 31, net of prepaid amounts	\$ 55,040	\$ 51,778
Current provision related to sales made in current period	\$ 31,219	\$ 36,297
Current provision related to sales made in prior periods	(2,334)	(6,490)
Alpharma acquisition	885	
Rebates paid	(35,474)	(55,692)
Balance at June 30, net of prepaid amounts	\$ 49,336	\$ 25,893
Current provision related to sales made in current period	\$ 30,200	\$ 27,225
Current provision related to sales made in prior periods	(360)	40
Alpharma acquisition	886	
Rebates paid	(41,124)	(34,028)
Balance at September 30, net of prepaid amounts	\$ 38,938	\$ 19,130

Rebates include commercial, Medicaid and Medicare rebates.

A competitor entered the market with a generic substitute for Altace® during December 2007 and additional competitors entered the market in June 2008. As a result of this competition, sales of Altace® and utilization of Altace® by rebate-eligible customers significantly decreased in each quarter of 2008 and 2009. The decrease in utilization of Altace® by rebate-eligible customers has, in turn, significantly decreased the current provision related to sales made in the current period and rebates paid in the table above. For a discussion regarding Altace® net sales, please see Altace® within the Sales of Key Products section below.

Our calculation for Medicaid, Medicare and commercial rebate reserves are based on estimates of utilization by rebate-eligible customers, estimates of the level of inventory of our products in the distribution channel that remain potentially subject to those rebates and the terms of our rebate obligations. During the first quarter of 2008, we estimated the effect that the initial generic substitute would have on Altace® utilization by rebate-eligible customers. Actual Altace® rebates for the first quarter were lower than originally anticipated, resulting in a change in estimate during the second quarter of 2008. This change in estimate resulted in a decrease in rebate expense of approximately \$5.0 million and a corresponding increase in Altace® net sales in the second quarter of 2008 and is included in the

current provision related to sales made in prior periods in the table above. As a result of this increase in net sales, the co-promotion expense related to net sales of Altace® in the second quarter of 2008 increased by approximately \$1.0 million. Accordingly, the net effect of the change in estimate on second quarter 2008 operating income was an increase of approximately \$4.0 million fully offsetting the effect of the estimate in the first quarter of 2008.

Table of Contents**Accrual for Returns (in thousands):**

	2009	2008
Balance at January 1	\$ 33,471	\$ 32,860
Current provision	2,883	4,450
Actual returns	(4,646)	(4,135)
Ending balance at March 31	\$ 31,708	\$ 33,175
Current provision	\$ 5,345	\$ 3,975
Actual returns	(6,062)	(6,845)
Ending balance at June 30	\$ 30,991	\$ 30,305
Current provision	\$ 5,926	\$ 2,927
Actual returns	(7,743)	(5,832)
Ending balance at September 30	\$ 29,174	\$ 27,400

Accrual for Chargebacks (in thousands):

	2009	2008
Balance at January 1	\$ 9,965	\$ 11,120
Current provision	28,176	20,212
Actual chargebacks	(27,244)	(21,080)
Ending balance at March 31	\$ 10,897	\$ 10,252
Current provision	\$ 26,704	\$ 25,574
Actual chargebacks	(27,958)	(25,286)
Ending balance at June 30	\$ 9,643	\$ 10,540
Current provision	\$ 28,155	\$ 21,283
Actual chargebacks	(28,041)	(22,918)
Ending balance at September 30	\$ 9,757	\$ 8,905

Branded Prescription Pharmaceuticals Segment

Three Months Ended September 30,	Change 2009 vs. 2008	Nine Months Ended September 30,	Change 2009 vs. 2008
---	---------------------------------	--	---------------------------------

Edgar Filing: KING PHARMACEUTICALS INC - Form 10-Q

	2009	2008	\$	%	2009	2008	\$	%
	(In thousands)				(In thousands)			
Branded Prescription Pharmaceutical Revenue:								
<i>Skelaxin</i> [®]	\$ 102,080	\$ 109,990	\$ (7,910)	(7.2)%	\$ 304,857	\$ 333,095	\$ (28,238)	(8.5)%
<i>Thrombin-JMI</i> [®]	43,409	66,813	(23,404)	(35.0)	139,310	197,585	(58,275)	(29.5)
<i>Flector</i> [®] <i>Patch</i>	40,397		40,397		95,794		95,794	
<i>Avinza</i> [®]	30,774	35,928	(5,154)	(14.3)	98,646	102,941	(4,295)	(4.2)
<i>Levoxyl</i> [®]	16,995	17,608	(613)	(3.5)	51,847	53,462	(1,615)	(3.0)
<i>Altace</i> [®]	10,119	29,950	(19,831)	(66.2)	27,989	154,485	(126,496)	(81.9)
<i>Embeda</i> [™]	11,230		11,230		11,230		11,230	
<i>Other</i>	28,410	41,590	(13,180)	(31.7)	106,555	145,398	(38,843)	(26.7)
Total revenue	\$ 283,414	\$ 301,879	\$ (18,465)	(6.1)%	\$ 836,228	\$ 986,966	\$ (150,738)	(15.3)%
Cost of revenues, exclusive of depreciation, amortization and impairments								
	\$ 79,351	\$ 74,178	\$ 5,173	7.0%	\$ 216,169	\$ 225,256	\$ (9,087)	(4.0)%

Table of Contents

Sales of Key Products

Skelaxin[®]

In January 2009, the U.S. District Court for the Eastern District of New York issued an order ruling invalid two patents related to Skelaxin[®]. In June 2009, the court entered judgment against King. We have appealed the judgment and plan to vigorously defend our interests. The entry of the court's order may lead to generic versions of Skelaxin[®] entering the market sooner than previously anticipated, which would likely cause net sales of Skelaxin[®] to decline significantly.

Net sales of Skelaxin[®] decreased in the third quarter and first nine months of 2009 from the third quarter and first nine months of 2008 primarily due to a decrease in prescriptions, partially offset by a price increase taken in the fourth quarter of 2008 and the second quarter of 2009. Due to a decrease in promotional efforts, total prescriptions for Skelaxin[®] decreased approximately 22.0% and 18.5% in the third quarter and first nine months of 2009, respectively, from the third quarter and first nine months of 2008, according to IMS America, Ltd. (IMS) monthly prescription data. We expect net sales of Skelaxin[®] will continue to decrease during 2009 as a result of the decrease in promotional efforts. We anticipate additional decreases in net sales if generic competition enters the market.

In January 2008, we entered into an agreement with CorePharma, LLC (CorePharma) granting CorePharma a license to launch an authorized generic version of Skelaxin[®] in December 2012, or earlier under certain conditions.

For a discussion regarding Skelaxin[®] litigation and the risk of potential generic competition for Skelaxin[®], please see Note 10, Commitments and Contingencies, in Part I, Item 1, Financial Statements.

Thrombin-JMI[®]

Net sales of our Thrombin-JMI[®] product decreased in the third quarter and first nine months of 2009 compared to the third quarter and first nine months of 2008, primarily due to additional price concessions and the market entry of two competing products which caused a decrease in gross sales. The first competing product entered the market in the fourth quarter of 2007 and another entered the market in the first quarter of 2008. Net sales of our Thrombin-JMI[®] product may continue to decrease as a result of competition.

Flector[®] Patch

Flector[®] Patch was part of the acquisition of Alpharma at the end of December 2008. Total prescriptions for Flector[®] Patch increased approximately 27.8% and 58.7% in the third quarter and first nine months of 2009, respectively, compared to the third quarter and first nine months of 2008, according to IMS monthly prescription data. At the time of acquisition, the wholesale inventory level of Flector[®] Patch exceeded our normal levels. During the first quarter of 2009, we reduced these inventories to a level consistent with our other promoted products. As a result, net sales of Flector[®] Patch were lower than prescription demand in the first quarter of 2009. We believe that Flector[®] Patch net sales more closely reflected prescription demand in the second quarter of 2009. Alpharma began selling Flector[®] Patch in January 2008.

Avinza[®]

Net sales of Avinza[®] decreased in the third quarter and first nine months of 2009 compared to the third quarter and first nine months of 2008 primarily due to a decrease in prescriptions, partially offset by a price increase taken in the first quarter of 2009. Total prescriptions for Avinza[®] decreased approximately 11.5% and 6.8% in the third quarter and first nine months of 2009, respectively, compared to the third quarter and first nine months of 2008, according to

IMS monthly prescription data.

On March 24, 2008, we received a warning letter from DDMAC regarding promotional material for Avinza® that was created and submitted to the DDMAC by Ligand Pharmaceuticals (the company from whom we acquired Avinza® in late February 2007). The letter expressed concern with the balance of the described risks and benefits associated with the use of the product and the justification for certain statements made in the promotional material. We discontinued the use of promotional materials created by Ligand prior to receiving the letter and have

Table of Contents

communicated this to DDMAC. In addition, DDMAC requested support for certain statements included in Avinza® promotional materials which were then in use. We promptly responded to this request and asked for a meeting with DDMAC to discuss this matter.

Our request resulted in a teleconference with DDMAC representatives on January 6, 2009. After this call, we immediately ceased the dissemination of promotional materials for Avinza® that included any statements with which DDMAC took issue in its March 24, 2008 letter. Further, we directed our sales representatives to discontinue the use of such materials and ceased all advertising containing the statements discussed in that letter. We have taken the additional corrective actions agreed upon with DDMAC.

For a discussion regarding the risk of potential generic competition for Avinza®, please see Note 10, Commitments and Contingencies, in Part I, Item 1, Financial Statements.

Embeda™

In August 2009, the FDA approved Embeda™ (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules, a long-acting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. We began selling Embeda™ in late September 2009.

Levoxyl®

Net sales of Levoxyl® decreased in the third quarter of 2009 compared to the third quarter of 2008 primarily due to a decrease in prescriptions, partially offset by price increases taken in the fourth quarter of 2008. Net sales of Levoxyl® decreased in the first nine months of 2009 compared to the first nine months of 2008 primarily due to decreases in prescriptions, partially offset by a decrease in wholesale inventory levels in 2008 and price increases taken in the fourth quarter of 2008. Total prescriptions for Levoxyl® decreased approximately 8.9% and 12.3% in the third quarter and first nine months of 2009, respectively, compared to the third quarter and first nine months of 2008, according to IMS monthly prescription data. We anticipate net sales for this product will decline in 2009 due to decreasing prescriptions.

Altace®

Net sales of Altace® decreased significantly in the third quarter and first nine months of 2009 from the third quarter and first nine months of 2008 due to competitors entering the market in December 2007 and June 2008 with generic substitutes for Altace®. Total prescriptions for Altace® decreased approximately 65.7% and 84.3% in the third quarter and first nine months of 2009, respectively, from the third quarter and first nine months of 2008 according to IMS monthly prescription data.

For a discussion regarding the generic competition for Altace®, please see Note 10, Commitments and Contingencies in Part I, Item 1, Financial Statements.

Other

Other branded prescription pharmaceutical products are not promoted through our sales force, and prescriptions for many of our products included in this category are declining. Net sales of other branded pharmaceutical products were lower in the third quarter of 2009 compared to the third quarter of 2008 primarily due to lower net sales of Cytomel® and a decrease in prescriptions. Net sales of other branded pharmaceutical products were lower in the first nine months of 2009 compared to the first nine months of 2008 primarily due to lower net sales of Sonata® and Cytomel®

and a decrease in prescriptions.

Table of Contents

In April 2009, a third party entered the market with a generic substitute for Cytomel[®]. As a result of the entry of generic competition, net sales declined in the second and third quarters of 2009 and we expect net sales of Cytomel[®] to continue to decline in the future. Net sales of Cytomel[®] decreased from \$14.1 million and \$38.0 million in the third quarter and first nine months of 2008, respectively, to \$6.6 million and \$27.9 million in the third quarter and first nine months of 2009, respectively.

Net sales of Sonata[®] decreased from \$4.2 million and \$30.3 million in the third quarter and first nine months of 2008, respectively, to \$1.4 million and \$3.3 million in the third quarter and first nine months of 2009, respectively, primarily due to competition entering the market with generic substitutes for Sonata[®]. The composition of matter patent covering Sonata[®] expired in June 2008, at which time several competitors entered the market with generic substitutes.

As a result of generic competition for Sonata[®] and Cytomel[®] and declining demand for many other products included in this category, we anticipate net sales of other branded prescription pharmaceutical products will continue to decline in 2009.

Cost of Revenues

Cost of revenues from branded pharmaceutical products decreased in the third quarter and first nine months of 2009 versus the third quarter and first nine months of 2008 primarily due to a decrease in unit sales of several key products, as discussed above, partially offset by additional cost of revenues for Flector[®] Patch which was part of the acquisition of Alharma at the end of December 2008.

The royalty rate on Skelaxin[®] increased in the second quarter of 2009 due to the achievement of certain regulatory milestones under our agreement with Mutual. For additional information on the Mutual agreement, please see Other within the Liquidity and Capital Resources section below.

At the time of our acquisition of Alharma, we valued the inventory that was acquired based on the accounting requirements for business combinations. As a result, we increased the carrying value of the Flector[®] Patch inventory by approximately \$7.8 million. During the third quarter and first nine months of 2009, the cost of revenues for the branded prescription pharmaceutical products segment reflects a charge of \$2.6 million and \$6.0 million, respectively, related to the sale of this marked-up inventory.

Special items are those particular material income or expense items that our management believes are not related to our ongoing, underlying business, are not recurring, or are not generally predictable. These items include, but are not limited to, merger and restructuring expenses; non-capitalized expenses associated with acquisitions, such as in-process research and development charges and inventory valuation adjustment charges; charges resulting from the early extinguishments of debt; asset impairment charges; expenses of drug recalls; and gains and losses resulting from the divestiture of assets. We believe the identification of special items enhances an analysis of our ongoing, underlying business and an analysis of our financial results when comparing those results to that of a previous or subsequent like period. However, it should be noted that the determination of whether to classify an item as a special item involves judgments by us.

Animal Health

Three Months Ended September 30, 2009		Nine Months Ended September 30, 2009	
	2008		2008

	(In thousands)		(In thousands)	
Animal Health revenue	\$ 95,843	\$	\$ 258,502	\$
Cost of revenues, exclusive of depreciation, amortization and impairments	53,372		170,474	

The Animal Health segment was part of the acquisition of Alpharma at the end of December 2008.

At the time of the acquisition of Alpharma, we valued the inventory that was acquired based on the accounting requirements for business combinations. As a result, we increased the carrying value of the Animal Health inventory

Table of Contents

by approximately \$34 million. During the first nine months of 2009, the cost of revenues for the Animal Health segment reflects a charge of \$34.1 million related to the sale of this marked-up inventory.

Meridian Auto-Injector

	Three Months Ended September 30, 2009		Change 2009 vs. 2008		Nine Months Ended September 30, 2009		Change 2009 vs. 2008	
	2008	(In thousands)	\$	%	2008	(In thousands)	\$	%
Meridian Auto-Injector revenue	\$ 71,841	\$ 67,515	\$ 4,326	6.4%	\$ 200,539	\$ 165,687	\$ 34,852	21.0%
Cost of revenues, exclusive of depreciation, amortization and impairments	28,505	24,705	3,800	15.4	77,820	61,819	16,001	25.9

Revenues and cost of revenues from our Meridian Auto-Injector segment increased in the third quarter of 2009 compared to the third quarter of 2008 primarily due to higher unit sales of EpiPen. Revenues and cost of revenues from our Meridian Auto-Injector segment increased in the first nine months of 2009 compared to the first nine months of 2008 primarily due to higher unit sales of EpiPen and higher unit sales of products sold to the government.

Revenues from the Meridian Auto-Injector segment fluctuate based on the buying patterns of Dey, L.P. and government customers. With respect to auto-injector products sold to government entities, demand for these products is affected by the cyclical nature of procurements as well as response to domestic and international events. Demand for EpiPen[®] is seasonal as a result of its use in the emergency treatment of allergic reactions for both insect stings or bites, more of which occur in the warmer months, and food allergies, for which demand increases in the months preceding the start of a new school year. Most of our EpiPen[®] sales are based on our supply agreement with Dey, L.P., which markets, distributes and sells the product worldwide, except for Canada, where it is marketed, distributed and sold by us. Total prescriptions for EpiPen[®] in the United States increased approximately 10.8% and 10.0% in the third quarter and the first nine months of 2009, respectively, compared to the third quarter and the first nine months of 2008, according to IMS monthly prescription data.

For a discussion regarding the risk of potential generic competition for EpiPen[®], please see Note 10. Commitments and Contingencies, in Part I, Item 1, Financial Statements.

Royalties

	Three Months Ended September 30, 2009		Change 2009 vs. 2009		Nine Months Ended September 30, 2009		Change 2009 vs. 2008	
	2008	(In thousands)	\$	%	2008	(In thousands)	\$	%

	(In thousands)				(In thousands)			
Royalty revenue	\$ 11,932	\$ 18,456	\$ (6,524)	(35.3)%	\$ 41,399	\$ 61,257	\$ (19,858)	(32.4)%
Cost of revenues, exclusive of depreciation, amortization and impairments	1,480	2,281	(801)	(35.1)	5,105	7,485	(2,380)	(31.8)

Revenues from royalties are derived primarily from payments we receive based on sales of Adenoscan[®]. We are not responsible for the marketing of this product.

On April 10, 2008, CV Therapeutics, Inc. and Astellas Pharma US, Inc. (Astellas) announced that the FDA approved regadenoson injection, an A2A adenosine receptor agonist product that competes with Adenoscan[®]. Regadenoson has been commercialized by Astellas. Astellas is also responsible for the marketing and sale of Adenoscan[®] pursuant to agreements we have with Astellas. With the commercial launch of regadenoson, sales of Adenoscan and our royalty have declined and may continue to decline. However, our agreements with Astellas provide for minimum royalty payments to us of \$40.0 million per year for three years (beginning June 1, 2008 and ending May 31, 2011). We will continue to receive royalties on the sale of Adenoscan[®] through expiration of the

Table of Contents

patents covering the product, but the minimum guaranteed portion of the royalty payments terminates upon certain events, including a finding of invalidity or unenforceability of the patents related to Adenoscan®.

In October 2007, we entered into an agreement with Astellas and a subsidiary of Teva Pharmaceutical Industries Ltd. providing Teva with the right to launch a generic version of Adenoscan® pursuant to a license in September 2012 or earlier under certain conditions.

Operating Costs and Expenses

	Three		Change		Nine		Change	
	Months Ended		2009 vs. 2008		Months Ended		2009 vs. 2008	
	2009	2008	\$	%	2009	2008	\$	%
	(In thousands)				(In thousands)			
Cost of revenues, exclusive of depreciation, amortization and impairments as shown below	\$ 162,797	\$ 101,465	\$ 61,332	60.4%	\$ 469,829	\$ 295,111	\$ 174,718	59.2%
Selling, general and administrative	135,742	99,278	36,464	36.7	401,640	341,109	60,531	17.7
Research and development	22,640	33,855	(11,215)	(33.1)	71,098	116,525	(45,427)	(39.0)
Depreciation and amortization	53,349	29,894	23,455	78.5	159,560	121,749	37,811	31.1
Asset impairments						39,429	(39,429)	(100.0)
Restructuring charges	1,653	1,153	500	43.4	51,178	1,670	49,508	>100.0
Total operating costs and expenses	\$ 376,181	\$ 265,645	\$ 110,536	41.6%	\$ 1,153,305	\$ 915,593	\$ 237,712	26.0%

Selling, General and Administrative Expenses

	Three		Change		Nine		Change	
	Months Ended		2009 vs. 2008		Months Ended		2009 vs. 2008	
	2009	2008	\$	%	2009	2008	\$	%
	(In thousands)				(In thousands)			
Selling, general and administrative, exclusive of co-promotion fees	\$ 134,315	\$ 93,291	\$ 41,024	44.0%	\$ 390,885	\$ 307,102	\$ 83,783	27.3%
					6,733		6,733	

Acquisition related costs								
Co-promotion fees	1,427	5,987	(4,560)	(76.2)	4,022	34,007	(29,985)	(88.2)
Total selling, general and administrative	\$ 135,742	\$ 99,278	\$ 36,464	36.7%	\$ 401,640	\$ 341,109	\$ 60,531	17.7%

As a percentage of total revenues, total selling, general, and administrative expenses were 29.3% and 25.6% in the third quarter of 2009 and in the third quarter of 2008, respectively. As a percentage of total revenues, total selling, general, and administrative expenses were 30.0% and 28.0% in the first nine months of 2009 and 2008, respectively.

Total selling, general and administrative expenses increased in the third quarter and first nine months of 2009 compared to the third quarter and first nine months of 2008 primarily due to the acquisition of Alpharma in late December of 2008, partially offset by a decrease in co-promotion expenses for fees that we pay to Wyeth under our Amended and Restated Co-Promotion Agreement (the Amended Co-Promotion Agreement). The decrease in co-promotion expense is due to a decrease in Altace[®] net sales and the lower percentage of net sales of Altace[®] that we pay Wyeth in 2009 compared to 2008 under the Amended Co-Promotion Agreement. For additional discussion regarding the Amended Co-Promotion Agreement, please see Other within the Liquidity and Capital

Table of Contents

Resources section below. For a discussion regarding net sales of Altace®, please see Altace® within the Sales of Key Products section above.

We incurred special charges of \$6.7 million in the first nine months of 2009 for costs related to the acquisition and integration of Alparma. For additional information related to the acquisition of Alparma, please see Note 7, Acquisitions, Dispositions, Co-Promotions and Alliances, in Part I, Item 1, Financial Statements.

Selling, general and administrative expense includes income of \$6.7 million and \$4.7 million in the third quarter of 2008 and the first nine months of 2008, respectively, primarily due to insurance recovery of professional fees, partially offset by professional fees related to the previously completed investigations of our company by the Office of the Inspector General of the U.S. Department of Health and Human Services (HHS/OIG) and the SEC, and the private plaintiff securities litigation. During the second and third quarters of 2008, we recorded anticipated insurance recovery of legal fees in the amounts of \$3.0 million and \$8.0 million, respectively, related to the securities litigation. For additional information, please see Note 10, Commitments and Contingencies, in Part I, Item 1, Financial Statements.

Research and Development Expense

	Three		Change		Nine		Change	
	Months Ended		2009 vs. 2008		Months Ended		2009 vs. 2008	
	2009	2008	\$	%	2009	2008	\$	%
	(In thousands)				(In thousands)			
Research and development	\$ 22,640	\$ 33,855	\$ (11,215)	(33.1)%	\$ 71,098	\$ 111,025	\$ (39,927)	(36.0)%
Research and development in-process upon acquisition						5,500	(5,500)	(100.0)
Total research and development	\$ 22,640	\$ 33,855	\$ (11,215)	(33.1)%	\$ 71,098	\$ 116,525	\$ (45,427)	(39.0)%

Research and development represents expenses associated with the ongoing development of investigational drugs and product life-cycle management projects in our research and development pipeline. These expenses decreased in the third quarter and first nine months of 2009 compared to the third quarter and first nine months of 2008 primarily due to milestone payments made in 2008. During the third quarter of 2008, we expensed and paid milestones of \$5.1 million associated with the acceptance of an investigational new drug application under our agreements with Pain Therapeutics. In the second quarter of 2008, we accrued development milestones of \$15.8 million, which were paid in the third quarter of 2008, associated with the acceptance of the NDA filing for Remoxy® by the FDA. Also, during the second quarter of 2008, we expensed and paid a \$5.0 million milestone payment to Acura associated with positive top-line results from the Phase III clinical trial evaluating Acurox™.

Research and development in-process upon acquisition represents the actual cost of acquiring rights to novel branded pharmaceutical projects in development from third parties, which costs were expensed during 2008 at the time of

acquisition. We classified these costs as special items and they include the following:

A charge of \$3.0 million in the first nine months of 2008 for our acquisition of in-process research and development related to the exercise of our portion for a third immediate-release opioid product under a License, Development and Commercialization Agreement with Acura to develop and commercialize certain opioid analgesic products utilizing Acura's Aversio® Technology in the United States, Canada and Mexico. We believe there is a reasonable probability of completing the project successfully; however, the success of the project depends on the successful outcome of the clinical development program and approval of the product by the FDA. The estimated cost to complete the project at the time of the execution of the agreement was approximately \$16.0 million.

A charge of \$2.5 million in the first nine months of 2008 for our acquisition of in-process research and development associated with our Product Development Agreement with CorePharma to develop new formulations of Skelaxin®. Any intellectual property created as a result of the agreement will belong to us and we will grant CorePharma a non-exclusive, royalty-free license to use this newly created intellectual property with any product not containing metaxalone. The success of the project depends on additional

Table of Contents

development activities and FDA approval. The estimated cost to complete the development activities at the time of the execution of the agreement was approximately \$2.5 million.

For a discussion regarding recent research and development activities, please see [Recent Developments](#) above.

Depreciation and Amortization Expense

Depreciation and amortization expense increased in the third quarter of 2009 compared to the third quarter of 2008 primarily due to an increase in depreciation and amortization expense associated with the acquisition of Alpharma in late December of 2008, and an increase in amortization expense associated with Skelaxin[®]. Depreciation and amortization expense increased in the first nine months of 2009 compared to the first nine months of 2008 primarily due to an increase in amortization expense associated with Skelaxin[®] and an increase in depreciation and amortization expense associated with Alpharma, which we acquired in late 2008, partially offset by a decrease in amortization expense associated with Altace[®].

Following the U.S. District Court's order ruling invalid two Skelaxin[®] patents on January 20, 2009, we estimated the potential effect on future net sales of the product. We believe that the intangible assets associated with Skelaxin[®] are not currently impaired based on estimated undiscounted cash flows associated with these assets. However, as a result of the order described above, we reduced the estimated remaining useful life of the intangible assets of Skelaxin[®] during the first quarter of 2009. The amortization expense associated with Skelaxin[®] increased to \$20.0 million in the third quarter of 2009 from \$6.0 million in the third quarter of 2008 and to \$60.1 million in the first nine months of 2009 from \$17.7 million in the first nine months of 2008. If our current estimates regarding future cash flows adversely change, we may have to further reduce the estimated remaining useful life and/or write off a portion or all of these intangible assets. As of September 30, 2009, the net intangible assets associated with Skelaxin[®] total approximately \$56.9 million.

Following the Circuit Court's decision in September 2007 invalidating our 722 patent that covered Altace[®], we undertook an analysis of its potential effect on future net sales of the product. Based upon this analysis, we reduced the estimated remaining useful life of Altace[®]. Accordingly, amortization of the remaining intangibles associated with Altace[®] was completed during the first quarter of 2008. The amortization expense associated with Altace[®] during the first quarter of 2008 was \$29.7 million.

In April 2009, a competitor entered the market with a generic substitute for Cytomel[®]. As a result, we lowered our future sales forecast for this product. We believe that the intangible assets associated with Cytomel[®] are not currently impaired based on estimated undiscounted cash flows associated with these assets. However, if our estimates regarding future cash flows adversely change, we may have to reduce the estimated remaining useful life and/or write off a portion or all of these intangible assets. As of September 30, 2009, the net intangible assets associated with Cytomel[®] total approximately \$10.6 million.

End-user demand for Synercid[®] has declined in recent years. As of September 30, 2009, the net intangible assets associated with Synercid[®] total approximately \$24.6 million. We believe that these intangible assets are not currently impaired based on estimated undiscounted cash flows associated with these assets. However, if our estimates regarding future cash flows prove to be incorrect or adversely change, we may have to reduce the estimated remaining useful life and/or write off a portion or all of these intangible assets.

In addition, certain generic pharmaceutical companies have challenged the patent covering Avinza[®]. For additional information, please see Note 10, [Commitments and Contingencies](#), in Part I, Item 1, [Financial Statements](#). If a generic version of Avinza[®] enters the market, we may have to write off a portion or all of the intangible assets associated with this product.

Depreciation and amortization expense included special items of \$0.7 million in the third quarter of 2008, and \$1.3 million and \$1.9 million in the first nine months of 2009 and 2008, respectively, due to accelerated depreciation on certain assets. There was no accelerated depreciation in the third quarter of 2009.

Table of Contents***Other Operating Expenses***

In addition to the special items described above, we incurred other special items affecting operating costs and expenses. These other special items included the following:

Asset impairment charges of \$39.4 million in the second quarter of 2008, primarily associated with a decline in end-user demand for Synercid®.

Restructuring charges of \$1.7 million and \$51.2 million in the third quarter and first nine months of 2009, respectively, primarily due to our restructuring initiative designed to partially offset the potential decline in Skelaxin® net sales in the event a generic competitor enters the market. For additional information on the first quarter 2009 restructuring event, please see Note 14, Restructuring Activities, in Part I, Item 1, Financial Statements.

Non-Operating Items

	Three Months		Nine Months	
	Ended September 30, 2009	2008	Ended September 30, 2009	2008
	(In thousands)		(In thousands)	
Interest income	\$ 1,027	\$ 8,110	\$ 5,321	\$ 31,000
Interest expense	(22,218)	(5,300)	(72,913)	(15,571)
Gain (loss) on investment	521		(826)	
Other, net	1,526	(1,024)	2,859	(1,851)
Total other (expense) income	\$ (19,144)	\$ 1,786	\$ (65,559)	\$ 13,578
Income tax expense	25,536	42,114	48,829	106,525

Gain (loss) on Investment

We incurred a gain of \$0.5 million and a loss of \$0.8 million in the third quarter of 2009 and first nine months of 2009, respectively, related to our investments in debt securities.

Interest Income

Interest income decreased during the third quarter and first nine months of 2009 compared to the third quarter and first nine months of 2008 primarily due to a lower average balance of cash, cash equivalents and investments in debt securities due to the acquisition of Alparma in late December 2008, and a decrease in interest rates.

Interest Expense

Interest expense increased in the third quarter and first nine months of 2009 compared to the third quarter and first nine months of 2008 primarily due to an increase in borrowings as a result of the acquisition of Alparma in late December 2008. The acquisition of Alparma was funded with available cash on hand, borrowings of \$425.0 million under the Senior Secured Revolving Credit Facility, as amended on December 5, 2008, and borrowings of \$200.0 million under a new Senior Secured Term Facility.

On January 1, 2009, we adopted the Financial Accounting Standards Board (FASB) statement that requires us to separately account for the liability and equity components of our \$400.0 million 11/4% Convertible Senior Notes due April 1, 2026 (the Convertible Senior Notes) that can be settled for cash based on the estimated nonconvertible debt borrowing rate. It requires retrospective application to all periods presented. Thus interest expense increased by \$4.5 million and \$4.2 million in the third quarter of 2009 and the third quarter of 2008, respectively, and \$13.3 million and \$12.4 million in the first nine months of 2009 and 2008, respectively, due to the adoption of this standard.

Table of Contents

Income Tax Expense

During the third quarter and first nine months of 2009, our effective income tax rate was 37.5% and 41.2%, respectively. These rates are greater than the statutory rate of 35% primarily due to losses from foreign subsidiaries with no tax benefit, taxes related to stock compensation and state taxes.

During each the third quarter and first nine months of 2008, our effective income tax rate was 33.8%. This rate varied from the statutory rate of 35% due primarily to tax benefits related to tax-exempt interest income and domestic manufacturing deductions, which benefits were partially offset by state taxes.

Liquidity and Capital Resources

General

We believe that existing balances of cash, cash equivalents, cash generated from operations and our existing revolving credit facility are sufficient to finance our current operations and working capital requirements on both a short-term and long-term basis. However, we cannot predict the amount or timing of our need for additional funds. We cannot provide assurance that funds will be available to us when needed on favorable terms, or at all.

Investments in Debt Securities

As of September 30, 2009, our investments in debt securities consisted solely of tax-exempt auction rate securities and did not include any mortgage-backed securities or any securities backed by corporate debt obligations. The tax-exempt auction rate securities that we hold are long-term variable rate bonds tied to short-term interest rates that are intended to reset through an auction process generally every seven, 28 or 35 days. Our investment policy requires us to maintain an investment portfolio with a high credit quality. Accordingly, our investments in debt securities are limited to issues which were rated AA or higher at the time of purchase.

In the event that we attempt to liquidate a portion of our holdings through an auction and are unable to do so, we term it an auction failure. On February 11, 2008, we began to experience auction failures. As of September 30, 2009, all our investments in auction rate securities, with a total par value of \$377.2 million, have experienced multiple failed auctions. In the event of an auction failure, the interest rate on the security is reset according to the contractual terms in the underlying indenture. As of November 2, 2009, we have received all scheduled interest payments associated with these securities.

The current instability in the credit markets may continue to affect our ability to liquidate these securities. The funds associated with failed auctions will not be accessible until a successful auction occurs, the issuer calls or restructures the underlying security, the underlying security matures or a buyer outside the auction process emerges. Based on the frequency of auction failures and the lack of market activity, current market prices are not available for determining the fair value of these investments. As a result, we have measured \$377.2 million in par value of our investments in debt securities and the UBS put right discussed below, or 44.7% of the assets that we have measured at fair value, using unobservable inputs which are classified as Level 3 measurements. For additional information regarding this, please see Note 4, Fair Value Measurements, in Part I, Item 1, Financial Statements.

As of September 30, 2009, there were cumulative unrealized holding losses of \$37.0 million recorded in accumulated other comprehensive income (loss) on the Condensed Consolidated Balance Sheets associated with investments in debt securities with a par value of \$323.9 million classified as available for sale. All of these investments in debt securities have been in continuous unrealized loss positions for greater than twelve months. As of September 30, 2009, we believed the decline was temporary and it was probable that the par amount of these auction rate securities

would be collectible under their contractual terms.

During the second quarter of 2009, we sold certain auction rate securities associated with student loans with a par value of \$20.4 million for \$18.9 million to the issuer and recognized a realized loss of \$1.4 million in the Condensed Consolidated Statement of Operations. During the fourth quarter of 2009, we received and accepted offers from two separate issuers of certain auction rate securities associated with student loans that were outstanding at September 30, 2009 with par values totaling \$60.9 million for \$56.7 million. The estimated fair market value of these auction rate securities at September 30, 2009 was \$52.3 million. The unrealized loss of \$8.6 million was

Table of Contents

recorded in accumulated other comprehensive income (loss) on the accompanying Condensed Consolidated Balance Sheet at September 30, 2009 as we had no intent to sell and believed it was more likely than not that we would not be required to sell the security prior to recovery. During the fourth quarter of 2009 a realized loss of \$4.2 million will be recorded in the Condensed Consolidated Statement of Operations. We have not sold any other investments in debt securities below par value during the periods presented in the accompanying Condensed Consolidated Statement of Operations.

During the fourth quarter of 2008, we accepted an offer from UBS Financial Services, Inc. (UBS) providing us the right to sell at par value certain auction rate securities outstanding at September 30, 2009 with a par value of \$38.3 million to UBS during the period from June 30, 2010 to July 2, 2012. We have elected the fair value option to account for this right. As a result, gains and losses associated with this right are recorded in other income (expense) in the Condensed Consolidated Statement of Operations. The value of the right to sell certain auction rate securities to UBS was estimated considering the present value of future cash flows, the fair value of the auction rate security and counterparty risk. As of September 30, 2009 and December 31, 2008, the fair value of the right to sell the auction rate securities to UBS at par was \$3.6 million and \$4.0 million, respectively. With respect to this right, during the third quarter and first nine months of 2009, we recognized an unrealized gain of less than \$0.1 million and an unrealized loss of \$0.4 million, respectively, in other income (expense) in the Condensed Consolidated Statement of Operations.

In addition, during the fourth quarter of 2008, we transferred the classification of the auction rate securities that are included in this right from available-for-sale securities to trading securities. As of September 30, 2009 and December 31, 2008, the fair value of the investments in debt securities classified as trading was \$34.7 million and \$36.0 million, respectively. During the third quarter and first nine months of 2009, we recognized unrealized gains related to these securities of \$0.5 million and \$1.0 million, respectively, in other income (expense) in the Condensed Consolidated Statement of Operations.

As of September 30, 2009, we had unrealized holding gains of \$0.9 million associated with a security that was previously impaired, as it was determined that the losses in previous periods were other-than-temporary.

As of September 30, 2009, we had approximately \$377.2 million, in par value, invested in tax-exempt auction rate securities which consisted of \$258.9 million associated with student loans backed by the Federal Family Education Loan Program (FFELP), \$89.4 million associated with municipal bonds in which performance is supported by bond insurers and \$28.9 million associated with student loans collateralized by loan pools which equal at least 200% of the bond issue.

As of September 30, 2009, we classified \$39.6 million of auction rate securities as current assets and \$292.0 million as long-term assets.

Skelaxin[®]

As previously disclosed, we are involved in multiple legal proceedings over patents relating to our product Skelaxin[®]. In January 2009, the U.S. District Court for the Eastern District of New York issued an order ruling invalid two of these patents. In June 2009, the Court entered judgment against us. We have appealed the judgment and intend to vigorously defend our interests. The entry of the order may lead to generic versions of Skelaxin[®] entering the market sooner than previously anticipated, which would likely cause net sales of Skelaxin[®] to decline significantly. For additional information regarding Skelaxin[®] litigation, please see Note 10, Commitments and Contingencies, in Part 1, Item 1, Financial Statements .

Following the decision of the District Court in January 2009, we conducted an extensive examination of the company and developed a restructuring initiative designed to partially offset the potential material decline in Skelaxin sales in

the event that a generic competitor enters the market. This initiative included, based on an analysis of our strategic needs: a reduction in sales, marketing and other personnel; leveraging of staff; expense reductions and additional controls over spending; and reorganization of sales teams. Our animal health activities were not affected by the restructuring.

Table of Contents

We incurred total restructuring costs of approximately \$50.0 million, almost all of which was paid during the second quarter of 2009. These costs relate to severance pay and other employee termination expenses. For additional information, please see Note 14, Restructuring Activities in Part I, Item 1, Financial Statements.

Alpharma

On December 29, 2008, we completed our acquisition of all the outstanding shares of Class A Common Stock, together with the associated preferred stock purchase rights, of Alpharma at a price of \$37.00 per share in cash, for an aggregate purchase price of approximately \$1.6 billion. Alpharma was a branded specialty pharmaceutical company with a growing specialty pharmaceutical franchise in the U.S. pain market with its Flector[®] Patch (diclofenac epolamine topical patch) and a pipeline of new pain medicines led by Embeda[™]. Alpharma is also a global leader in the development, registration, manufacture and marketing of MFAs and water soluble therapeutics for food-producing animals, including poultry, cattle and swine.

The acquisition was financed with available cash on hand, borrowings under the Senior Secured Revolving Credit Facility of \$425.0 million and borrowings under the Term Loan of \$200.0 million. For additional information on the borrowings, please see below.

In connection with the acquisition of Alpharma, we together with Alpharma executed a consent order (the Consent Order) with the U.S. Federal Trade Commission. The Consent Order required us to divest the assets related to Alpharma's branded oral long-acting opioid analgesic drug Kadian[®] to Actavis Elizabeth, L.L.C., (Actavis LLC). In accordance with the Consent Order, effective upon the acquisition of Alpharma, on December 29, 2008, we divested the Kadian[®] product to Actavis LLC. Actavis LLC is entitled to sell Kadian[®] as a branded or generic product. Prior to this divestiture, Actavis LLC supplied Kadian[®] to Alpharma.

Actavis LLC will pay a purchase price of up to an aggregate of \$127.5 million in cash based on the achievement of certain Kadian[®] quarterly gross profit-related milestones for the period beginning January 1, 2009 and ending June 30, 2010. The maximum purchase price payment associated with each calendar quarter is as follows:

	Maximum Purchase Price Payment
First Quarter 2009	\$ 30.0 million
Second Quarter 2009	25.0 million
Third Quarter 2009	25.0 million
Fourth Quarter 2009	20.0 million
First Quarter 2010	20.0 million
Second Quarter 2010	7.5 million

None of the quarterly payments above, when combined with all prior payments made by Actavis LLC, shall exceed the aggregate amount of gross profits from the sale of Kadian[®] in the United States by Actavis LLC and its affiliates for the period beginning on January 1, 2009 and ending on the last day of such calendar quarter. Any quarterly purchase price payment that is not paid by Actavis LLC due to the application of such provision will be carried forward to the next calendar quarter, increasing the maximum quarterly payment in the subsequent quarter. However, the cumulative purchase price payable by Actavis LLC will not exceed the lesser of (a) \$127.5 million and (b) the gross profits from the sale of Kadian[®], as determined by the agreement, in the United States by Actavis LLC and its affiliates for the period from January 1, 2009 through June 30, 2010. At the time of the divestiture, we recorded a

receivable of \$115.0 million reflecting the present value of the estimated future purchase price payments from Actavis LLC. There was no gain or loss recorded as a result of the divestiture. In accordance with the agreement, quarterly payments will be received one quarter in arrears. During the third quarter of 2009 we received \$25.0 million from Actavis LLC related to the second quarter of 2009 gross profit from sales. During the first nine months of 2009 we received \$59.8 million from Actavis LLC, \$55.0 million related to gross profit from sales during the first and second quarters of 2009 and \$4.8 million related to inventory sold to Actavis LLC of the time of the divestiture.

Table of Contents

As part of the integration of Alpharma, management developed a restructuring initiative to eliminate redundancies in operations created by the acquisition. This initiative included, based on an analysis of our strategic needs: a reduction in sales, marketing and other personnel; leveraging of staff; expense reductions and additional controls over spending; and reorganization of sales teams.

We estimated total costs of approximately \$69.3 million associated with this restructuring plan, almost all of which are cash-related costs. All employee termination costs are expected to be paid by the end of 2011. All contract termination costs are expected to be paid by the end of 2018. For additional information, please see Note 14, Restructuring Activities, in Part I, Item 1, Financial Statements.

During the first quarter of 2009, we paid \$385.2 million to redeem the Convertible Senior Notes of Alpharma outstanding at the time of the acquisition and at December 31, 2008. For additional information, please see Alpharma Convertible Senior Notes in Certain Indebtedness and Other Matters.

Senior Secured Revolving Credit Facility

On April 23, 2002, we established a \$400.0 million five-year Senior Secured Revolving Credit Facility which was scheduled to mature in April 2007. On April 19, 2007, this facility was terminated and replaced with a new \$475.0 million five-year Senior Secured Revolving Credit Facility, as amended on December 5, 2008 (the Revolving Credit Facility). The Revolving Credit Facility matures in April 2012 or in September 2011 if the Convertible Senior Notes have not been refinanced. In connection with the acquisition of Alpharma on December 29, 2008, we borrowed \$425.0 million in principal amount under the Revolving Credit Facility.

During the third quarter and first nine months of 2009, we made payments of \$18.6 million and \$152.8 million, respectively, on the Revolving Credit Facility, \$91.3 million in excess of that required by the terms of the Revolving Credit Facility during the first nine months of 2009. The average interest rate on borrowings under the Revolving Credit Facility was 5.8% in the third quarter of 2009 and 5.9% in the first nine months of 2009. The availability under the Revolving Credit Facility was reduced to \$336.5 million as of September 30, 2009. As of September 30, 2009, the remaining undrawn commitment amount under the Revolving Credit Facility totals approximately \$61.3 million after giving effect to outstanding letters of credit totaling approximately \$3.0 million.

Under the Revolving Credit Facility, we are required to make annual prepayments equal to 50% of our annual excess cash flows, which can be reduced to 25% upon the existence of certain conditions. In addition, we are required to make prepayments upon the occurrence of certain events, such as an asset sale, the issuance of debt or equity or the liquidation of auction rate securities. These mandatory prepayments will be allocated among the Revolving Credit Facility and the Term Facility described below in accordance with those agreements and will permanently reduce the commitments under the Revolving Credit Facility. However, commitments under the Revolving Credit Facility will not be reduced in any event below \$150.0 million.

Under the terms of the Revolving Credit Facility the credit commitment will be automatically and permanently reduced, on a quarterly basis, to the amounts set forth below:

December 31, 2009	\$ 403.8 million
December 31, 2010	308.8 million
December 31, 2011	213.8 million
March 31, 2012	190.0 million

We have the right to prepay, without penalty (other than customary breakage costs), any borrowing under the Revolving Credit Facility.

For additional discussion regarding the Revolving Credit Facility, please see Senior Secured Revolving Credit Facility within the Certain Indebtedness and Other Matters section below.

Senior Secured Term Facility

On December 29, 2008, we entered into a \$200.0 million term loan credit agreement, comprised of a four-year senior secured term loan facility (the Term Facility) with a maturity date of December 28, 2012 or in September 2011 if the Convertible Senior Notes have not been refinanced. During the third quarter and first nine months of

Table of Contents

2009, we made payments of \$105.5 million and \$171.3 million, respectively, on the Term Facility, \$97.6 million and \$131.5 million, respectively, in excess of that required by our repayment schedule and the provisions related to mandatory prepayments under the Term Facility. The average interest rate on borrowings under the Term Facility was 8.1% in the third quarter and first nine months of 2009.

In October 2009, we paid the outstanding balance of the Senior Secured Term Facility, of \$28.7 million, completing our repayment obligations under the facility.

For additional discussion regarding the Term Facility, please see *Senior Secured Term Facility* within the *Certain Indebtedness and Other Matters* section below.

CorePharma

In June 2008, we entered into a Product Development Agreement with CorePharma to collaborate in the development of new formulations of metaxalone that we currently market under the brand name Skelaxin®. Under the Agreement, we and CorePharma granted each other non-exclusive cross-licenses to certain pre-existing intellectual property. Any intellectual property created as a result of the agreement will belong to us and we will grant CorePharma a non-exclusive, royalty-free license to use this newly created intellectual property with any product not containing metaxalone. In the second quarter of 2008, we made a non-refundable cash payment of \$2.5 million to CorePharma. Under the terms of the agreement, we will reimburse CorePharma for its incurred cost to complete the development activities under the agreement, subject to a cap. In addition, we could be required to make milestone payments based on the achievement and success of specified development activities and the achievement of specified net sales thresholds of such formulations, as well as royalty payments based on net sales.

Acura

In October 2007, we entered into a License, Development and Commercialization Agreement with Acura to develop and commercialize certain opioid analgesic products utilizing Acura's Aversio® Technology in the United States, Canada and Mexico. The agreement provides us with an exclusive license for Acurox® Tablets and another opioid product utilizing Acura's Aversio® Technology. In addition, the agreement provides us with an option to license all future opioid analgesic products developed utilizing Acura's Aversio® Technology. In May 2008 and December 2008, we exercised our options for third and fourth immediate-release opioid products under the agreement. In connection with the exercise of the options, we paid non-refundable option exercise fees to Acura of \$3.0 million for each option.

Under the terms of the agreement, we made a non-refundable cash payment of \$30.0 million to Acura in December 2007. In addition, we will reimburse Acura for all research and development expenses incurred beginning from September 19, 2007 for Acurox® Tablets and all research and development expenses related to future products after the exercise of our option to an exclusive license for each future product. During January 2008, we made an additional payment of \$2.0 million to Acura, which was accrued as of December 31, 2007, for certain research and development expenses incurred by Acura prior to the closing date of the agreement. We may make additional non-refundable cash milestone payments to Acura based on the successful achievement of certain clinical and regulatory milestones for Acurox® Tablets and for each other product developed under the agreement. In June 2008, we made a milestone payment of \$5.0 million associated with positive top-line results from the Phase III clinical trial evaluating Acurox® Tablets. We will also make an additional \$50.0 million non-refundable cash milestone payment to Acura in the first year that the aggregate net sales of all products developed under the agreement exceeds \$750.0 million. In addition, we will make royalty payments to Acura ranging from 5% to 25% based on the level of combined annual net sales of all products developed under the agreement.

Altace[®]

In December 2007, a third party launched a generic substitute for Altace[®]. In June 2008, additional competitors entered the market with generic substitutes for Altace[®]. As a result of the entry of generic competition, Altace[®] net sales decreased in 2008 and we expect net sales of Altace[®] will continue to decline significantly during 2009. For a discussion regarding the generic competition for Altace[®], please see Note 10, Commitments and Contingencies, in Part I, Item 1, Financial Statements.

Table of Contents

Following the Circuit Court's decision in September 2007 invalidating our 722 Patent that covered Altace[®], our senior management team conducted an extensive examination of our company and developed a restructuring initiative. This initiative included a reduction in personnel, staff leverage, expense reductions and additional controls over spending, reorganization of sales teams and a realignment of research and development priorities. We incurred total costs of approximately \$67.0 million in connection with this initiative. This total included a contract termination payment paid to Depomed, Inc. in October of 2007 of approximately \$29.7 million. We made additional cash payments of \$22.2 million during the first quarter of 2008 primarily related to employee termination costs. For additional information, please see Note 14, Restructuring Activities, in Part I, Item 1, Financial Statements.

Avinza[®]

In September 2006, we entered into a definitive asset purchase agreement and related agreements with Ligand Pharmaceuticals Incorporated (Ligand) to acquire rights to Avinza[®] (morphine sulfate long-acting). Avinza[®] is a long-acting formulation of morphine and is indicated as a once-daily treatment for moderate to severe pain in patients who require continuous opioid therapy for an extended period of time.

As part of the transaction, we have agreed to pay Ligand an ongoing royalty and assume payment of Ligand's royalty obligations to third parties. We paid Ligand a royalty of 15% of net sales of Avinza[®] until October 2008. Subsequent royalty payments to Ligand will be based upon calendar year net sales of Avinza[®] as follows:

If calendar year net sales are less than \$200.0 million, the royalty payment will be 5% of all net sales.

If calendar year net sales are greater than \$200.0 million, then the royalty payment will be 10% of all net sales up to \$250.0 million, plus 15% of net sales greater than \$250.0 million.

Other

In June 2000, we entered into a Co-Promotion Agreement with Wyeth to promote Altace[®] in the United States and Puerto Rico through October 29, 2008, with possible extensions as outlined in the Co-Promotion Agreement. Under the agreement, Wyeth paid an upfront fee to us of \$75.0 million. In connection with the Co-Promotion Agreement, we agreed to pay Wyeth a promotional fee based on annual net sales of Altace[®]. In July 2006, we entered into an Amended and Restated Co-Promotion Agreement with Wyeth regarding Altace[®]. Effective January 1, 2007, we assumed full responsibility for selling and marketing Altace[®]. We have paid or will pay Wyeth a reduced annual fee as follows:

For 2006, 15% of Altace[®] net sales up to \$165.0 million, 42.5% of Altace[®] net sales in excess of \$165.0 million and less than or equal to \$465.0 million, and 52.5% of Altace[®] net sales that are in excess of \$465.0 million and less than or equal to \$585.0 million.

For 2007, 30% of Altace[®] net sales, with the fee not to exceed \$178.5 million.

For 2008, 22.5% of Altace[®] net sales, with the fee not to exceed \$134.0 million.

For 2009, 14.2% of Altace[®] net sales, with the fee not to exceed \$84.5 million.

For 2010, 25% of Altace[®] net sales, with the fee not to exceed \$5.0 million.

The annual fee is accrued quarterly based on a percentage of Altace[®] net sales at a rate equal to the expected relationship of the expected fee for the year to applicable expected Altace[®] net sales for the year.

In March 2006, we acquired the exclusive right to market, distribute and sell EpiPen® throughout Canada and certain other assets from AllereX Laboratory LTD (AllereX). Under the terms of the agreements, the initial purchase price was approximately \$23.9 million, plus acquisition costs of approximately \$0.7 million. As an additional component of the purchase price, we pay AllereX an earn-out equal to a percentage of future sales of EpiPen® in Canada over a fixed period of time. As these additional payments accrue, we will increase intangible assets by the amount of the accrual. As of September 30, 2009, we have incurred a total of \$11.5 million for these earn-out payments. The aggregate amount of these payments will not exceed \$13.2 million.

Table of Contents

In December 2005, we entered into a cross-license agreement with Mutual. Under the terms of the agreement, each of the parties has granted the other a worldwide license to certain intellectual property, including patent rights and know-how, relating to metaxalone. As of January 1, 2006, we began paying royalties on net sales of products containing metaxalone to Mutual. This royalty increased in the fourth quarter of 2006 and the second quarter of 2009 due to the achievement of certain milestones. The royalty percentage we pay to Mutual is currently in the low-double-digits and could potentially increase by an additional 10% depending on the achievement of certain regulatory and commercial milestones in the future. In the event certain specified net sales levels are not achieved, the royalty could be reduced to a lower double-digit or single-digit rate. No increases in the royalty rate are presently anticipated. The royalty we pay to Mutual is in addition to the royalty we pay to Elan Corporation, plc (Elan) on our current formulation of metaxalone, which we refer to as Skelaxin®.

During the fourth quarter of 2005, we entered into a strategic alliance with Pain Therapeutics, Inc. to develop and commercialize Remoxy® and other opioid painkillers. Remoxy® is an investigational novel formulation of long-acting oxycodone with a proposed indication for the treatment of moderate to severe pain. Under the strategic alliance, we made an upfront cash payment of \$150.0 million in December 2005 and made a milestone payment of \$5.0 million in July 2006 to Pain Therapeutics. In August 2008, we made milestone payments totaling \$20.0 million. In addition, we may pay additional milestone payments of up to \$125.0 million in cash based on the successful clinical and regulatory development of Remoxy® and other opioid products. This amount includes \$15.0 million upon FDA approval of Remoxy®. In March 2009, we exercised rights under our Collaboration Agreement with Pain Therapeutics and assumed sole control and responsibility for the development of Remoxy®. This includes all communications with the FDA regarding Remoxy® and ownership of the Remoxy® NDA. We are responsible for research and development expenses related to this alliance subject to certain limitations set forth in the agreement. After regulatory approval and commercialization of Remoxy® or other products developed through this alliance, we will pay a royalty of 15% of the cumulative net sales up to \$1.0 billion and 20% of the cumulative net sales over \$1.0 billion.

Governmental Pricing Investigation and Related Matters

For information on these matters, please see Note 10, Commitments and Contingencies, in Part I, Item 1, Financial Statements.

Patent Challenges

Certain generic companies have challenged patents on Skelaxin®, Avinza® and EpiPen®. For additional information, please see Note 10, Commitments and Contingencies, in Part I, Item 1, Financial Statements. If a generic version of Skelaxin®, Avinza® or EpiPen® enters the market, our business, financial condition, results of operations and cash flows could be materially adversely affected.

Cash Flows***Operating Activities***

	Nine Months Ended September 30, 2009 2008 (In thousands)	
Net cash provided by operating activities	\$ 262,164	\$ 349,884

Our net cash from operations was lower in 2009 than in 2008 primarily due to a decrease in net sales of several key branded prescription pharmaceutical products. While total net sales increased from 2008 to 2009, gross margins decreased due to a change in the composition of net sales. The branded prescription pharmaceutical segment net sales decreased, while net sales in the Meridian Auto-Injector and Animal Health segments increased. Our branded prescription pharmaceutical segment has higher gross margins than our other segments. The decrease in net sales in the branded prescription pharmaceutical segment was partially offset by a decrease in co-promotion fees. Please see the section entitled Results of Operations for a discussion of net sales, selling, general and administrative expenses and co-promotion fees.

Table of Contents

In addition, we made cash payments related to the Skelaxin® and Alpharma restructuring actions during the first nine months of 2009 which reduced operating cash flows. For information regarding the restructuring actions, please see Note 14, Restructuring Activities in Part I, Item 1, Financial Statements.

The following table summarizes the changes in operating assets and liabilities and deferred taxes for the nine months ended September 30, 2009 and 2008.

	Nine Months Ended September 30, 2009 2008 (In thousands)	
Accounts receivable, net of allowance	\$ 17,672	\$ 14,563
Inventories	11,495	17,917
Prepaid expenses and other current assets	(11,908)	(16,151)
Accounts payable	(53,472)	(2,294)
Accrued expenses and other liabilities	(81,352)	(152,662)
Income taxes payable	(18,141)	46,411
Deferred revenue	(3,510)	(3,510)
Other assets	9,835	23,177
Deferred taxes	41,460	12,957
Total changes in operating assets and liabilities and deferred taxes	\$ (87,921)	\$ (59,592)

Investing Activities

	Nine Months Ended September 30, 2009 2008 (In thousands)	
Net cash (used in) provided by investing activities	\$ (12,389)	\$ 863,583

Our cash flows from investing activities for 2009 were primarily due to payments made in connection with our acquisition of Alpharma of \$70.2 million and capital expenditures of \$29.6 million, partially offset by proceeds related to the sale of Kadian® of \$59.8 million and proceeds from the sale of debt securities of \$38.5 million. Our cash flows from investing activities for 2008 were primarily due to net sales of our investments in debt securities of \$906.7 million, partially offset by capital expenditures of \$45.5 million.

We anticipate capital expenditures, including capital lease obligations, for the year ending December 31, 2009 of approximately \$40.0 to \$45.0 million, which will be funded with cash from operations. The principal capital expenditures are anticipated to include costs associated with the preparation of our facilities to manufacture new products as they emerge from our research and development pipeline.

Financing Activities

**Nine Months
Ended September 30,
2009 2008
(In thousands)**

Net cash used in financing activities	\$ (713,554)	\$ (2,025)
---------------------------------------	--------------	------------

Our cash flows used in financing activities for 2009 were primarily related to payments on long-term debt, which included \$385.2 million related to Alpharma's convertible debt.

Our cash flows used in financing activities for 2008 were primarily related to activities associated with our stock compensation plans, including the exercise of employee stock options.

Table of Contents

Certain Indebtedness and Other Matters

Convertible Senior Notes

During 2006, we issued the Convertible Senior Notes. The Convertible Senior Notes are unsecured obligations and are guaranteed by each of our domestic subsidiaries on a joint and several basis. The Convertible Senior Notes accrue interest at an initial rate of 11/4%. Beginning with the six-month interest period that commences on April 1, 2013, we will pay additional interest during any six-month interest period if the average trading price of the Convertible Senior Notes during the five consecutive trading days ending on the second trading day immediately preceding the first day of such six-month period equals 120% or more of the principal amount of the Convertible Senior Notes. Interest is payable on April 1 and October 1 of each year, beginning October 1, 2006.

On or after April 5, 2013, we may redeem for cash some or all of the Convertible Senior Notes at any time at a price equal to 100% of the principal amount of the Convertible Senior Notes to be redeemed, plus any accrued and unpaid interest, and liquidated damages, if any, to but excluding the date fixed for redemption. Holders may require us to purchase for cash some or all of their Convertible Senior Notes on April 1, 2013, April 1, 2016 and April 1, 2021, or upon the occurrence of a fundamental change, at 100% of the principal amount of the Convertible Senior Notes to be purchased, plus any accrued and unpaid interest, and liquidated damages, if any, up to but excluding the purchase date.

Senior Secured Revolving Credit Facility

On April 23, 2002, we established a \$400.0 million, five-year Senior Secured Revolving Credit Facility which was scheduled to mature in April 2007. On April 19, 2007, this facility was terminated and replaced with a new \$475.0 million five-year Senior Secured Revolving Credit Facility, as amended on December 5, 2008 (the Revolving Credit Facility). The Revolving Credit Facility matures in April 2012 or in September 2011 if the Convertible Senior Notes have not been refinanced. In connection with our acquisition of Alparma on December 29, 2008, we borrowed \$425.0 million in principal. The Revolving Credit Facility requires us to pledge as collateral substantially all of our assets, including 100% of the equity of our U.S. subsidiaries and 65% of the equity of any material foreign subsidiaries. Our obligations under this facility are unconditionally guaranteed on a senior basis by all of our U.S. subsidiaries. As of September 30, 2009, \$272.2 million was outstanding under the Revolving Credit Facility and letters of credit totaled \$3.0 million.

Under the terms of the Revolving Credit Facility, the credit commitments will be automatically and permanently reduced, on a quarterly basis. Additionally, we have the right, without penalty (other than customary breakage costs), to prepay any borrowing under the Revolving Credit Facility and, subject to certain conditions, we are required to make mandatory prepayments. For additional information, please see the discussion in the section titled Liquidity and Capital Resources Senior Secured Revolving Credit Facility above.

Our borrowings under the Revolving Credit Facility bear interest at annual rates that, at our option, will be either:

a base rate generally defined as the sum of (i) the greater of (a) the prime rate of Credit Suisse and (b) the federal funds effective rate plus 0.5% and (ii) 4.0%; or

an adjusted rate generally defined as the sum of (i) the product of (a) LIBOR (by reference to the British Banking Association Interest Settlement Rates) and (b) a fraction, the numerator of which is one and the denominator of which is the number one minus certain maximum statutory reserves for Eurocurrency liabilities and (ii) 5.0%.

Interest on our borrowings is payable quarterly, in arrears, for base rate loans and at the end of each interest rate period (but not less often than quarterly) for LIBO rate loans. We are required to pay an unused commitment fee on the difference between committed amounts and amounts actually borrowed under the Revolving Credit Facility equal to 0.5% per annum. We are required to pay a letter of credit participation fee based upon the aggregate face amount of outstanding letters of credit equal to 5.0% per annum.

Table of Contents

The Revolving Credit Facility requires us to meet certain financial tests, including, without limitation:

maintenance of maximum funded debt to consolidated EBITDA ratios that range from 1.50:1 to 3.25:1 (depending on dates and the occurrence of certain events relating to certain patents); and

maintenance of minimum consolidated EBITDA to interest expense ratios that range from 3.75:1 to 4.00:1 (depending on dates and the occurrence of certain events relating to certain patents).

As of September 30, 2009 and throughout 2009, we were in compliance with these covenants.

In addition, the Revolving Credit Facility contains certain covenants that, among other things, restrict additional indebtedness, liens and encumbrances, sale and leaseback transactions, loans and investments, acquisitions, dividends and other restricted payments, transactions with affiliates, asset dispositions, mergers and consolidations, prepayments, redemptions and repurchases of other indebtedness, capital expenditures and other matters customarily restricted in such agreements. The Revolving Credit Facility contains customary events of default, including, without limitation, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to certain other material indebtedness in excess of specified amounts, certain events of bankruptcy and insolvency, certain ERISA events, judgments in excess of specified amounts, certain impairments to the guarantees, and change in control.

The Revolving Credit Facility requires us to maintain hedging agreements that will fix the interest rates on 50% of our outstanding long-term debt beginning 90 days after the amendment to the facility for a period of not less than two years. Accordingly, in March 2009, we entered into an interest rate swap with an aggregate notional amount of \$112.5 million which was designated as a cash flow hedge of the overall variability of cash flows. As a result of the reduction of our variable rate long-term debt, we maintain greater than 50% of our outstanding long-term debt at fixed rates and, therefore, an interest rate swap is no longer required. In September 2009, we terminated the interest rate swap for \$0.8 million and recognized the cost in interest expense during the third quarter 2009.

In connection with the borrowings, we incurred approximately \$22.2 million of deferred financing costs that are being amortized ratably from the date of the borrowing through the maturity date.

Senior Secured Term Facility

On December 29, 2008, we entered into a \$200.0 million term loan credit agreement, comprised of a four-year senior secured term loan facility (the Term Facility) with a maturity date of December 28, 2012 or in September 2011 if the Convertible Senior Notes have not been refinanced. We borrowed \$200.0 million under the Term Facility and received proceeds of \$192.0 million, net of the discount at issuance. The Term Facility required us to pledge as collateral substantially all of our assets, including 100% of the equity of our U.S. subsidiaries and 65% of the equity of any material foreign subsidiaries. Our obligations under this facility were unconditionally guaranteed on a senior basis by all of our U.S. subsidiaries. As of September 30, 2009, the carrying value of the borrowings under the Term Facility was \$28.4 million. In October 2009, we paid the outstanding balance of the Senior Secured Term Facility, of \$28.7 million, completing our repayment obligations under the facility.

For additional information please see the discussion in the section titled Liquidity and Capital Resources Senior Secured Term Facility above.

Prior to our completing repayment of the Term Facility, it required us to meet certain financial tests, including, without limitation:

maintenance of maximum funded debt to consolidated EBITDA ratios that range from 1.50:1 to 3.25:1 (depending on dates and the occurrence of certain events relating to certain patents); and

maintenance of minimum consolidated EBITDA to interest expense ratios that range from 3.75:1 to 4.00:1 (depending on dates and the occurrence of certain events relating to certain patents).

As of September 30, 2009 and throughout 2009, we were in compliance with these covenants.

Table of Contents

In addition, the Term Facility contained certain covenants that, among other things, restricted additional indebtedness, liens and encumbrances, sale and leaseback transactions, loans and investments, acquisitions, dividends and other restricted payments, transactions with affiliates, asset dispositions, mergers and consolidations, prepayments, redemptions and repurchases of other indebtedness, capital expenditures and other matters customarily restricted in such agreements. The Term Facility contained customary events of default, including, without limitation, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to certain other material indebtedness in excess of specified amounts, certain events of bankruptcy and insolvency, certain ERISA events, judgments in excess of specified amounts, certain impairments to the guarantees, and change in control.

The Term Facility required us to maintain hedging agreements that fixed the interest rates on 50% of our outstanding long-term debt beginning 90 days after the borrowing under the facility for a period of two years. Accordingly, in March 2009, we entered into an interest rate swap with an aggregate notional amount of \$112.5 million which was designated as a cash flow hedge used to offset the overall variability of cash flows. As a result of the reduction of our variable rate long-term debt, we maintain greater than 50% of our outstanding long-term debt at fixed rates and therefore an interest rate swap was no longer required. In September 2009, we terminated the interest rate swap for \$0.8 million and recognized the cost in interest expense during the third quarter 2009.

In connection with the borrowings, we incurred approximately \$8.7 million of deferred financing costs that were amortized ratably from the date of the borrowing based on our repayments.

Alpharma Convertible Senior Notes

At the time of our acquisition of Alpharma, Alpharma had \$300.0 million of Convertible Senior Notes outstanding (the Alpharma Notes). The Alpharma Notes were convertible into shares of Alpharma's Class A common stock at an initial conversion rate of 30.6725 Alpharma common shares per \$1,000 principal amount. The conversion rate of the Alpharma Notes was subject to adjustment upon the direct or indirect sale of all or substantially all of Alpharma's assets or more than 50% of the outstanding shares of the Alpharma common stock to a third party (a Fundamental Change). In the event of a Fundamental Change, the Alpharma Notes included a make-whole provision that adjusted the conversion rate by a predetermined number of additional shares of Alpharma's common stock based on (1) the effective date of the Fundamental Change and (2) Alpharma's common stock market price as of the effective date. The acquisition of Alpharma by us was a Fundamental Change. As a result, Alpharma Notes converted in connection with the acquisition were entitled to be converted at an increased rate of 34.7053 Alpharma common shares, at the acquisition price of \$37 per share, per \$1,000 principal amount of the Alpharma Notes at a date no later than 35 trading days after the occurrence of the Fundamental Change.

During the first quarter of 2009, we paid \$385.2 million to redeem the Alpharma Notes.

Impact of Inflation

We have experienced only moderate raw material and labor price increases in recent years. In general, the price increases we have passed along to our customers have offset inflationary pressures.

Recently Issued Accounting Standards

For information regarding recently issued accounting standards, please see Note 11, Accounting Developments, in Part I, Item 1, Financial Statements.

Critical Accounting Policies and Estimates

We have chosen accounting policies that we believe are appropriate to accurately and fairly report our operating results and financial position, and apply those accounting policies in a consistent manner.

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and

Table of Contents

disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

Significant estimates for which it is reasonably possible that a material change in estimate could occur in the near term include forecasted future cash flows used in testing for impairments of intangible and tangible assets and loss accruals for excess inventory and fixed purchase commitments under our supply contracts. Forecasted future cash flows in particular require considerable judgment and are subject to inherent imprecision. In the case of impairment testing, changes in estimates of future cash flows could result in a material impairment charge and, whether they result in an immediate impairment charge, could result prospectively in a reduction in the estimated remaining useful life of tangible or intangible assets, which could be material to the financial statements.

Other significant estimates include accruals for Medicaid, Medicare, and other rebates, returns and chargebacks, allowances for doubtful accounts and estimates used in applying the revenue recognition policy.

We are subject to risks and uncertainties that may cause actual results to differ from the related estimates, and our estimates may change from time to time in response to actual developments and new information.

The significant accounting estimates that we believe are important to aid in fully understanding our reported financial results include the following:

Intangible assets, goodwill and other long-lived assets. When we acquire product rights in conjunction with either business or asset acquisitions, we allocate an appropriate portion of the purchase price to intangible assets, goodwill and other long-lived assets. The purchase price is allocated to products, acquired research and development, if any, and other intangibles using the assistance of valuation consultants. We estimate the useful lives of the assets by factoring in the characteristics of the products such as: patent protection, competition by products prescribed for similar indications, estimated future introductions of competing products and other issues. The factors that drive the estimate of the life of the asset are inherently uncertain. We use the straight-line method of amortization for our intangible assets.

We review our property, plant and equipment and intangible assets for possible impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. We review our goodwill for possible impairment annually, during the first quarter, or whenever events or circumstances indicate that the carrying amount may not be recoverable. In any event, we evaluate the remaining useful lives of our intangible assets each reporting period to determine whether events and circumstances warrant a revision to the remaining period of amortization. This evaluation is performed through our quarterly evaluation of intangibles for impairment. Further, on an annual basis, we review the life of each intangible asset and make adjustments as deemed appropriate. In evaluating goodwill for impairment, we estimate the fair value of our individual business reporting units on a discounted cash flow basis. Assumptions and estimates used in the evaluation of impairment may affect the carrying value of long-lived assets, which could result in impairment charges in future periods. Such assumptions include projections of future cash flows and, in some cases, the current fair value of the asset. In addition, our depreciation and amortization policies reflect judgments on the estimated useful lives of assets.

We may incur impairment charges in the future if prescriptions for, or sales of, our products are less than current expectations and result in a reduction of our estimated undiscounted future cash flows. This may be caused by many factors, including competition from generic substitutes, significant delays in the manufacture or supply of materials, the publication of negative results of studies or clinical trials, new legislation or regulatory proposals.

Table of Contents

The gross carrying amount and accumulated amortization as of September 30, 2009 are as follows:

	Gross Carrying Amount	Accumulated Amortization (In thousands)	Net Book Value
<i>Branded Prescription Pharmaceuticals</i>			
Avinza®	\$ 285,700	\$ 68,848	\$ 216,852
Skelaxin®	278,853	221,997	56,856
Sonata®	61,961	61,961	
Flector® Patch	130,000	8,864	121,136
Neuroscience	756,514	361,670	394,844
Synercid®	70,959	46,404	24,555
Other hospital	8,442	6,655	1,787
Hospital	79,401	53,059	26,342
Bicillin®	92,350	34,045	58,305
Other legacy products	324,035	279,107	44,928
Legacy products	416,385	313,152	103,233
Total Branded	1,252,300	727,881	524,419
<i>Animal Health</i>	170,000	7,167	162,833
<i>Meridian Auto-Injector</i>	182,587	47,480	135,107
<i>Royalties</i>	3,731	3,501	230
Total intangible assets	\$ 1,608,618	\$ 786,029	\$ 822,589

The amounts of impairments and amortization expense for the three months ended September 30, 2009 and 2008 are as follows:

	Three Months Ended September 30, 2009		Three Months Ended September 30, 2008	
	Impairments	Amortization Expense	Impairments	Amortization Expense
	(In thousands)		(In thousands)	
<i>Branded Prescription Pharmaceuticals</i>				
Avinza®	\$	\$ 6,639	\$	\$ 6,638
Skelaxin®		20,041		5,973

Edgar Filing: KING PHARMACEUTICALS INC - Form 10-Q

Flector® Patch		2,954		
Neuroscience		29,634		12,611
Synercid®		1,485		1,491
Other hospital		76		76
Hospital		1,561		1,567
Bicillin®		925		926
Other legacy products		1,430		2,970
Legacy products		2,355		3,896
Total Branded		33,550		18,074
<i>Animal Health</i>		2,348		
<i>Meridian Auto-Injector</i>		2,102		1,981
<i>Royalties</i>		11		185
Total	\$	\$	38,011	\$
				\$
				20,240

Table of Contents

The amounts of impairments and amortization expense for the nine months ended September 30, 2009 and 2008 are as follows:

	Nine Months Ended September 30, 2009		Nine Months Ended September 30, 2008	
	Impairments (In thousands)	Amortization Expense (In thousands)	Impairments (In thousands)	Amortization Expense (In thousands)
<i>Branded Prescription Pharmaceuticals</i>				
Avinza®	\$	\$ 19,915	\$	\$ 19,915
Skelaxin®		60,123		17,686
Sonata®				315
Flector® Patch		8,864		
Neuroscience		88,902		37,916
Synercid®		4,453	38,064	6,241
Other hospital		228		228
Hospital		4,681	38,064	6,469
Bicillin®		2,775		2,777
Altace®				29,687
Other legacy products		4,290	1,251	8,964
Legacy products		7,065	1,251	41,428
Total Branded		100,648	39,315	85,813
<i>Animal Health</i>		7,167		
<i>Meridian Auto-Injector</i>		6,199		5,846
<i>Royalties</i>		324		552
Total	\$	\$ 114,338	\$ 39,315	\$ 92,211

The remaining amortization periods for significant products are as follows:

	Remaining Life at September 30, 2009
Skelaxin®	9 months
Avinza®	8 years 2 months
Flector® Patch	10 years 3 months
Synercid®	4 years 3 months

Bicillin®

15 years 9 months

Inventories. Our inventories are valued at the lower of cost or market value. We evaluate our entire inventory for short-dated or slow-moving product and inventory commitments under supply agreements based on projections of future demand and market conditions. For those units in inventory that are so identified, we estimate their market value or net sales value based on current realization trends. If the projected net realizable value is less than cost, on a product basis, we make a provision to reflect the lower value of that inventory. This methodology recognizes projected inventory losses at the time such losses are evident rather than at the time goods are actually sold. We maintain supply agreements with some of our vendors which contain minimum purchase requirements. We estimate future inventory requirements based on current facts and trends. Should our minimum purchase requirements under supply agreements, or if our estimated future inventory requirements exceed actual inventory quantities that we will be able to sell to our customers, we record a charge in costs of revenues.

Accruals for rebates, returns and chargebacks. We establish accruals for returns, chargebacks and Medicaid, Medicare and commercial rebates in the same period we recognize the related sales. The

Table of Contents

accruals reduce revenues and are included in accrued expenses. At the time a rebate or chargeback payment is made or a product return is received, which occurs with a delay after the related sale, we record a reduction to accrued expenses and, at the end of each quarter, adjust accrued expenses for differences between estimated and actual payments. Due to estimates and assumptions inherent in determining the amount of returns, chargebacks and rebates, the actual amount of product returns and claims for chargebacks and rebates may be different from our estimates.

Our product returns accrual is primarily based on estimates of future product returns over the period during which customers have a right of return which is in turn based in part on estimates of the remaining shelf life of our products when sold to customers. Future product returns are estimated primarily on historical sales and return rates. We also consider the level of inventory of our products in the distribution channel. We base our estimate of our Medicaid rebate, Medicare rebate, and commercial rebate accruals on estimates of usage by rebate-eligible customers, estimates of the level of inventory of our products in the distribution channel that remain potentially subject to those rebates, and the terms of our commercial and regulatory rebate obligations. We base our estimate of our chargeback accrual on our estimates of the level of inventory of our products in the distribution channel that remain subject to chargebacks, and specific contractual and historical chargeback rates. The estimate of the level of our products in the distribution channel is based on data provided by our three key wholesalers under inventory management agreements.

Our accruals for returns, chargebacks and rebates are adjusted as appropriate for specific known developments that may result in a change in our product returns or our rebate and chargeback obligations. In the case of product returns, we monitor demand levels for our products and the effects of the introduction of competing products and other factors on this demand. When we identify decreases in demand for products or experience higher than historical rates of returns caused by unexpected discrete events, we further analyze these products for potential additional supplemental reserves.

Revenue recognition. Revenue is recognized when title and risk of loss are transferred to customers, collection of sales is reasonably assured and we have no further performance obligations. This is generally at the time products are received by the customer. Accruals for estimated returns, rebates and chargebacks, determined based on historical experience, reduce revenues at the time of sale and are included in accrued expenses. Medicaid and certain other governmental pricing programs involve particularly difficult interpretations of relevant statutes and regulatory guidance, which are complex and, in certain respects, ambiguous. Moreover, prevailing interpretations of these statutes and guidance can change over time. We launched Embedatm in late September 2009. We have recognized revenue on Embedatm in a manner consistent with our other products, as described above, which is generally at the time the product is received by the customer. We believe Embedatm has similar characteristics of certain of our other pharmaceutical products such that we can reliably estimate expected returns of the product. Royalty revenue is recognized based on a percentage of sales (namely, contractually agreed-upon royalty rates) reported by third parties.

A WARNING ABOUT FORWARD-LOOKING STATEMENTS

This report includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to analyses and other information which are based on forecasts of future results and estimates of amounts that are not yet determinable. These statements also relate to our future prospects, developments and business strategies.

These forward-looking statements are identified by their use of terms and phrases, such as anticipate, believe, could, estimate, expect, intend, may, plan, predict, project, will and other similar terms and phrases, including assumptions. These statements are contained in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections, as well as other sections of this report. You should not unduly

rely on our forward-looking statements.

Table of Contents

Forward-looking statements in this report include, but are not limited to, those regarding:

the potential of, including anticipated net sales and prescription trends for, our branded prescription pharmaceutical products, particularly Skelaxin[®], Avinza[®], Thrombin-JMI[®], Flector[®] Patch, Embeda[™], Levoxy[®], Altace[®], Cytome[®] and Synercid[®];

expectations regarding the enforceability and effectiveness of product-related patents, including, in particular, patents related to Skelaxin[®], Avinza[®] and Adenoscan[®];

expected trends and projections with respect to particular products, reportable segment and income and expense line items;

the adequacy of our liquidity and capital resources;

anticipated capital expenditures;

the development, approval and successful commercialization of Remoxy[®], Acurox[®] Tablets, CorVue[™] and other products;

the cost of and the successful execution of our growth and restructuring strategies;

anticipated developments and expansions of our business;

our plans for the manufacture of some of our products, including products manufactured by third parties;

the potential costs, outcomes and timing of research, clinical trials and other development activities involving pharmaceutical products, including, but not limited to, the magnitude and timing of potential payments to third parties in connection with development activities;

the development of product line extensions;

the expected timing of the initial marketing of certain products;

products developed, acquired or in-licensed that may be commercialized;

our intent, beliefs or current expectations, primarily with respect to our future operating performance;

expectations regarding sales growth, gross margins, manufacturing productivity, capital expenditures and effective tax rates;

expectations regarding the outcome and potential financial effects of various pending legal proceedings, including the Skelaxin[®], Avinza[®] and EpiPen[®] patent challenges, litigation, and other legal proceedings described in this report;

expectations regarding our financial condition and liquidity as well as future cash flows and earnings; and

expectations regarding our ability to liquidate our holdings of auction rate securities and the temporary nature of unrealized losses recorded in connection with some of those securities.

These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those contemplated by our forward-looking statements. We do not undertake any obligation to update any forward-looking statements or other information in this report until the effective date of our future reports required by applicable laws.

Item 3. *Quantitative and Qualitative Disclosures about Market Risk*

We are exposed to market risk for changes in the market values of some of our investments, the effect of interest rate changes and the effect of changes in foreign currency exchange rates. We have derivative financial instruments associated with utility contracts which qualify as normal purchase and sales and derivatives associated with the Convertible Senior Notes.

We are subject to interest rate risk on our variable rate debt as changes in interest rates could adversely affect earnings and cash flows.

Table of Contents

We have marketable securities which are carried at fair value based on the quoted price for identical securities in an active market. Gains and losses on securities are based on the specific identification method.

The fair market value of long-term fixed interest rate debt is subject to interest rate risk. Generally, the fair market value of fixed interest rate debt will decrease as interest rates rise and increase as interest rates fall. In addition, the fair value of our convertible debentures is affected by our stock price.

Foreign currency exchange rate movements create fluctuations in U.S. Dollar reported amounts of foreign subsidiaries whose local currencies are their respective functional currencies.

Item 4. *Controls and Procedures*

As of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the Exchange Act)). Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective to reasonably ensure that information required to be disclosed and filed under the Exchange Act is recorded, processed, summarized and reported within the time periods specified, and that management will be timely alerted to material information required to be included in our periodic reports filed with the SEC.

On December 29, 2008, we completed our acquisition of Alpharma. As permitted by the rules and regulations of the SEC, we excluded Alpharma from our evaluation of our internal control over financial reporting as of December 31, 2008. Total assets of Alpharma represented approximately 39.7% of, and were included in, our consolidated total assets as of December 31, 2008. Since we acquired Alpharma at the end of December 2008, the financial results of Alpharma were not included in our financial results for the year ended December 31, 2008.

The accompanying financial statements for the quarter ended September 30, 2009 include the results of operations, financial position, and cash flows of Alpharma. The operations of Alpharma's pharmaceutical business have been integrated into our branded prescription pharmaceuticals segment and therefore were subject to internal controls over financial reporting established by our management prior to the acquisition.

However, the assets, liabilities, results of operations and cash flows of the Alpharma Animal Health segment included in the accompanying 2009 financial statements were principally subject, during the quarter ended September 30, 2009, to internal controls over financial reporting established by Alpharma management prior to the acquisition. We are in the process of evaluating the effectiveness of the acquired Alpharma controls together with our legacy internal controls over financial reporting and will report the results of our assessment of effectiveness as of December 31, 2009.

Except as described above, there were no changes in our internal control over financial reporting that occurred during the quarter ended September 30, 2009 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

Item 1. *Legal Proceedings*

The information required by this Item is incorporated by reference to Note 10, Commitments and Contingencies, in Part I, Item 1, Financial Statements.

Item 1A. Risk Factors

We have disclosed a number of material risks under Item 1A of our annual report on Form 10-K for the year ended December 31, 2008, which we filed with the Securities and Exchange Commission on March 2, 2009. The following risk factor has changed materially since we filed that report.

Table of Contents

An expansion of restrictions on, or bans of, the use of antibiotics used in food-producing animals could result in a decrease in our sales.

The issue of the potential transfer of increased bacterial resistance to human pathogens due to the use of certain antibiotics in certain food-producing animals is the subject of discussions on a worldwide basis and, in certain instances, has led to government restrictions on the use of antibiotics in these food-producing animals. The sales of our animal health segment are principally antibiotic-based products for use with food-producing animals; therefore, future limitations in major markets, including the U.S., or negative publicity regarding this use of antibiotic-based products, could have a negative impact on our business, financial condition, results of operations and cash flows.

While most of the government activity in this area has involved products other than those that we offer for sale, the European Union (EU) and a number of non-EU countries, including Norway and Turkey, banned the use of zinc bacitracin, a feed antibiotic growth promoter manufactured by us and others that has been used in livestock feeds for over 40 years, as a feed additive growth promoter. We have not sold this product as a feed additive growth promoter in these countries since the bans took effect (initially in the EU in July 1999; in Turkey, Bulgaria and Romania (the latter two now part of the EU) in 2000; and in Norway in January 2006). The EU ban is based upon the Precautionary Principle, which states that a product may be withdrawn from the market based upon a finding of a potential threat of serious or irreversible damage even if such finding is not supported by scientific certainty.

Taiwan, South Korea and Brazil have implemented, or are expected to implement shortly, restrictions on the use of antibiotics in animal feed. We have marketed antibiotics for use in food-producing animals in these countries but will be required to curtail or discontinue those practices. The actions by these countries may negatively impact our business as a result of reduced sales. It is not yet known whether this reduction will be material to our financial position or results of operations.

Discussions of the antibiotic resistance issue continue actively in the U.S. Various sources have published reports concerning possible adverse human effects from the use of antibiotics in food animals. Some of these reports have asserted that major animal producers, some of whom are our customers or the end-users of our products, are reducing the use of antibiotics.

In July 2009, FDA officials expressed support for a phase-out of growth promotion/feed efficiency uses of antibiotics in food-producing animals. Legislation pending before Congress would, if it were to become law, require the FDA to withdraw the approval of such nontherapeutic uses of antibiotics unless the FDA determines, within two years of enactment, that there is a reasonable certainty of no harm to human health due to the development of antimicrobial resistance that is attributable in whole or in part to the nontherapeutic use of the drug in food-producing animals. Under the proposed legislation, this finding may be based on evidence submitted by the holder of the approved product application or developed by the FDA on its own initiative. We cannot predict whether this legislation will become law or, if it does, whether the FDA would agree that this standard has been satisfied for bacitracin-based products.

In July 2005, the FDA withdrew the approval of an antibiotic poultry water medication due to concerns regarding antibiotic resistance in humans. While we do not market this drug, this ruling could be significant if its conclusions were expanded to the medicated feed additives sold by us. In the absence of new legislation, it is uncertain what additional actions, if any, the FDA may take for approved animal drug products. However, the FDA has established a rating system to be used to compare the risks associated with the use of specific antibiotic products in food producing animals, including those sold by us. While we do not believe that the presently proposed risk assessment system would be materially adverse to our business, it is subject to change prior to adoption or to later amendment.

We cannot predict whether the present ban of zinc bacitracin products may be expanded or whether other antibiotic restrictions will be introduced. If any one of the following events occurs, the resultant loss of sales could be material to our financial condition, cash flows and results of operations:

additional countries, such as the U.S., where we have material sales of bacitracin-based products, restrict or ban the use of zinc bacitracin or other antibiotic feed additives;

Table of Contents

countries which are significant importers of meat act to prevent the importation of products from countries that allow the use of bacitracin-based or other antibiotic-containing products;

there is an increase in public pressure to discontinue the use of antibiotic feed additives; or

consumers or retailers decide to purchase fewer meat products from animals fed antibiotics.

Item 5. *Other Information*

On September 4, 2007, Alpharma Ireland Limited (*Alpharma Ireland*), now our wholly-owned subsidiary, entered into an Exclusive License Agreement (*License Agreement*) with IDEA AG, a privately-held biopharmaceutical company headquartered in Munich, Germany (*IDEA*), through which Alpharma Ireland obtained the exclusive U.S. license and distribution rights from IDEA to market ketoprofen in Transfersome® gel, a prescription topical NSAID (non-steroidal anti-inflammatory drug). Transfersome® gel is IDEA's proprietary technology platform for delivering drugs to targeted areas through the skin barrier. The License Agreement was amended on March 31, 2008. We acquired Alpharma Ireland's parent company, Alpharma Inc., on December 29, 2008.

Based upon a review of the progress of the licensed product's development and our view of its commercial potential, on August 18, 2009, pursuant to provisions in the License Agreement, Alpharma Ireland provided 90 days' written notice to IDEA of its intention to terminate the License Agreement, including the automatic termination of certain warrants, described below, and a related registration rights agreement. The agreement was terminated in October 2009, which was earlier than the end of the original 90-day notice period. The financial terms of the License Agreement included a \$60 million license fee payment from Alpharma Ireland to IDEA, made at the time that the parties entered into the License Agreement, as well as: the issuance of two warrants for the purchase of Class A Common Stock of Alpharma Inc., exercisable upon the occurrence of certain regulatory-related events; milestone payments based upon development and regulatory events, patent issuance and the results of a certain Phase III clinical trial; and specified royalties to IDEA on net product sales. IDEA was to have paid the costs of specified studies, including two Phase III clinical trials with Alpharma Ireland paying additional amounts if it used certain data from one of the Phase III clinical trials for specified promotional purposes. Prior to U.S. product approval, Alpharma Ireland was obligated to make certain market development expenditures. During the 50 months commencing two months prior to the commercial launch of the licensed product in the U.S., Alpharma Ireland would have also been responsible for substantial sales, marketing and medical education expenses.

By its terms, the License Agreement was to expire upon the later of the expiration of all U.S. patent rights licensed by IDEA to Alpharma Ireland or 2029; however, prior to a commercial launch of the licensed product in the U.S., Alpharma Ireland had the right to terminate the License Agreement upon 90 days' prior written notice to IDEA.

For purposes of this report, Carla M. Shumate, Senior Vice President Finance, Controller, is acting as principal financial officer.

Item 6. *Exhibits*

**Exhibit
Number**

Description

- 3.1(1) Second Amended and Restated By laws of King Pharmaceuticals, Inc.
- 31.1 Certificate of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Edgar Filing: KING PHARMACEUTICALS INC - Form 10-Q

- 31.2 Certificate of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32.1 Certificate of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
- 32.2 Certificate of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(1) Incorporated by reference to King's Current Report on Form 8-K filed on September 17, 2009.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

KING PHARMACEUTICALS, INC.

By: /s/ Brian A. Markison
Brian A. Markison
President and Chief Executive Officer

Date: November 5, 2009

By: /s/ Carla M. Shumate
Carla M. Shumate
Senior Vice President Finance, Controller

Date: November 5, 2009